Anti-MuSK antibodies for treatment of neuromuscular disorders

By developing anti-MuSK antibodies to bind to MuSK and activate their signaling, the problem of limited existing ALS treatment methods has been solved, significantly improved motor function and muscle health in ALS patients, and a new treatment plan for ALS is provided.

CN119013308APending Publication Date: 2024-11-22ARGENX BVBA(BE) +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380018748.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-05-13
Filing Date
2023-01-27
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

There are limited existing treatments for ALS, especially inadequate effects on muscle function, and ALS is considered a genetic heterogeneous disease, resulting in no available customized treatment options that can help all patients with ALS.

Method used

Develop anti-MuSK antibodies based molecules, including anti-MuSK antibodies, their epitope-binding domains, antigen-binding fragments and antibody derivatives, for binding to human muscle-specific tyrosine protein kinase (MuSK), activate or enhance their signaling Conduct and phosphorylation, thus used to treat neuromuscular diseases.

Benefits of technology

Through the combination with MuSK, the motor function, muscle contraction characteristics and anti-fatigue ability are significantly improved, and the survival time of ALS patients is extended, providing new treatment options for ALS and other similar diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure GDA0005081132150000321
    Figure GDA0005081132150000321
  • Figure GDA0005081132150000331
    Figure GDA0005081132150000331
  • Figure GDA0005081132150000341
    Figure GDA0005081132150000341
Patent Text Reader

Abstract

The present invention relates to anti-MuSK antibodies or antigen-binding fragments thereof for use in the treatment of neuromuscular disorders in human subjects. In one embodiment, the antibody, or antigen-binding fragment thereof, is combined with an anticholinergic compound.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Related Applications

[0002] This application claims priority to U.S. Provisional Patent Application Serial No. 63 / 364,685 filed on May 13, 2022 and EP Application No. 22154118.8 filed on January 28, 2022, the entire disclosures of which are hereby incorporated by reference.

[0003] References to sequence listings

[0004] This application contains a sequence listing submitted electronically in ST.26 format and incorporated herein by reference in its entirety (the ST.26 copy was created on January 27, 2023, named "196198_SL.XML" and is 364,704 bytes in size). Technical Field

[0005] The present invention relates to an anti-MuSK antibody or an antigen-binding fragment thereof for use in treating neuromuscular disorders, such as ALS (amyotrophic lateral sclerosis) in human subjects. In one embodiment, the antibody or antigen-binding fragment thereof is combined with an anticholinergic compound. Background Art

[0006] ALS is an adult-onset, non-cell autonomous neuromuscular / neurodegenerative disorder that results in the progressive loss of upper and lower motor neurons (MNs), leading to gradual paralysis and death over 2 to 5 years. Neuromuscular junction (NMJ) denervation is a hallmark of ALS [1] and is present in several disease models of ALS [2-6], even before MN death [1,3].

[0007] The currently approved ALS treatment (Riluzole) benefits only 20% of ALS patients by extending lifespan by approximately three months. Riluzole has very limited effects on muscle function. Furthermore, ALS is considered a genetically heterogeneous disease that may represent several subgroups with different underlying pathological states. Due to the different underlying disease mechanisms, there are currently no available treatments and it is unlikely that patient-tailored treatments will help all ALS patients.

[0008] Thus, there remains a need for new treatments for ALS and other ALS-like diseases ("ALS-like diseases"). BRIEF DESCRIPTION OF THE DRAWINGS

[0009] FIG. 1 Combination treatment improves motor function in SOD1G37R mice. ARGX-119 treatment was initiated at P400 (pre-disease onset or asymptomatic) and darifenacin treatment was initiated at approximately P425 (disease onset) and continued until sacrifice (approximately P520). A) A diagram depicting the rotarod apparatus used to assess motor function, coordination, and balance after wheel acceleration. B) Waiting time (seconds) to land on the rotarod for mice treated with ARGX-119 antibody (large gray circles), mice treated with ARGX-119 + darifenacin combination treatment (black triangles), mice treated with darifenacin (small gray circles), and mice treated with double placebo (gray squares) from approximately 400 to 520 days of age. C) Grip dynamometer used to monitor overall strength of the forelimbs and hindlimbs of mice. D) Evolution of grip strength measurements during the course of treatment, from approximately P400 to P520 for each group. E) Evolution of body weight measurements during the course of treatment, from approximately P400 to P520 for each group. *p<0.05, ***p<0.001, ****p<0.0001. One-way ANOVA and multiple t-test.

[0010] FIG2 Treatment improves the contractile properties of EDL muscles. A) Diagram of the nerve and muscle stimulation electrodes and muscle force sensor setup for eliciting muscle contractions. Examples of raw data showing muscle contractions triggered by nerve or muscle stimulation for calculation of contractile capacity ratios. B to C) Peak twitch force of EDL muscles generated by nerve stimulation (B) or muscle stimulation (C) at different frequencies (5 Hz to 300 Hz) from mice treated with ARGX-119 antibody (grey circles) and ARGX-119 + darifenacin combination treatment (black triangles) and mice treated with double placebo (grey squares). D) Bar graph showing the mean ± SEM of the EDL muscle contractile capacity ratio expressed as a percentage, representing the ratio of peak force generated by nerve stimulation to muscle stimulation (stimulation frequency of 5 Hz to 100 Hz). E) Histogram showing the mean ± SEM of EDL muscle weights from mice treated with ARGX-119 antibody, combination treatment, and placebo. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. One-way ANOVA and multiple t-test were repeated.

[0011] FIG3 Combination treatment improves contractile properties of soleus muscle. A to B) Peak twitch force of soleus (SOL) muscle produced by nerve stimulation (A) or muscle stimulation (B) at different frequencies (5 Hz to 300 Hz) in mice treated with ARGX-119 antibody (grey circles) and ARGX-119 + darifenacin combination treatment (black triangles) and double placebo treated mice (grey squares). C) Bar graph showing mean ± SEM of the ratio of SOL muscle contractility expressed as a percentage, representing the ratio of peak force produced by nerve stimulation to muscle stimulation (stimulation frequency of 5 Hz to 100 Hz). D) Histogram showing mean ± SEM of EDL muscle weight from ARGX-119 antibody, combination treated and placebo treated mice. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. One-way ANOVA and multiple t-tests were repeated.

[0012] FIG. 4 Combination treatments preserve muscle fatigue properties. A) A diagram showing an EDL fatigue protocol consisting of 18 trainings of 10 stimuli at 120 Hz, 300 ms (1 round per second). Nine of the 10 sessions used separate nerve stimulation, and muscle stimulation was superimposed on the nerve stimulation every 10 stimulations. The fatigue protocol was followed by a 30-minute recovery period. B to C) Peak contractile force during the fatigue protocol and recovery period for nerve stimulation (B) and nerve + muscle (C) of the EDL muscle is expressed as a percentage of the initial baseline force generated before the fatigue protocol. Note that the placebo-treated (grey squares) were more resistant to fatigue than the animals double-treated with ARGX-119 + darifenacin (black triangles) and treated with the ARGX-119 antibody (grey circles). This illustrates a significant change in the normal fast-twitch muscle properties, which are usually highly fatigable. D to E) Peak contractile force during the fatigue protocol and recovery period for nerve stimulation (D) and nerve + muscle (E) of the SOL muscle is expressed as a percentage of the initial baseline force produced before the fatigue protocol. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Repeated one-way ANOVA and multiple t-tests. DETAILED DESCRIPTION

[0013] General Definition

[0014] The following terms or definitions are provided only to help understand the present invention. Unless explicitly defined herein, all terms used herein have the same meaning as for those skilled in the art of the present invention. For definitions and terms in the art, practitioners particularly refer to Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Press, Plainsview, New York (1989); and Ausubel et al., Current Protocols in Molecular Biology (Supplement 47), John Wiley & Sons, New York (1999). The definitions provided herein should not be interpreted as having a scope less than that understood by those of ordinary skill in the art.

[0015] Unless otherwise indicated, it will be obvious to the skilled person that all methods, steps, techniques and operations not specifically described in detail can be performed in a manner known per se and have been performed. For example, reference is again made to the standard manuals, the general background technology mentioned above and the further references cited therein.

[0016] As used herein, unmodified nouns mean one or more unless the context clearly indicates otherwise.

[0017] As used herein, the term "comprising" is synonymous with "including" or "containing" and is inclusive or open-ended without excluding additional non-recorded members, compounds, products, elements or method steps. The expression "consisting essentially of" used in the context of a product or composition ("a product consisting essentially of" or "a composition consisting essentially of") means that additional molecules may be present, but such molecules do not change the characteristics / activity / function of the product or composition. For example, if the composition itself will exhibit similar characteristics / activity / function to one of the antibodies or one of the antibody fragments, the composition may consist essentially of the antibody or antibody fragment.

[0018] The recitation of numerical ranges by endpoints includes all numbers and fractions subsumed within the corresponding ranges, as well as the recited endpoints.

[0019] The term "about" as used herein in relation to measurable values ​​such as parameters, amounts, temporal durations, etc., is intended to encompass variations of + / -10% or less, preferably + / -5% or less, more preferably + / -1% or less, and still more preferably + / -0.1% or less, of or relative to the specified value, within which such variations are suitable for implementation in the disclosed invention. It should be understood that the value to which the modifier "about" refers is itself also specifically and preferably disclosed.

[0020] The terms 'disorder' and 'disease' are used interchangeably herein.

[0021] As used herein, amino acid residues will be referred to by either their full names or according to the standard three-letter or one-letter amino acid codes.

[0022] As used herein, the terms "polypeptide" or "protein" are used interchangeably and refer to a polymeric form of amino acids of any length (which may include coded and non-coded amino acids, chemically or biochemically modified or derivatized amino acids), and polypeptides with modified peptide backbones. A "peptide" is also a polymer of amino acids, typically up to 50 amino acids in length. A polypeptide or peptide is represented by an amino acid sequence.

[0023] As used herein, the terms "nucleic acid molecule", "polynucleotide", "polynucleic acid", "nucleic acid" are used interchangeably and refer to a polymeric form of nucleotides (deoxyribonucleotides or ribonucleotides or their analogs) of any length. Nucleic acid molecules are represented by nucleic acid sequences, which are primarily characterized by their base sequences. Polynucleotides can have any three-dimensional structure and can perform any known or unknown function. Non-limiting examples of polynucleotides include genes, gene fragments, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, control regions, isolated RNA of any sequence, nucleic acid probes, and primers. Nucleic acid molecules can be linear or circular.

[0024] The term "homology" used herein means at least secondary structural identity or similarity between two macromolecules from the same or different taxa, particularly between two polypeptides or polynucleotides, wherein the similarity is attributed to a common ancestor. Therefore, the term "homologue" means a macromolecule so related with the secondary and optionally tertiary structural similarities. In order to compare two or more nucleotide sequences, the "sequence identity (percentage)" between a first nucleotide sequence and a second nucleotide sequence can be calculated using methods known to those skilled in the art, such as by dividing the number of nucleotides identical to the nucleotides at the corresponding position in the first nucleotide sequence by the total number of nucleotides in the first nucleotide sequence and multiplying by 100%, or by using a known computer algorithm for sequence alignment, such as NCBIBlast. When determining the degree of sequence similarity between two amino acid sequences, those skilled in the art may consider so-called "conservative" amino acid substitutions, which can generally be described as amino acid substitutions in which one amino acid residue is replaced by another amino acid residue with a similar chemical structure and has little or no effect on the function, activity or other biological properties of the polypeptide. Possible conservative amino acid substitutions have been exemplified herein. If an amino acid sequence and a nucleic acid sequence have 100% sequence identity over their entire length, they are referred to as "identical".

[0025] Throughout this application, each time a specific amino acid sequence SEQ ID NO (taking SEQ ID NO: Y as an example) is mentioned, it can be replaced by: a polypeptide comprising an amino acid sequence having at least 80% sequence identity or similarity to the amino acid sequence SEQ ID NO: Y. Throughout this application, the phrase "a sequence at least X% identical to another sequence" can be replaced by "a sequence having at least X% sequence identity to another sequence".

[0026] In other preferred embodiments, each amino acid sequence described herein has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity or higher identity with a given amino acid sequence, respectively, by virtue of its percent identity (at least 80%) with the given amino acid sequence, respectively. In a preferred embodiment, sequence identity is determined by comparing the full length of the sequences identified herein. In other preferred embodiments, each amino acid sequence described herein has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% similarity or higher similarity with the given amino acid sequence by virtue of its percentage of similarity (at least 80%) with the given amino acid sequence. In a preferred embodiment, sequence similarity is determined by comparing the full length of the sequences identified herein. Unless otherwise specified herein, identity or similarity with a given SEQ ID NO means identity or similarity based on the full length of the sequence (i.e., over its full length or as a whole).

[0027] "Sequence identity" is defined herein as the relationship between two or more amino acid (polypeptide or protein) sequences or two or more nucleic acid (polynucleotide) sequences, as determined by comparing the sequences. The identity between two amino acid sequences is preferably determined by assessing their identity over the entire SEQ ID NO as identified herein, or a portion thereof. A portion thereof may mean at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90% of the length of the SEQ ID NO.

[0028] In the art, "identity" also means the degree of sequence relatedness between amino acid sequences, as appropriate, as determined by the match between strings of such sequences. "Similarity" between two amino acid sequences is determined by comparing the amino acid sequence of one polypeptide and its conservative amino acid substitutes to the sequence of a second polypeptide. "Identity" and "similarity" can be readily calculated by known methods, including but not limited to those described below:

[0029] Computational Molecular Biology, Lesk, A.M., ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D.W., ed, Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part l, Griffin, A.M., and Griffin, H.G., eds, Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heine, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds, M Stockton Press, New York, 1991; and Carillo, H., and Lipman, D., SIAM J. Applied Math., 48:1073(1988).

[0030] Preferred methods for determining identity are designed to give maximum matching between the sequences tested. Methods for determining identity and similarity are incorporated into publicly available computer programs. Preferred computer program methods for determining identity and similarity between two sequences include, for example, GCG program packages (Devereux, J., et al., Nucleic Acids Research 12 (1): 387 (1984)), BestFit, FASTA, BLASTN and BLASTP (Altschul, SF et al., J. Mol. Biol. 215: 403-410 (1990)), EMBOSS Needle (Madeira, F., et al., Nucleic Acids Research 47 (W1): W636-W641 (2019)). The BLAST program is publicly available from NCBI and other sources (BLAST manual, Altschul, S., et al., NCBI NLM NIH Bethesda, MD 20894; Altschul, S., et al., J. Mol. Biol. 215:403-410 (1990)). The EMBOSS program is publicly available from EMBL-EBI. The well-known Smith-Waterman algorithm can also be used to determine identity. The EMBOSS Needle program is a preferred program for use.

[0031] Preferred parameters for polypeptide sequence comparison include the following: Algorithm: Needleman and Wunsch, J. Mol. Biol. 48(3): 443-453 (1970); Comparison matrix: BLOSUM62, which is from Henikoff and Henikoff, Proc. Natl. Acad. Sci. USA. 89: 10915-10919 (1992); Gap opening penalty: 10, and gap extension penalty: 0.5. A program that can be used with these parameters is publicly available as the EMBOSS Needle program from EMBL-EBI. The foregoing parameters are the default parameters for global pairwise alignments of proteins (and no penalty for end gaps).

[0032] Preferred parameters for nucleic acid comparisons include the following: Algorithm: Needleman and Wunsch, J. Mol. Biol. 48: 443-453 (1970); Comparison matrix: DNAfull; Gap opening penalty: 10; Gap extension penalty: 0.5. Programs that can be used for these parameters are publicly available as the EMBOSS Needle program from EMBL-EBI. The aforementioned parameters are the default parameters for global pairwise alignments of nucleotide sequences (and no penalty for end gaps).

[0033] As used herein, the terms 'disorder' and 'disease' are used interchangeably.

[0034] Also provided herein are embodiments wherein any embodiment described herein may be combined with any one or more additional embodiments, as long as the combinations are not mutually exclusive.

[0035] Anti-MuSK antibodies and antigen-binding fragments thereof

[0036] All antibodies or antigen binding fragments thereof defined herein are encompassed by the present invention as such.The antibodies or antigen binding fragments thereof are also useful for treating neuromuscular disorders in human subjects.

[0037] The present invention relates to anti-MuSK antibody-based molecules, including anti-MuSK antibodies, epitope binding domains thereof, antigen-binding fragments thereof and antibody derivatives (for treating neuromuscular diseases or disorders). In one embodiment, the wording "antibody-based molecules" can be replaced by the word "antibody" or by the expression "antibody or a functional fragment thereof" or by the expression "antibody or antigen-binding fragment".

[0038] The term "anti-MuSK antibody" can be replaced by the term "MuSK antibody".

[0039] Any anti-MuSK antibody-based molecule, including anti-MuSK antibodies, epitope binding domains thereof, antigen binding fragments thereof, and antibody derivatives capable of binding to muscle-specific tyrosine protein kinase (MuSK), is encompassed by the present invention. In one embodiment, such anti-MuSK antibodies are also capable of activating signaling and / or phosphorylation of MuSK. The present invention provides the insight that such antibody-based molecules can be used to treat conditions in which a subject requires increased MuSK signaling or MuSK phosphorylation, such as neuromuscular diseases or conditions. Thus, in a first aspect, an anti-MuSK antibody or antigen binding fragment thereof for use in treating a neuromuscular condition in a human subject is provided.

[0040] MuSK is a receptor tyrosine kinase that is expressed in skeletal muscle and has a critical, primary role in the formation and maintenance of neuromuscular synapses (Burden et al., “The Role of MuSK in Synapse Formation and Neuromuscular Disease,” Cold Spring Harb. Perspect. Biol. 5:a009167 (2013), which is hereby incorporated by reference in its entirety). MuSK is a single-pass, 120 kDa transmembrane protein consisting of an extracellular region containing three Ig-like domains and a frizzled (Fz)-like domain and an intracellular region containing a juxtamembrane region, a kinase domain, and a short cytoplasmic tail (Jennings et al., "Muscle-Specific trk-Related Receptor with a Kringle Domain Defines a Distinct Class of Receptor Tyrosine Kinases," Proc. Natl. Acad. Sci. USA 90:2895-2899 (1993) and Valenzuela et al., "Receptor Tyrosine Kinase Specific for the Skeletal Muscle Lineage: Expression in Embryonic muscle, at the Neuromuscular Junction, and After Injury," Neuron 15:573-584 (1995), which are hereby incorporated by reference in their entirety). MuSK phosphorylation is stimulated by synaptobrevin, a signal provided by motor neurons. Once activated, MuSK stimulates the following pathways: (1) clustering and anchoring AChRs and other muscle proteins that are critical for synaptic transmission, (2) enhancing transcription of genes encoding synaptic proteins in muscle "synaptic nuclei," and (3) promoting the generation of retrograde signals that promote presynaptic differentiation and attachment of motor nerve terminals to muscle. In the absence of MuSK, neuromuscular synapses cannot form (Burden et al., "The Role of MuSK in Synapse Formation and Neuromuscular Disease," Cold Spring Harb. Perspect. Biol. 5:a009167 (2013), which is hereby incorporated by reference in its entirety).In addition to its role during synapse formation, MuSK is required for maintenance of adult synapses, as inhibition of MuSK expression in adult muscle results in severe defects in pre- and postsynaptic differentiation (Kong et al., "Inhibition of Synapse Assembly in Mammalian Muscle in vivo by RNA Interference," EMBO Rep 5:183-188 (2004) and Hesser et al., "Synapse Disassembly and Formation of New Synapses in Postnatal Muscle Upon Conditional Inactivation of MuSK," Mol. Cell. Neurosci. 31:470-480 (2006), which are hereby incorporated by reference in their entireties). Consistent with these findings in mice, mutations that impair MuSK kinase activity or inhibit signaling steps downstream of MuSK result in myasthenia gravis (CM), characterized by defects in synaptic structure and function, leading to muscle weakness and fatigue (Beeson et al., "Dok-7 Mutations Underlie a Neuromuscular Junction Synaptopathy," Science 313: 1975-1978 (2006); Muller et al., "Phenotypical Spectrum of DOK7 Mutations in Congenital Myasthenic Syndromes," Brain 130: 1497-1506 (2007); and Selcen et al., "A Compensatory Subpopulation of Motor Neurons in a Mouse Model of Amyotrophic Lateral Sclerosis," J. Comp. Neurol. 490: 209-219 (2008), which are hereby incorporated by reference in their entireties).

[0041] The amino acid sequence of human MuSK has the following amino acid sequence of SEQ ID NO:129.

[0042] MRELVNIPLVHILTLVAFSGTEKLPKAPVITTPLETVDALVEEVATFMCAVESYPQPEISWTRNKILIKLFDTR

[0043] YSI RENGQLLTILSVEDSDDGIYCCTANNGVGGAVESCGALQVKMKPKITRPPINVKIIEGLKAVLPCTTMG

[0044] NPKPSVSWIKGDSPLRENSRIAVLESGSLRIH NVQKEDAGQYRCVAKNSLGTAYSKVVKLEVEVFARILRA

[0045] PESH NVTFGSFVTLHCTATGIPVPTITWI ENGNAVSSGSIQESVKDRVIDSRLQLFITKPGLYTCIATN KHGE

[0046] KFSTAKAAATISIAEWSKPQKDNKGYCAQYRGEVC NAVLAKDALVFLNTSYADPEEAQELLVHTAWNELK

[0047] VVSPVCRPAAEALLCNHIFQECSPGVVPTPIPICREYCLAVKELFCAKEWLVMEEKTHRGLYRSEMHLLS

[0048] VPECSKLPSM HWD PTACARLPH LDYN KEN LKTFPPMTSSKPSVDIPN LPSSSSSSFSVSPTYSMTVI ISIM

[0049] SSFAIFVLLTITTLYCCRRRKQWKNKKRESAAVTLTTLPSELLLDRLHPN PMYQRMPLLLNPKLLSLEYPR

[0050] NNIEYVRDIGEGAFGRVFQARAPGLLPYEPFTMVAVKMLKEEASADMQADFQREAALMAEFDNPNIVKLL

[0051] GVCAVGKPMCLLFEYMAYGDLN EFLRSMSPHTVCSLSHSDLSMRAQVSSPGPPPLSCAEQLCIARQVAA

[0052] GMAYLSERKFVHRDLATRNCLVGENMVVKIADFGLSRNIYSADYYKANENDAIPIRWMPPESIFYNRYTTE

[0053] SDVWAYGVVLWEIFSYGLQPYYGMAHEEVIYYVRDGNILSCPENCPVELYNLMRLCWS

[0054] KLPADRPSFTSIHRILERMCERAEGTVSV(SEQ ID NO:129)

[0055] According to the present invention, the MuSK antibody-based molecules described herein bind to an epitope within the frizzled (Fz)-like domain of the MuSK protein. The Fz-like domain of MuSK has the amino acid sequence of SEQ ID NO: 130 as shown below.

[0056] DNKGYCAQYRGEVCNAVLAKDALVFLNTSYADPEEAQELLVHTAWNELKVVSPVCRPAAEALLCNHIFQ

[0057] ECSPGVVPTPIPICREYCLAVKELFCAKEWLVMEEKTHRGLYRSEMHLLSVPECSKLPSMHWDPTACARL(SEQ ID NO: 130)

[0058] The term "epitope" as used herein refers to an antigenic determinant that can bind to an antibody. An epitope generally comprises a surface group of a molecule such as an amino acid or a sugar side chain, and generally has a specific three-dimensional structural feature, as well as a specific charge feature. The difference between conformational and non-conformational epitopes is that the binding to the former (rather than the latter) is lost in the presence of a denaturing solvent. An epitope may comprise amino acid residues that are directly involved in binding (also referred to as the immunodominant component of an epitope) and other amino acid residues that are not directly involved in binding, such as amino acid residues that are effectively blocked by a specific antigen-binding peptide (in other words, amino acid residues are in the "footprint" of a specific antigen-binding peptide). An epitope generally comprises at least 3, and more generally at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more amino acids with unique spatial conformations.

[0059] In one embodiment, the MuSK antibody or antigen binding fragment used according to the present invention binds to the MuSK Frizzled (Fz)-like domain. In one embodiment, the MuSK antibody or antigen binding fragment immunospecifically binds to an epitope in the MuSK Fz-like domain sequence of SEQ ID NO: 130 more frequently, more rapidly, more persistently and / or with greater affinity or avidity than an alternative epitope. In one embodiment, the MuSK antibody-based molecules described herein immunospecifically bind to any 2, 3, 4, 5, 6, 7, 8, 9, 10 or more amino acid residues of SEQ ID NO: 130. As used herein, the terms "affinity", "specific binding", "binding", "immunospecific binding", "binding activity" or "specific binding activity" refer to the extent to which an antibody or antibody fragment as defined herein binds to an epitope within the MuSK-Fz-like domain sequence of SEQ ID NO: 130.

[0060] In one embodiment, the MuSK antibody-based molecules disclosed herein bind to the MuSK Fz-like domain with an affinity corresponding to a KD of about 10-7 M or less. For example, the MuSK antibody-based molecules disclosed herein bind to the MuSK Fz-like domain with an affinity corresponding to a KD of about 10-7 M or less. D The MuSK antibody-based molecules disclosed herein have a K corresponding to the following: D The affinity of the K D The affinity of the MuSK antibody-based molecule to bind to a non-specific antigen (e.g., bovine serum albumin, casein, etc.) is at least 10-fold lower, such as at least 100-fold lower, such as at least 1,000-fold lower, such as at least 10,000-fold lower, such as at least 100,000-fold lower. The amount of reduction in affinity depends on the KD of the antibody, so when the KD of the antibody is very low (i.e., the antibody is highly specific), then the amount of affinity for the antigen is lower than the affinity for the non-specific antigen, which can be at least 10,000-fold lower. As used herein, the term "kd" (seconds) -1The term "K" (M-1 x sec-1 or 1 / M) used herein refers to the association rate constant for a specific antibody-antigen interaction. The term "K" (M-1 x sec-1 or 1 / M) used herein refers to the dissociation rate constant for a specific antibody-antigen interaction. The term "K" (M) used herein refers to the dissociation equilibrium constant for a specific antibody-antigen interaction and is obtained by dividing kd by ka. The term "K" used herein refers to the association rate constant for a specific antibody-antigen interaction. A "(M-1 or 1 / M) refers to the association equilibrium constant for a specific antibody-antigen interaction and is obtained by dividing ka by kd.

[0061] In one embodiment, the molecules based on MuSK antibodies described herein have pH-dependent binding affinity to MuSK, which allows antibody recycling to enhance antigen binding. For example, in one embodiment, the association rate constant or dissociation rate constant may be different under acidic and neutral and alkaline pH conditions. In one embodiment, compared with neutral pH conditions (e.g., pH of about 7.0 to 7.9), the molecules based on MuSK antibodies described herein have a higher dissociation rate constant under acidic pH conditions (e.g., pH <7.0). In some embodiments, compared with neutral pH (pH of about 7.4), the molecules based on MuSK antibodies described herein have a 2-fold to 3-fold high dissociation rate constant (i.e., reduced binding affinity) under acidic pH (e.g., pH of about 5.5). In one embodiment, the molecules based on MuSK antibodies are combined with MuSK Fz-like domains, and their affinity is higher under neutral pH conditions than under acidic pH conditions. In other words, in one embodiment, a MuSK antibody-based molecule binds to a MuSK Fz-like domain with a higher dissociation rate under acidic pH conditions than under neutral pH conditions. Neutral pH conditions can be defined as a pH comprising 7.0 to 7.9. Acidic pH conditions can be defined as a pH less than 7.0. Higher can mean at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 250%, 300% higher. Antibodies with this pH-dependent dissociation profile dissociate from the antigen after binding and activation but before lysosomal degradation. Once dissociated, the antibody is transported back into circulation via the neonatal Fc receptor and released to bind more antigen.

[0062] In some embodiments, the binding of the MuSK antibodies of the present invention to their respective epitopes within the Fz-like domain activates MuSK signaling. In particular, when the MuSK antibodies of the present invention bind to their respective epitopes in the MuSK Fz-like domain, this binding induces MuSK phosphorylation and activation. Relative to the MuSK phosphorylation induced by synaptobrevin activation, the MuSK antibodies of the present invention induce about 50% to about 100% of MuSK phosphorylation (as measured in, for example, a C2C12 phosphorylation assay). In one embodiment, the MuSK antibodies of the present invention induce about 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% 95% of MuSK phosphorylation (relative to the MuSK phosphorylation induced by synaptobrevin activation). In one embodiment, the molecules based on the MuSK antibodies of the present invention induce about 90% to about 100% of MuSK phosphorylation (relative to the MuSK phosphorylation induced by synaptobrevin activation) when MuSK binds. Phosphorylation of MuSK can be assessed using techniques known to the skilled person, such as western blot or C2C12 myotube phosphorylation assay.Such antibodies that activate MuSK signaling (ie induce dimerization of MuSK, induce MuSK tyrosine phosphorylation) are agonist antibodies.

[0063] In some embodiments, the MuSK antibodies of the present invention, i.e., MuSK antibodies that bind to the Fz-domain of MuSK, do not interfere with (i.e., do not block, hinder, inhibit or reduce) natural ligand binding and stimulation of MuSK. In some embodiments, the MuSK antibody co-stimulates MuSK activation with its natural ligand (i.e., synaptobrevin) to produce an additive activation effect, such as MuSK phosphorylation. Therefore, in some embodiments, the MuSK antibodies of the present invention enhance natural MuSK activation induced by natural ligand binding, i.e., phosphorylation. Such MuSK antibodies are agonist antibodies. In some embodiments, the antibodies of the present invention are combined with natural ligands to activate MuSK (i.e., MuSK phosphorylation) to>100% of endogenous activation levels, such as at least 110%, 130%, 150%, 200% of endogenous activation levels.

[0064] Thus, in one embodiment, the activities of the MuSK antibody-based molecules of the invention include: (i) binding to an epitope of human muscle-specific tyrosine protein kinase (MuSK) present in the MuSK frizzled (Fz)-like domain sequence of SEQ ID NO: 130, wherein the antibody-based molecule induces MuSK phosphorylation upon binding to its epitope, and / or (ii) binding to the MuSK Fz-like domain does not block, hinder or inhibit phosphorylation induced by a natural or endogenous MuSK ligand, and may enhance phosphorylation induced by the natural or endogenous MuSK ligand, and (iii) binding to the MuSK Fz-like domain occurs with a higher affinity at neutral pH than at acidic pH. All of these features have been further defined herein.

[0065] Antibody-based molecules include, but are not limited to, antibodies, complete antibodies, epitope binding fragments of complete antibodies, antigen binding fragments of complete antibodies, and antibody derivatives. The epitope binding fragment of an antibody can be obtained by the actual fragmentation of a parent antibody (e.g., Fab or (Fab)2 fragment). Alternatively, an epitope binding fragment is an amino acid sequence comprising a part of the amino acid sequence of such a parent antibody. As used herein, if a molecule is obtained by the actual chemical modification of a parent antibody or a portion thereof, or if the amino acid sequence it comprises is substantially similar to the amino acid sequence of such a parent antibody or its associated portion (e.g., less than 30%, less than 20%, less than 10% or less than 5% with such a parent molecule or such its associated portion, or the difference with such a parent molecule or its associated portion is 10 amino acid residues or less than 10, 9, 8, 7, 6, 5, 4, 3 or 2 amino acid residues), the molecule is referred to as an antibody (or its associated portion) "derivative".

[0066] In some embodiments, the antibody-based molecules of the present invention are complete immunoglobulins or molecules with epitope binding 333 amino acids encoding such fragments in recombinant cells (see, e.g., Evans et al. "Rapid Expression Of An Anti-Human C5 Chimeric Fab Utilizing A Vector That Replicates In COS And 293 Cells," J. Immunol. Meth. 184: 123-38 (1995), which is hereby incorporated by reference in its entirety). For example, a chimeric gene encoding a portion of a F(ab')2 fragment may include DNA sequences encoding a CH1 domain and a heavy chain hinge region, followed by a translation stop codon to produce such truncated antibody fragment molecules. Suitable fragments capable of binding to a desired epitope can be easily screened for use in the same manner as complete antibodies.

[0067] Antibody derivatives include those molecules containing at least one epitope binding domain of an antibody and are typically formed using recombinant techniques. An exemplary antibody derivative includes single-chain Fv (scFv). ScFv is formed by two domains, VL and VH, of the Fv fragment, which may be encoded by different genes. Using recombinant methods, such gene sequences or their encoding cDNAs are linked by flexible linkers (usually having about 10, 12, 15 or more amino acid residues), which enables them to be made into a single protein chain in which VL and VH associate to form a monovalent epitope binding molecule (see, e.g., Bird et al. "Single-Chain Antigen-Binding Proteins," Science 242:423-426 (1988); and Huston et al. "Protein Engineering Of Antibody Binding Sites: Recovery Of Specific Activity In An Anti-Digoxin Single-Chain Fv Analogue Produced In Escherichiacoli," Proc. Natl. Acad. Sci. (USA) 85:5879-5883 (1988), which are hereby incorporated by reference in their entireties). Alternatively, by using a flexible linker that is not too short (e.g., not less than about 9 residues) to enable the VL and VH of different single polypeptide chains to associate together, it is possible to form a bispecific antibody with binding specificities for two different epitopes.

[0068] In another embodiment, the antibody derivative is a divalent or bivalent single-chain variable fragment, which is modified by connecting two scFvs in series (i.e., tandem scFvs) or dimerizing them to form a diabody (Holliger et al. "'Diabodies': Small Bivalent And Bispecific Antibody Fragments," Proc. Natl. Acad. Sci. (USA) 90 (14), 6444-8 (1993), which is hereby incorporated by reference in its entirety). In yet another embodiment, the antibody is a triabody, i.e., a trivalent single-chain variable fragment, which is modified by connecting three scFvs in series or in a trimer form to form a triabody. In another embodiment, the antibody is a tetrabody of four single-chain variable fragments. In another embodiment, the antibody is a "linear antibody", which is an antibody comprising a tandem Fd segment pair (VH-CH1-VH-CH1) that forms an antigen binding region pair (see Zapata et al. Protein Eng. 8(10): 1057-1062 (1995), which is incorporated herein by reference in its entirety). In another embodiment, the antibody derivative is a minibody, which consists of a single-chain Fv region coupled to a CH3 region (i.e., scFv-CH3).

[0069] These and other useful antibody fragments and derivatives in the context of the present invention are also discussed herein. It should also be understood that, unless otherwise indicated, the term antibody-based molecule also includes antibody-like polypeptides, such as chimeric antibodies and humanized antibodies, antigen-binding fragments, and antibody fragments (epitope binding fragments, antigen-binding fragments, or functional fragments) that retain the ability to specifically bind to an antigen, which are provided by any known technology, such as enzymatic cleavage, peptide synthesis, and recombinant technology.

[0070] As used herein, the antibodies produced can be of any isotype. "Isotype" as used herein refers to the immunoglobulin class (e.g., IgG1, IgG2, IgG3, IgG4, IgD, IgA, IgE, or IgM) encoded by the heavy chain constant region gene. The selection of isotype is usually guided by the desired effector function, such as antibody-dependent cellular cytotoxicity (ADCC) induction. Exemplary isotypes are IgG1, IgG2, IgG3, and IgG4. Particularly useful isotypes of the MuSK antibodies disclosed herein include IgG1 and IgG2.

[0071] Human light chain constant regions κ or λ can be used. If desired, the class of the MuSK antibody of the present invention can be converted by known methods. For example, an antibody of the present invention that was originally IgM can be converted to an IgG antibody of the present invention. In addition, class switching technology can be used to convert one IgG subclass to another, such as from IgG1 to IgG2. Therefore, the effector function of the antibody of the present invention can be changed to, for example, IgG1, IgG2, IgG3, IgG4, IgD, IgA, IgE or IgM antibodies for a variety of therapeutic uses by isotype switching.

[0072] In one embodiment, one, two or more amino acid substitutions are introduced into the IgG constant region Fc region to alter the effector function of the antibody-based molecule. For example, a polypeptide selected from the group consisting of polypeptides according to the EU numbering system ( https: / / www.imgt.org / IMGTScientificChart / Hu IGHGnber.html#notesand Edelman, GM et al., Proc. Natl. Acad. USA, 63, 78-85 (1969). PMID: 5257969) numbered amino acid residues 234, 235, 236, 237, 238, 239, 243, 265, 267, 268, 292, 297, 300, 318, 320, 322, 327, 328, 329, 330, 331, 332 and 396 are replaced with different amino acid residues so that the antibody-based molecule has an altered affinity for the effector ligand but retains antigen binding ability. In one embodiment, amino acid 234 or 235 has been replaced. In another embodiment, amino acids 234 and 235 have been replaced. In this context, the preferred amino acid sequence of the human IgG constant Fc region comprises SEQ ID NO: 266 or SEQ ID NO: 267. In this context, for example, amino acids 234 and 235 numbered according to the EU numbering system correspond to amino acids 7 and 8 in SEQ ID NOs: 266 and 267 (i.e., human IgG constant Fc regions of antibody-based molecules disclosed herein), or amino acids 234 and 235 numbered according to the EU numbering system correspond to amino acids 238 and 239 in SEQ ID NOs: 268 and 270 (i.e., human full-length heavy chains of antibody-based molecules disclosed herein). The positions are usually different because the lengths of the variable regions are different, which introduces a "delta" in the numbering. In the case described above, this delta is 4. Thus, when identifying the corresponding position in SEQ ID NO: 266 or SEQ ID NO: 267 or SEQ ID NO: 268 or SEQ ID NO: 270, the same is true for the other amino acid positions identified above (i.e., 236, 237, 238, 239, 243, 265, 267, 268, 292, 297, 300, 318, 320, 322, 327, 328, 329, 330, 331, 332, and 396). In the application as filed, the position of the amino acid may be referred to using the EU numbering system or using the actual position in a given Fc region (e.g., SEQ ID NO: 266 or SEQ ID NO: 267) or in a full-length heavy chain (e.g., SEQ ID NO: 268 or 270).

[0073] Thus, in one embodiment, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or 17 amino acid substitutions are introduced into SEQ ID NO: 266 or SEQ ID NO: 267. In one embodiment, 1, 2, 3, 4 amino acid substitutions are introduced into SEQ ID NO: 266 or SEQ ID NO: 267. In one embodiment, 1 or 2 amino acid substitutions are introduced into SEQ ID NO: 266 or SEQ ID NO: 267. Thus, in one embodiment, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or 17 amino acid substitutions are introduced into SEQ ID NO: 266 or SEQ ID NO: 267 and the substitutions are introduced at an amino acid position selected from amino acid residues 234, 235, 236, 237, 239, 243, 267, 292, 297, 300, 318, 320, 322, 328, 330, 332 and 396 of said sequence as numbered according to the EU numbering system. In one embodiment, 1 or 2 amino acid substitutions are introduced into SEQ ID NO: 266 or SEQ ID NO: 267. In one embodiment, amino acid 234 or 235 of SEQ ID NO: 266 or SEQ ID NO: 267 has been substituted as numbered according to the EU numbering system. In another embodiment, amino acid 234 or 235 of SEQ ID NO: 266 and 267, numbered according to the EU numbering system, has been substituted.

[0074] The effector ligand with which affinity is changed can be, for example, an Fc receptor or the C1 component of complement. The method is described in more detail in the following: U.S. Patent Nos. 5,624,821 and 5,648,260, each of which is incorporated herein by reference in its entirety. In one embodiment, one or more amino acid substitutions can be introduced into the Fc region of the antibody-based molecule described herein to remove potential glycosylation sites on the Fc region, which can reduce Fc receptor binding (see, for example, Shields R Let al., (2001) J Biol Chem 276: 6591-604, which is incorporated herein by reference in its entirety). In one embodiment, the binding to the same ligand is reduced by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or is no longer detectable compared to the binding of an antibody without any amino acid substitutions in its human IgG constant Fc region to an effector ligand.

[0075] In a first embodiment, one or more of the following mutations have been introduced into the constant region of an antibody-based molecule described herein (all numbered according to the EU numbering system): N297A substitution; N297Q substitution; L234A substitution; L234D substitution; L234E substitution; L234G substitution; L234H substitution; L234F substitution; L234K substitution; L234Q substitution; L234R substitution; L234S substitution; L234T substitution; L235A substitution; L235D substitution; L235E substitution; L235F substitution; L235G substitution; L235V substitution; L235H substitution; L235I substitution; L235K substitution; L235R substitution; L235S substitution; L235T substitution; 35S replacement; L235T replacement; L235Q replacement; L237A replacement; S239D replacement; E233P replacement; L234V replacement; C236 deletion; G236E replacement; G236R replacement; G236K replacement; G237A replacement; P238A replacement; F243L replacement; D265A replacement; S267E replacement; H268A replacement; R292P replacement; Y300L replacement; K322A replacement; K322Q replacement; A327Q replacement; L328F replacement; L328R replacement; P329A replacement; P329G replacement; A330L replacement; A330S replacement; P331S replacement; I332E replacement or P396L replacement.

[0076] In a second embodiment, one or more of the following mutations have been introduced into the constant region of an antibody-based molecule described herein (all numbered according to the EU numbering system): L234A and / or L235A substitution; L234A and L235A substitution; L234A, L235A and P329G substitution; L234A, L235A and G236K substitution; L234A, L235A and G236E substitution; L234A, L235A and G236R substitution; L234A and G236R substitution; L234A, L235S and G236R substitution; L234A, L235T and G236R substitution; L234D, L235H and G236R substitution; L234 D, L235K and G236R replacement; L234D and G236R replacement; L234D, L235Q and G236R replacement; L234D, L235S and G236R replacement; L234E, L235D and G236R replacement; L234E, L235H and G236R replacement; L234E, L235I and G236R replacement; L234G, L235H and G236R replacement; L234G, L235Q and G236R replacement; L234G, L235S and G236R replacement; L234H, L235I and G236R replacement; L234H, L235S and G236R replacement; L234K, L235Q and G236 R replacement; L234K, L235R and G236R replacement; L234K, L235S and G236R replacement; L234K, L235T and G236R replacement; L234K, L235V and G236R replacement; L234Q, L235A and G236R replacement; L234Q, L235D and G236R replacement; L234Q, L235H and G236R replacement; L234Q and G236R replacement; L234Q, L235Q and G236R replacement; L234Q, L235R and G236R replacement; L234Q, L235S and G236R replacement; L234Q, L235T and G236R replacement; L234Q, L235 35V and G236R replaced; L234R, L235D and G236R replaced; L234R, L235E and G236R replaced; L234R, L235H and G236R replaced; L234R, L235I and G236R replaced; L234R, L235K and G236R replaced; L234R and G236R replaced; L234R, L235Q and G236R replaced; L234R, L235R and G236R replaced; L234R, L235T and G236R replaced; L234S, L235E and G236R replaced; L234S, L235G and G236R replaced; L234S, L235H and G236R replaced;L234S, L235I and G236R replaced; L234S and G236R replaced; L234S, L235R and G236R replaced; L234S, L235T and G236R replaced; L234S, L235V and G236R replaced; L234T, L235A and G236R replaced; L234T, L235D and G236R, L234T, L235H and G236R replaced; L234T, L235I and G236R replaced; L234T, L235K and G236R replaced; L234T, L235Q and G236R replaced ; L234T, L235R and G236R substitution; L234T, L235S and G236R substitution; L234T, L235T and G236R substitution; L234T, L235V and G236R substitution; G236R and L328R substitution; L234A, L235A, G237A, P238S, H268A, A330S and P331S substitution; E233P, L234V, L235A, G326 deletion, A327G, A330S and P331S substitution; L235A and G236R substitution; L235S and G236R substitution. ;

[0077] In a third embodiment, one or more of the following mutations have been introduced into the Fc region of an antibody-based molecule described herein, SEQ ID NO: 266 or SEQ ID NO: 267 (both numbered according to the EU numbering system): N297A substitution; N297Q substitution; L234A substitution; L234D substitution; L234E substitution; L234G substitution; L234H substitution; L234F substitution; L234K substitution; L234Q substitution; L234R substitution; L234S substitution; L234T substitution; L235A substitution; L235D substitution; L235E substitution; L235F substitution; L235G substitution; L235V substitution; L235H substitution; L235I substitution; L235K substitution; L235R substitution; L235S substitution; L235T substitution; L235Q Replacement; L237A replacement; S239D replacement; E233P replacement; L234V replacement; C236 deletion; G236E replacement; G236R replacement; G236K replacement; G237A replacement; P238A replacement; F243L replacement; D265A replacement; S267E replacement; H268A replacement; R292P replacement; Y300L replacement; K322A replacement; K322Q replacement; A327Q replacement; L328F replacement; L328R replacement; P329A replacement; P329G replacement; A330L replacement; A330S replacement; P331S replacement; I332E replacement or P396L replacement.

[0078] In a fourth embodiment, one or more of the following mutations have been introduced into the Fc region of an antibody-based molecule described herein: SEQ ID NO: 266 or SEQ ID NO:267 (all numbered according to the EU numbering system): L234A and / or L235A replacement; L234A and L235A replacement; L234A, L235A and P329G replacement; L234A, L235A and G236K replacement; L234A, L235A and G236E replacement; L234A, L235A and G236R replacement; L234A and G236R replacement; L234A, L235S and G236R replacement; L234A, L235T and G236R replacement; L234D, L235H and G236R replacement; L234D, L235K and G236R replacement; L234D and G236R replacement; L234D, L235Q and G236R replacement; L234D, L235S and G236R replacement; L234E, L235D and G236R replacement; L234E, L235H and G236R replacement; L234E, L235I and G236R replacement; L234G, L235H and G236R replacement; L234G, L235Q and G236R replacement; L234G, L235S and G236R replacement; L234H, L235I and G236R replacement; L234H, L235S and G236R replacement; L234K, L235Q and G236R replacement; L234 K, L235R and G236R replacement; L234K, L235S and G236R replacement; L234K, L235T and G236R replacement; L234K, L235V and G236R replacement; L234Q, L235A and G236R replacement; L234Q, L235D and G236R replacement; L234Q, L235H and G236R replacement; L234Q and G236R replacement; L234Q, L235Q and G236R replacement; L234Q, L235R and G236R replacement; L234Q, L235S and G236R replacement; L234Q, L235T and G236R replacement; L2 34Q, L235V and G236R replaced; L234R, L235D and G236R replaced; L234R, L235E and G236R replaced; L234R, L235H and G236R replaced; L234R, L235I and G236R replaced; L234R, L235K and G236R replaced; L234R and G236R replaced; L234R, L235Q and G236R replaced; L234R, L235R and G236R replaced; L234R, L235T and G236R replaced; L234S, L235E and G236R replaced; L234S, L235G and G236R replaced;L234S, L235H and G236R replaced; L234S, L235I and G236R replaced; L234S and G236R replaced; L234S, L235R and G236R replaced; L234S, L235T and G236R replaced; L234S, L235V and G236R replaced; L234T, L235A and G236R replaced; L234T, L235D and G236R, L234T, L235H and G236R replaced; L234T, L235I and G236R replaced; L234T, L235K and G236R replaced; L234T, L235 5Q and G236R substitution; L234T, L235R and G236R substitution; L234T, L235S and G236R substitution; L234T, L235T and G236R substitution; L234T, L235V and G236R substitution; G236R and L328R substitution; L234A, L235A, G237A, P238S, H268A, A330S and P331S substitution; E233P, L234V, L235A, G326 deletion, A327G, A330S and P331S substitution; L235A and G236R substitution; L235S and G236R substitution. ;

[0079] In one embodiment, one or more of the following mutations are introduced into the Fc region of an antibody-based molecule described herein, SEQ ID NO: 266 or SEQ ID NO: 267: L234A and / or L235A substitutions (both numbered according to the EU numbering system). In one embodiment, the following mutations are introduced into the Fc region of an antibody-based molecule described herein, SEQ ID NO: 266 or SEQ ID NO: 267: L234A and L235A substitutions, both numbered according to the EU numbering system. This embodiment produces an antibody-based molecule having a heavy chain represented by SEQ ID NO: 268 or SEQ ID NO: 270.

[0080] In the context of the present invention, such antibodies with altered, reduced or even abolished effector function are attractive.

[0081] In one embodiment, an anti-MuSK antibody or antigen-binding fragment thereof is provided, which: - is an agonist MuSK antibody and / or

[0082] -Effector function has been reduced or eliminated.

[0083] The antibodies or antigen-binding fragments thereof are preferably used to treat a neuromuscular disorder in a human subject.

[0084] In one embodiment, an anti-MuSK antibody or antigen-binding fragment thereof is provided which: - binds to the MuSK frizzled (Fz)-like domain sequence of SEQ ID NO: 129,

[0085] - is an agonist MuSK antibody and / or

[0086] -Effector function has been reduced or eliminated.

[0087] The antibodies or antigen-binding fragments thereof are preferably used to treat a neuromuscular disorder in a human subject.

[0088] As previously described herein, reduced or eliminated effector function can be obtained by introducing mutations into the human IgG constant Fc region. Preferably, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or 17 amino acid substitutions are introduced into the Fc region. Preferably, at least 1, 2, 3, 4 amino acid substitutions are introduced into the Fc region.

[0089] The Fc region may comprise SEQ ID NO: 266 or SEQ ID NO: 267 and the substitution is introduced at an amino acid position selected from amino acid residues 234, 235, 236, 237, 238, 239, 243, 265, 267, 268, 292, 297, 300, 318, 320, 322, 327, 328, 329, 330, 331, 332 and 396 of said sequence according to the EU numbering system.

[0090] In one embodiment, the Fc region may comprise SEQ ID NO: 266 or SEQ ID NO: 267 and the substitution is introduced at an amino acid position selected from amino acid residue 234 or 235 of said sequence according to the EU numbering system.

[0091] In one embodiment, the Fc region may comprise SEQ ID NO: 266 or SEQ ID NO: 267 and the substitution is introduced at an amino acid position selected from amino acid residues 234 and 235 of said sequence according to the EU numbering system.

[0092] In one embodiment, one or more of the following mutations (all numbered according to the EU numbering system) have been introduced into a human IgG constant Fc region of an antibody-based molecule described herein, SEQ ID NO: 266 or SEQ ID NO: 267: N297A substitution; N297Q substitution; L234A substitution; L234D substitution; L234E substitution; L234G substitution; L234H substitution; L234F substitution; L234K substitution; L234Q substitution; L234R substitution; L234S substitution; L234T substitution; L235A substitution; L235D substitution; L235E substitution; L235F substitution; L235G substitution; L235V substitution; L235H substitution; L235I substitution; L235K substitution; L235R substitution; L235S substitution; L235T substitution; L235Q substitution; L235 7A replacement; S239D replacement; E233P replacement; L234V replacement; C236 deletion; G236E replacement; G236R replacement; G236K replacement; G237A replacement; P238A replacement; F243L replacement; D265A replacement; S267E replacement; H268A replacement; R292P replacement; Y300L replacement; K322A replacement; K322Q replacement; A327Q replacement; L328F replacement; L328R replacement; P329A replacement; P329G replacement; A330L replacement; A330S replacement; P331S replacement; I332E replacement or P396L replacement.

[0093] In one embodiment, each of the combinations of mutations previously described in the fourth embodiment of the present application in the human IgG constant Fc region of the antibody-based molecules described herein may be prepared.

[0094] In a preferred embodiment, L234A or L235A substitutions are introduced into the human IgG constant Fc region of the antibody-based molecules described herein. In a more preferred embodiment, L234A and L235A substitutions are introduced into the human IgG constant Fc region of the antibody-based molecules described herein. This embodiment produces an antibody-based molecule having a heavy chain represented by SEQ ID NO: 268 or SEQ ID NO: 270.

[0095] In an even more preferred embodiment, the anti-MuSK antibody or antigen-binding fragment thereof comprises:

[0096] a) a heavy chain variable domain (VH) comprising an amino acid sequence having at least 80% identity or similarity to SEQ ID NO: 234 and

[0097] b) a light chain variable domain (VL) comprising an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 235.

[0098] In this context, the identity or similarity is at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%.

[0099] Preferred anti-MuSK antibodies or antigen-binding fragments thereof comprise:

[0100] a) a full-length heavy chain comprising SEQ ID NO: 268 and

[0101] b) the full length light chain comprising SEQ ID NO:269.

[0102] Preferred anti-MuSK antibodies or antigen-binding fragments thereof comprise:

[0103] a) a full-length heavy chain comprising SEQ ID NO: 270 and

[0104] b) the full length light chain comprising SEQ ID NO:271.

[0105] In one embodiment, the antibody-based molecules of the present invention are "humanized", especially if they are to be used for therapeutic purposes. The term "humanization" refers to a chimeric molecule, usually prepared using recombinant techniques, having an antigen binding site derived from an immunoglobulin from a non-human species and a remaining immunoglobulin structure based on the structure and / or sequence of a human immunoglobulin. The antigen binding site may comprise a complete non-human antibody variable domain fused to a human constant domain, or only the complementarity determining region (CDR) of such a variable domain grafted to an appropriate human framework region of a human variable domain. The framework residues of such a humanized molecule may be wild-type (e.g., fully human), or they may be modified to comprise one or more amino acid substitutions not present in a human antibody (the sequence of which has been used as the basis for humanization). Humanization reduces or eliminates the likelihood that the constant region of the molecule will act as an immunogen in a human individual, but the likelihood of an immune response to the foreign variable region remains unchanged (LoBuglio, AF et al. "Mouse / Human Chimeric Monoclonal Antibody In Man: Kinetics And Immune Response," Proc. Natl. Acad. Sci. USA 86: 4220-4224 (1989), which is hereby incorporated by reference in its entirety). Another approach focuses not only on providing constant regions of human origin, but also on modifying the variable regions to reconstruct them as close to human form as possible. The variable regions of both the heavy and light chains contain three complementarity determining regions (CDRs), which vary in response to the antigen in question and determine the binding ability. The CDRs are flanked by four framework regions (FRs), which are relatively conserved in a given species and are assumed to provide a scaffold for the CDRs. When a non-human antibody is prepared against a specific antigen, the variable region can be "reconstructed" or "humanized" by grafting the CDRs derived from the non-human antibody onto the FRs present in the human antibody to be modified. Suitable methods for humanizing the non-human antibodies described herein are known in the art, see e.g.

[0106] Sato,K.et al.,Cancer Res 53;851-856(1993);Riechmann,L et al.,“Reshaping Human Antibodies for Therapy,”Nature 332:323-327(1988);Verhoeyen,M.et al.,“Reshaping Human Antibodies:Grafting An Antilysozyme Activity,”Science 239:1534-1536(1988);Kettleborough,C.A.et al.,“Humanization OfA MouseMonoclonal Antibody By CDR-Grafting:The Importance Of Framework Residues OnLoop Conformation,”Protein Engineering 4:773-3783(1991);Maeda,H.et al.,“Construction Of Reshaped Human Antibodies With HIV-Neutralizing Activity,”Human Antibodies Hybridoma 2:124-134(1991);Gorman,S.D.et al.,“Reshaping ATherapeutic CD4 Antibody,”Proc.Natl.Acad.Sci.USA 88:4181-4185(1991);Tempest,P.R.et al.,“Reshaping A Human Monoclonal Antibody To Inhibit HumanRespiratory Syncytial Virus Infection In Vivo,"Bio / Technology 9:266-271(1991);Co,M.S.et al.,“Humanized Antibodies For Antiviral Therapy,”Proc.Natl.Acad.Sci.USA 88:2869-2873(1991);Ca rter,P.et al.,“Humanization OfAnAnti-p185her2Antibody For Human CancerTherapy,”Proc Natl.Acad.Sci.USA 89: 4285-4289 (1992); and Co, MS et al., "Chimeric And Humanized Antibodies WithSpecificity For The CD33 Antigen," J. Immunol. 148: 1149-1154 (1992).

[0107] , which is hereby incorporated by reference in its entirety. In some embodiments, the humanized MuSK antibodies of the present invention retain all CDR sequences (e.g., humanized antibodies comprising all six CDRs from llama or mouse antibodies). In other embodiments, the humanized MuSK antibodies of the present invention have one or more CDRs (one, two, three, four, five, six) that are changed relative to the original antibody. Methods for humanizing antibodies are well known in the art and are suitable for humanizing the antibodies disclosed herein (see, e.g., U.S. Pat. No. 5,225,539 to Winter; U.S. Pat. Nos. 5,530,101 and 5,585,089 to Queen and Selick; U.S. Pat. No. 5,859,205 to Robert et al.; U.S. Pat. No. 6,407,213 to Carter; and U.S. Pat. No. 6,881,557 to Foote, which are hereby incorporated by reference in their entirety).

[0108] In some antibodies, only a portion of the CDRs, a subset of CDR residues required for binding called "specificity determining residues" (SDRs), are needed to maintain antibody binding. CDR residues that do not contact the antigen and are not in the SDR can be identified based on previous studies of Kabat CDR regions outside the Chothia hypervariable loops (see Kabat et al., Sequences of Proteins of Immunological Interest. National Institutes of Health Publication No. 91-3242 (1992); Chothia, C. et al., "Canonical Structures For The Hypervariable Regions Of Immunoglobulins," J. Mol. Biol. 196:901-917 (1987), which are incorporated herein by reference in their entireties), by molecular modeling and / or empirically or as described in Gonzales, NR et al., "SDR Grafting Of A Murine Antibody Using Multiple Human Germline Templates To Minimize Its Immunogenicity," Mol. Immunol. 41:863-872 (2004), which are incorporated herein by reference in their entireties. In such a humanized antibody, at a position where one or more donor CDR residues do not exist or where the entire donor CDR is omitted, the amino acid residue occupying the position may be the amino acid residue occupying the corresponding position in the acceptor antibody sequence (by Kabat numbering). The number of such replacements of the acceptor of the donor amino acid in the included CDR reflects the balance of competitive considerations. Such replacements may be beneficial for reducing the number of non-human amino acids in the humanized antibody, and thereby reduce potential immunogenicity. However, replacements may also cause changes in affinity, and preferably avoid a significant reduction in affinity. Replacements may also result in changes in activity. It is also preferred to avoid such replacements that result in a significant reduction in activity. In this case, the antibody or antibody fragment should still exhibit the detectable activity of the antibody as defined earlier herein or at least exhibit the activity of the antibody to a certain extent. The replacement position in the CDR and the amino acid to be replaced may also be selected empirically.

[0109] Phage display technology can be used alternatively to improve (or reduce) the CDR affinity of the antibody-based molecule of the present invention. This technology (called affinity maturation) adopts mutagenesis or "CDR walking" and uses the target antigen or its antigen fragment for reselection to identify the antibody with CDR that binds to the antigen with higher (or lower) affinity when compared with the initial or parent antibody (see, for example, Glaser et al., "Antibody Engineering By Codon-Based Mutagenesis In A Filamentous Phage Vector System," J. Immunology 149: 3903-3913 (1992), which is hereby incorporated by reference as a whole). Mutagenesis of the entire codon rather than a single nucleotide leads to a semi-random library of amino acid mutations. The library can be composed of a variant clone library, each variant clone differs from another member of such a library in that a single amino acid in a single CDR is changed, and it contains variants that may represent each possible amino acid replacement of each CDR residue. Can be by immobilized mutant and labeled antigen contact to screen for the mutant with improved (or reduced) binding affinity to antigen.Any screening method known in the art can be used to identify the binding molecule (for example, ELISA) based on variant antibody with improved or reduced affinity to antigen (see Wu, H. et al., "Stepwise In Vitro Affinity Maturation Of Vitaxin, An Alphav Beta3-Specific Humanized mAb," Proc. Natl. Acad. Sci. USA 95: 6037-6042 (1998); Yelton et al., "Affinity Maturation Of The BR96 Anti-Carcinoma Antibody By Codon-Based Mutagenesis," J. Immunology 155: 1994 (1995), which is hereby incorporated by reference in its entirety).“CDR walking” to randomize the light chain can be used (see Schier, R. et al., “Isolation Of Picomolar Affinity Anti-c-erbB-2 Single-Chain Fv By Molecular Evolution Of The Complementarity Determining Regions In The Center Of The Antibody Binding Site,” J. Mol. Biol. 263:551-567 (1996), which is hereby incorporated by reference in its entirety).

[0110] Methods for affinity maturation of MuSK antibody molecules are described herein and disclosed in e.g.

[0111] Krause,J.C.et al.,“An Insertion Mutation T hat Distorts AntibodyBinding Site Arcnitecture Enhances Function of a Human Antibody,”MBio.2(1):e00345-10(2011);Kuan,C.T.et al.,“Affinity-Matured Anti-Glycoprotein NMBRecombinant Immunotoxins Targeting Malignant Gliomas And Melanomas,”Int.J.Cancer 10.1002 / ijc.25645(2010);Hackel,B.J.et al.,“Stability And CDRComposition Biases Enrich Binder Functionality Landscapes,”J.Mol.Biol.401(1):84-96(2010);Montgomery,D.L.et al.,“Affinity Maturation And CharacterizationOf A Human Monoclonal Antibody Against HlV-1gp41.”MAbs1(5):462-474(2009);Gustchina,E.et al.,“Affinity Maturation By Targeted Diversification Of TheCDR-H2Loop Of A Monoclonal Fab Derived From A Synthetic Human AntibodyLibrary And Directed Against The Internal Trimeric Coiled-Coil Of Gp41 YieldsA Set Of Fabs With Improved HIV-1Neutralization Potency And Breadth," Virology393(1):112-119(2009); Finlay, WJ.et al., "Affinity Maturation Of A Humanized RatAntibody For Anti-RAGE Therapy: Comprehensive Mutagenesis Reveals A High LevelOf Mutational Plasticity Both Inside And Outside The Complementarity-Determining Regions," J.Mol.Biol.388(3):541-558(2009); Bostrom, J.et al., "Improving Antibody Binding Affinity And Specificity For TherapeuticDevelopment," Methods Mol. Biol. 525: 353-376 (2009); Steidl, S. et al., "ln VitroAffinity Maturation Of Human GM-CSF Antibodies By Targeted CDR-Diversification," Mol.Immunol.46(1):135-144(2008); and Barderas, R.et al., "Affinity Maturation Of Antibodies Assisted By ln Silico Modeling," Proc.Natl.Acad.Sci.USA 105(26):9029-9034(2008),

[0112] It is hereby incorporated by reference in its entirety.

[0113] In the context of the present application, an amino acid alteration (change or modification) may be an amino acid substitution, addition, deletion or chemical modification.

[0114] In one embodiment, a MuSK antibody-based molecule as described herein comprises the amino acid sequences of any one, any two, any three, any four, any five, or any six of the CDRs as provided in Tables 1 and 2 herein.

[0115] In one embodiment, the antibody-based molecule that binds to human muscle-specific tyrosine protein kinase (MuSK) comprises a heavy chain variable domain, wherein the heavy chain variable domain comprises:

[0116] (i) a complementarity determining region 1 (CDR-H1) comprising an amino acid sequence of any one of SEQ ID NOs: 1 to 16, 135, 136, 147 to 149, or a modified amino acid sequence of any one of SEQ ID NOs: 1 to 16, 135, 136, 147 to 149, wherein the modified sequence has 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NOs: 1 to 16, 135, 136, 147 to 149; (ii) a complementarity determining region 2 (CDR-H2) comprising an amino acid sequence of any one of SEQ ID NOs: 17 to 32, 137, 138, 150 to 155, or a modified amino acid sequence of any one of SEQ ID NOs: 17 to 32, 137, 138, 150 to 155, wherein the modified sequence has 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NOs: NOs: 17 to 32, 137, 138, 150 to 155 have 1, 2, 3, 4 or 5 amino acid changes; and

[0117] (iii) a complementarity determining region 3 (CDR-H3) comprising an amino acid sequence of any one of SEQ ID NOs: 33 to 48, 139, 140, 156 to 158, 240 to 251, or a modified amino acid sequence of any one of SEQ ID NOs: 33 to 48, 139, 140, 156 to 158, or 240 to 251, wherein the modified sequence has 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NOs: 33 to 48, 139, 140, 156 to 158, or 240 to 251.

[0118] In one embodiment, an antibody-based molecule that binds to human muscle-specific tyrosine protein kinase (MuSK) comprises: (i) a heavy chain variable domain comprising: a CDR-H1 of SEQ ID NO: 1 or a CDR-H1 having 1, 2, 3, 4, or 5 amino acid changes relative to SEQ ID NO: 1, a CDR-H2 of SEQ ID NO: 17 or a CDR-H2 having 1, 2, 3, 4, or 5 amino acid changes relative to SEQ ID NO: 17, and a CDR-H3 of SEQ ID NO: 33 or a CDR-H3 having 1, 2, 3, 4, or 5 amino acid changes relative to SEQ ID NO: 33; (ii) a heavy chain variable domain comprising: a CDR-H1 of SEQ ID NO: 2 or a CDR-H1 having 1, 2, 3, 4, or 5 amino acid changes relative to SEQ ID NO: 2, a CDR-H2 of SEQ ID NO: 18 or a CDR-H2 having 1, 2, 3, 4, or 5 amino acid changes relative to SEQ ID NO: 18, and a CDR-H3 of SEQ ID NO: 33 or a CDR-H3 having 1, 2, 3, 4, or 5 amino acid changes relative to SEQ ID NO: 33. (iii) a heavy chain variable domain comprising: a CDR-H1 of SEQ ID NO:3 or a CDR-H1 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:3, a CDR-H2 of SEQ ID NO:19 or a CDR-H2 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:19, and a CDR-H3 of SEQ ID NO:35 or a CDR-H3 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:35; (iv) a heavy chain variable domain comprising: a CDR-H1 of SEQ ID NO:4 or a CDR-H1 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:4, a CDR-H2 of SEQ ID NO:20 or a CDR-H2 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:20 ID NO:20 having 1, 2, 3, 4 or 5 amino acid changes in CDR-H2, and SEQ ID NO:36 CDR-H3 or SEQ ID NO:36 having 1, 2, 3, 4 or 5 amino acid changes in CDR-H3;(v) a heavy chain variable domain comprising: a CDR-H1 of SEQ ID NO:5 or a CDR-H1 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:5, a CDR-H2 of SEQ ID NO:21 or a CDR-H2 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:21, and a CDR-H3 of SEQ ID NO:37 or a CDR-H3 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:37; (vi) a heavy chain variable domain comprising: a CDR-H1 of SEQ ID NO:6 or a CDR-H1 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:6, a CDR-H2 of SEQ ID NO:22 or a CDR-H2 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:22, and a CDR-H3 of SEQ ID NO:38 or a CDR-H3 of SEQ ID NO:39. NO:38 has a CDR-H3 with 1, 2, 3, 4 or 5 amino acid changes; (vii) a heavy chain variable domain comprising: the CDR-H1 of SEQ ID NO:7 or a CDR-H1 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:7, the CDR-H2 of SEQ ID NO:23 or a CDR-H2 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:23, and the CDR-H3 of SEQ ID NO:39 or a CDR-H3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:39; (viii) a heavy chain variable domain comprising: the CDR-H1 of SEQ ID NO:8 or a CDR-H1 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:8, the CDR-H2 of SEQ ID NO:24 or a CDR-H2 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: NO:24 has a CDR-H2 with 1, 2, 3, 4 or 5 amino acid changes, and SEQ ID NO:40 CDR-H3 or a CDR-H3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:40; (ix) a heavy chain variable domain comprising: SEQ ID NO:9 CDR-H1 or a CDR-H1 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:9, SEQ ID NO:25 CDR-H2 or a CDR-H2 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:25, and SEQ ID NO:41 CDR-H3 or a CDR-H3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:41;(x) a heavy chain variable domain comprising: a CDR-H1 of SEQ ID NO:10 or a CDR-H1 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:10, a CDR-H2 of SEQ ID NO:26 or a CDR-H2 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:26, and a CDR-H3 of SEQ ID NO:42 or a CDR-H3 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:42; (xi) a heavy chain variable domain comprising: a CDR-H1 of SEQ ID NO:11 or a CDR-H1 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:11, a CDR-H2 of SEQ ID NO:27 or a CDR-H2 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:27, and a CDR-H3 of SEQ ID NO:43 or a CDR-H3 of SEQ ID NO:44. NO:43 has a CDR-H3 with 1, 2, 3, 4 or 5 amino acid changes; (xii) a heavy chain variable domain comprising: the CDR-H1 of SEQ ID NO:12 or a CDR-H1 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:12, the CDR-H2 of SEQ ID NO:28 or a CDR-H2 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:28, and the CDR-H3 of SEQ ID NO:44 or a CDR-H3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:44; (xiii) a heavy chain variable domain comprising: the CDR-H1 of SEQ ID NO:13 or a CDR-H1 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:13, the CDR-H2 of SEQ ID NO:29 or a CDR-H2 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: NO:29 having 1, 2, 3, 4 or 5 amino acid changes in CDR-H2, and SEQ ID NO:45 CDR-H3 or CDR-H3 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:45; (xiv) a heavy chain variable domain comprising: SEQ ID NO:14 CDR-H1 or CDR-H1 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:14, SEQ ID NO:30 CDR-H2 or CDR-H2 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:30, and SEQ ID NO:46 CDR-H3 or CDR-H3 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:46;(xv) a heavy chain variable domain comprising: a CDR-H1 of SEQ ID NO:15 or a CDR-H1 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:15, a CDR-H2 of SEQ ID NO:31 or a CDR-H2 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:31, and a CDR-H3 of SEQ ID NO:47 or a CDR-H3 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:47; (xvi) a heavy chain variable domain comprising: a CDR-H1 of SEQ ID NO:16 or a CDR-H1 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:16, a CDR-H2 of SEQ ID NO:32 or a CDR-H2 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:32, and a CDR-H3 of SEQ ID NO:48 or a CDR-H3 of SEQ ID NO:49. NO:48 has a CDR-H3 with 1, 2, 3, 4 or 5 amino acid changes; (xvii) a heavy chain variable domain comprising: CDR-H1 of SEQ ID NO:135 or a CDR-H1 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:135, CDR-H2 of SEQ ID NO:137 or a CDR-H2 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:137, and CDR-H3 of SEQ ID NO:139 or a CDR-H3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:139; and (xviii) a heavy chain variable domain comprising: CDR-H1 of SEQ ID NO:136 or a CDR-H1 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:136, CDR-H2 of SEQ ID NO:138 or a CDR-H2 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:138 NO: 138 has a CDR-H2 with 1, 2, 3, 4 or 5 amino acid changes, and a CDR-H3 of SEQ ID NO: 140 or a CDR-H3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 140. The sequences of the heavy chain CDRs are provided in Table 1. ;

[0119] In one embodiment, an antibody-based molecule that binds to human muscle-specific tyrosine protein kinase (MuSK) comprises: (ii.a) a heavy chain variable domain comprising: CDR-H1 of SEQ ID NO:2 or a CDR-H1 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:2, CDR-H2 of SEQ ID NO:18 or a CDR-H2 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:18, and CDR-H3 (X2m1) of SEQ ID NO:240 or a CDR-H3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:240; (ii.b) a heavy chain variable domain comprising: CDR-H1 of SEQ ID NO:2 or a CDR-H1 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:2, CDR-H2 of SEQ ID NO:18 or a CDR-H2 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: NO:18 has a CDR-H2 with 1, 2, 3, 4 or 5 amino acid changes, and CDR-H3 (X2m2) of SEQ ID NO:241 or a CDR-H3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:241; (ii.c) a heavy chain variable domain comprising: CDR-H1 of SEQ ID NO:2 or a CDR-H1 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:2, CDR-H2 of SEQ ID NO:18 or a CDR-H2 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:18, and CDR-H3 (X2m3) of SEQ ID NO:242 or a CDR-H3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:242; (ii.d) a heavy chain variable domain comprising: CDR-H1 of SEQ ID NO:2 or a CDR-H1 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: NO:2 has 1, 2, 3, 4 or 5 amino acid changes in CDR-H1, SEQ ID NO:18 CDR-H2 or CDR-H2 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:18, and SEQ ID NO:243 CDR-H3 (X2m4) or CDR-H3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:243; (ii.e) a heavy chain variable domain comprising: CDR-H1 of SEQ ID NO:2 or a CDR-H1 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:2, CDR-H2 of SEQ ID NO:18 or a CDR-H2 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:18, and CDR-H3 (X2m5) of SEQ ID NO:244 or a CDR-H3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:244; (ii.f) a heavy chain variable domain comprising: CDR-H1 of SEQ ID NO:2 or a CDR-H1 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:2, CDR-H2 of SEQ ID NO:18 or a CDR-H2 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:18, and NO:245 CDR-H3 (X2m6) or CDR-H3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:245; (ii.g) a heavy chain variable domain comprising: SEQ ID NO:2 CDR-H1 or CDR-H1 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:2, SEQ ID NO:18 CDR-H2 or CDR-H2 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:18, and SEQ ID NO:246 CDR-H3 (X2m7) or CDR-H3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:246; (ii.h) a heavy chain variable domain comprising: SEQ ID NO:2 CDR-H1 or CDR-H1 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:2, SEQ ID NO:18 CDR-H2 or CDR-H2 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:18, and SEQ ID NO:246 CDR-H3 (X2m7) or CDR-H3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:246; CDR-H2 of SEQ ID NO: 18 or CDR-H2 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 18, and CDR-H3 (X2m8) of SEQ ID NO: 247 or CDR-H3 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 247.

[0120] In one embodiment, an antibody-based molecule that binds to human muscle-specific tyrosine protein kinase (MuSK) comprises: (xvii.a) a heavy chain variable domain comprising: CDR-H1 of SEQ ID NO: 135 or a CDR-H1 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 135, CDR-H2 of SEQ ID NO: 137 or a CDR-H2 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 137, and CDR-H3 (X17m1) of SEQ ID NO: 248 or a CDR-H3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 248; (xvii.b) a heavy chain variable domain comprising: CDR-H1 of SEQ ID NO: 135 or a CDR-H1 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 135, CDR-H2 of SEQ ID NO: 137 or a CDR-H2 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 137, and CDR-H3 (X17m1) of SEQ ID NO: 248 or a CDR-H3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 248. NO: 137 or a CDR-H2 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 137, and CDR-H3 (X17m2) of SEQ ID NO: 249 or a CDR-H3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 249; (xvii.c) a heavy chain variable domain comprising: CDR-H1 of SEQ ID NO: 135 or a CDR-H1 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 135, CDR-H2 of SEQ ID NO: 137 or a CDR-H2 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 137, and CDR-H3 (X17m3) of SEQ ID NO: 250 or a CDR-H3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: NO:250 has a CDR-H3 with 1, 2, 3, 4 or 5 amino acid changes; (xvii.d) a heavy chain variable domain, which comprises: CDR-H1 of SEQ ID NO:135 or a CDR-H1 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:135, CDR-H2 of SEQ ID NO:137 or a CDR-H2 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:137, and CDR-H3 (X17m6) of SEQ ID NO:251 or a CDR-H3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:251.

[0121] In one embodiment, an antibody-based molecule that binds to human muscle-specific tyrosine protein kinase (MuSK) comprises a heavy chain variable domain, wherein the heavy chain variable domain comprises: (xix) a heavy chain variable domain comprising: a CDR-H1 of SEQ ID NO: 147 or a CDR-H1 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 147, a CDR-H2 of SEQ ID NO: 150 or a CDR-H2 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 150, and a CDR-H3 of SEQ ID NO: 156 or a CDR-H3 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 156; (xx) a heavy chain variable domain comprising: a CDR-H1 of SEQ ID NO: 148 or a CDR-H1 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 148, a CDR-H2 of SEQ ID NO: 151 or a CDR-H2 of SEQ ID NO: 152 ID NO:151 has a CDR-H2 with 1, 2, 3, 4 or 5 amino acid changes, and CDR-H3 of SEQ ID NO:157 or a CDR-H3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:157; (xxi) a heavy chain variable domain, which comprises: CDR-H1 of SEQ ID NO:149 or a CDR-H1 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:149, CDR-H2 of SEQ ID NO:152 or a CDR-H2 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:152, and CDR-H3 of SEQ ID NO:158 or a CDR-H3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:158.

[0122] In one embodiment, an antibody-based molecule that binds to human muscle-specific tyrosine protein kinase (MuSK) comprises a heavy chain variable domain, wherein the heavy chain variable domain comprises (xxii) a heavy chain variable domain comprising: CDR-H1 of SEQ ID NO: 147 or a CDR-H1 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 147, CDR-H2 of SEQ ID NO: 153 or a CDR-H2 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 153, and CDR-H3 (3B2g1m1 / 3B2g2m1) of SEQ ID NO: 156 or a CDR-H3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 156; (xxiii) a heavy chain variable domain comprising: CDR-H1 of SEQ ID NO: 147 or a CDR-H1 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: NO:147 having a CDR-H1 with 1, 2, 3, 4 or 5 amino acid changes, SEQ ID NO:154 CDR-H2 or a CDR-H2 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:154, and SEQ ID NO:156 CDR-H3 (3B2g1m2 / 3B2g2m2) or a CDR-H3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:156; (xxi) a heavy chain variable domain comprising: SEQ ID NO:147 CDR-H1 or a CDR-H1 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:147, SEQ ID NO:155 CDR-H2 or a CDR-H2 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:155, and SEQ ID NO:156 CDR-H3 (3B2g1m2 / 3B2g2m2) or a CDR-H3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:156; The CDR-H3 of SEQ ID NO: 156 (3B2g1m4 / 3B2g2m4) or a CDR-H3 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 156. The sequences of the heavy chain CDRs are provided in Table 1.

[0123] In one embodiment, an antibody-based molecule that binds to human muscle-specific tyrosine protein kinase (MuSK) comprises: (i) a heavy chain variable domain comprising a CDR-H1 of SEQ ID NO: 1, a CDR-H2 of SEQ ID NO: 17, and a CDR-H3 of SEQ ID NO: 33; (ii) a heavy chain variable domain comprising a CDR-H1 of SEQ ID NO: 2, a CDR-H2 of SEQ ID NO: 18, and a CDR-H3 of SEQ ID NO: 34; (iii) a heavy chain variable domain comprising a CDR-H1 of SEQ ID NO: 3, a CDR-H2 of SEQ ID NO: 19, and a CDR-H3 of SEQ ID NO: 35; (iv) a heavy chain variable domain comprising a CDR-H1 of SEQ ID NO: 4, a CDR-H2 of SEQ ID NO: 20, and a CDR-H3 of SEQ ID NO: 36; (v) a heavy chain variable domain comprising a CDR-H1 of SEQ ID NO: 5, a CDR-H2 of SEQ ID NO: 6, and a CDR-H3 of SEQ ID NO: 7. NO:21 and CDR-H2 of SEQ ID NO:37; (vi) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO:6, CDR-H2 of SEQ ID NO:22 and CDR-H3 of SEQ ID NO:38; (vii) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO:7, CDR-H2 of SEQ ID NO:23 and CDR-H3 of SEQ ID NO:39; (viii) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO:8, CDR-H2 of SEQ ID NO:24 and CDR-H3 of SEQ ID NO:40; (ix) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO:9, CDR-H2 of SEQ ID NO:25 and CDR-H3 of SEQ ID NO:41; (x) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO:9, CDR-H2 of SEQ ID NO:25 and CDR-H3 of SEQ ID NO:41 NO:10, CDR-H1 of SEQ ID NO:26, and CDR-H3 of SEQ ID NO:42; (xi) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO:11, CDR-H2 of SEQ ID NO:27, and CDR-H3 of SEQ ID NO:43; (xii) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO:12, CDR-H2 of SEQ ID NO:28, and CDR-H3 of SEQ ID NO:44;(xiii) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 13, CDR-H2 of SEQ ID NO: 29, and CDR-H3 of SEQ ID NO: 45; (xiv) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 14, CDR-H2 of SEQ ID NO: 30, and CDR-H3 of SEQ ID NO: 46; (xv) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 15, CDR-H2 of SEQ ID NO: 31, and CDR-H3 of SEQ ID NO: 47; (xvi) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 16, CDR-H2 of SEQ ID NO: 32, and CDR-H3 of SEQ ID NO: 48; (xvii) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 135, CDR-H2 of SEQ ID NO: 137, and CDR-H3 of SEQ ID NO: and (xviii) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 136, CDR-H2 of SEQ ID NO: 138, and CDR-H3 of SEQ ID NO: 140. The sequences of the heavy chain CDR sequences are provided in Table 1 below. ;

[0124] In one embodiment, an antibody-based molecule that binds to human muscle-specific tyrosine protein kinase (MuSK) comprises: (ii.a) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 2, CDR-H2 of SEQ ID NO: 18, and CDR-H3 of SEQ ID NO: 240 (X2m1); (ii.b) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 2, CDR-H2 of SEQ ID NO: 18, and CDR-H3 of SEQ ID NO: 241 (X2m2); (ii.c) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 2, CDR-H2 of SEQ ID NO: 18, and CDR-H3 of SEQ ID NO: 242 (X2m3); (ii.d) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 2, CDR-H2 of SEQ ID NO: 18, and CDR-H3 of SEQ ID NO: 242 (X2m3). NO:243 CDR-H3 (X2m4); (ii.e) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO:2, CDR-H2 of SEQ ID NO:18, and CDR-H3 of SEQ ID NO:244 (X2m5); (ii.f) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO:2, CDR-H2 of SEQ ID NO:18, and CDR-H3 of SEQ ID NO:245 (X2m6); (ii.g) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO:2, CDR-H2 of SEQ ID NO:18, and CDR-H3 of SEQ ID NO:246 (X2m7); (ii.h) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO:2, CDR-H2 of SEQ ID NO:18, and CDR-H3 of SEQ ID NO:247; CDR-H3 of NO:247 (X2m8).

[0125] In one embodiment, an antibody-based molecule that binds to human muscle-specific tyrosine protein kinase (MuSK) comprises: (xvii.a) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 135, CDR-H2 of SEQ ID NO: 137, and CDR-H3 of SEQ ID NO: 248 (X17m1); (xvii.b) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 135, CDR-H2 of SEQ ID NO: 137, and CDR-H3 of SEQ ID NO: 249 (X17m2); (xvii.c) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 135, CDR-H2 of SEQ ID NO: 137, and CDR-H3 of SEQ ID NO: 250 (X17m3); (xvii.d) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 135, CDR-H2 of SEQ ID NO: 137, and CDR-H3 of SEQ ID NO: 250 (X17m3). CDR-H2 of SEQ ID NO:137 and CDR-H3 of SEQ ID NO:251 (X17m6).

[0126] In one embodiment, an antibody-based molecule that binds to human muscle-specific tyrosine protein kinase (MuSK) comprises a heavy chain variable domain, wherein the heavy chain variable domain comprises: (xix) a heavy chain variable domain comprising a CDR-H1 of SEQ ID NO: 147, a CDR-H2 of SEQ ID NO: 150, and a CDR-H3 of SEQ ID NO: 156; (xx) a heavy chain variable domain comprising a CDR-H1 of SEQ ID NO: 148, a CDR-H2 of SEQ ID NO: 151, and a CDR-H3 of SEQ ID NO: 157; (xxi) a heavy chain variable domain comprising a CDR-H1 of SEQ ID NO: 149, a CDR-H2 of SEQ ID NO: 152, and a CDR-H3 of SEQ ID NO: 158;

[0127] In one embodiment, an antibody-based molecule that binds to human muscle-specific tyrosine protein kinase (MuSK) comprises a heavy chain variable domain, wherein the heavy chain variable domain comprises: (xxii) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 147, CDR-H2 of SEQ ID NO: 153, and CDR-H3 of SEQ ID NO: 156 (3B2g1m1 / 3B2g2m1); (xxiii) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 147, CDR-H2 of SEQ ID NO: 154, and CDR-H3 of SEQ ID NO: 156 (3B2g1m2 / 3B2g2m2); (xxiv) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 147, CDR-H2 of SEQ ID NO: 155, and CDR-H3 of SEQ ID NO: 156 (3B2g1m2 / 3B2g2m2). CDR-H3 (3B2g1m4 / 3B2g2m4) of NO: 156. The sequences of the heavy chain CDR sequences are provided in Table 1 below.

[0128] In one embodiment, an antibody-based molecule that binds to human muscle-specific tyrosine protein kinase (MuSK) comprises a heavy chain variable domain, wherein the heavy chain variable domain comprises CDR-H1 of SEQ ID NO: 147, CDR-H2 of SEQ ID NO: 153, or a CDR-H2 amino acid sequence having at least 0, 1, 2, 3, 4, or 5 alterations relative to SEQ ID NO: 153, and CDR-H3 (3B2g2m1) of SEQ ID NO: 156. In one embodiment, the CDR-H2 amino acid sequence has at least 0, 1, 2, 3, 4, or 5 alterations relative to SEQ ID NO: 153. According to this embodiment, the CDR-H2 amino acid sequence has at least 0, 1, 2, 3, 4, or 5 alterations relative to SEQ ID NO: 153, wherein the alterations occur at residues 1, 2, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or any combination thereof.

[0129] In one embodiment, the antibody-based molecule that binds to human muscle-specific tyrosine protein kinase (MuSK) comprises a heavy chain variable domain, wherein the heavy chain variable domain comprises:

[0130] - a CDR-H1 amino acid sequence comprising SEQ ID NO: 147 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 147,

[0131] - a CDR-H2 amino acid sequence comprising SEQ ID NO: 153 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 153, and

[0132] - A CDR-H3 amino acid sequence comprising SEQ ID NO: 156 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 156 (3B2g2m1).

[0133] In one embodiment, CDR-H2 of the antibody comprises proline (P) at position 3, tryptophan (W) at position 4, and serine (S) or asparagine (N) at position 5.

[0134] In one embodiment, the antibody-based molecule that binds to human muscle-specific tyrosine protein kinase (MuSK) comprises a heavy chain variable domain, wherein the heavy chain variable domain comprises:

[0135] - a CDR-H1 amino acid sequence comprising or consisting of SEQ ID NO: 147,

[0136] - a CDR-H2 amino acid sequence comprising or consisting of SEQ ID NO: 153, and

[0137] - a CDR-H3 amino acid sequence comprising or consisting of SEQ ID NO: 156 (3B2g2m1).

[0138] The sequences of the heavy chain CDR sequences are provided in Table 1 below.

[0139]

[0140]

[0141]

[0142] In some embodiments, the MuSK antibody-based molecules disclosed herein further comprise a light chain variable domain. The light chain variable domain comprises:

[0143] (i) a complementarity determining region 1 (CDR-L1) having an amino acid sequence of any one of SEQ ID NOs: 49 to 64, 141, 142, 159 to 169, or a modified amino acid sequence of any one of SEQ ID NOs: 49 to 64, 141, 142, or 159 to 169, said modified sequence having at least 80% sequence identity to any one of SEQ ID NOs: 49 to 64, 141, 142, or 159 to 169;

[0144] (ii) a complementarity determining region 2 (CDR-L2) having an amino acid sequence of any one of SEQ ID NOs: 65 to 80, 143, 144, 170 to 179, or a modified amino acid sequence of any one of SEQ ID NOs: 65 to 80, 143, 144 or 170 to 179, said modified sequence having at least 80% sequence identity to any one of SEQ ID NOs: 65 to 80, 143, 144 or 170 to 179; and

[0145] (iii) a complementarity determining region 3 (CDR-L3) having an amino acid sequence of any one of SEQ ID NOs: 81 to 96, 145, 146, 180 to 195, or a modified amino acid sequence of any one of SEQ ID NOs: 81 to 96, 145, 146 or 180 to 195, wherein the modified sequence has at least 80% sequence identity with any one of SEQ ID NOs: 81 to 96, 145, 146 or 180 to 195.

[0146] In some embodiments, the MuSK antibody-based molecules disclosed herein further comprise a light chain variable domain. The light chain variable domain comprises:

[0147] (iv) a complementarity determining region 1 (CDR-L1) having an amino acid sequence of any one of SEQ ID NOs: 49 to 64, 141, 142, 159 to 169, or a modified amino acid sequence of any one of SEQ ID NOs: 49 to 64, 141, 142 or 159 to 169 having 1, 2, 3, 4 or 5 amino acid changes relative to any one of SEQ ID NOs: 49 to 64, 141, 142 or 159 to 169;

[0148] (v) a complementarity determining region 2 (CDR-L2) having an amino acid sequence of any one of SEQ ID NOs: 65 to 80, 143, 144, 170 to 179, or a modified amino acid sequence of any one of SEQ ID NOs: 65 to 80, 143, 144 or 170 to 179 having 1, 2, 3, 4 or 5 amino acid changes relative to any one of SEQ ID NOs: 65 to 80, 143, 144 or 170 to 179; and

[0149] (vi) a complementarity determining region 3 (CDR-L3) having an amino acid sequence of any one of SEQ ID NOs: 81 to 96, 145, 146, 180 to 195, or a modified amino acid sequence of any one of SEQ ID NOs: 81 to 96, 145, 146 or 180 to 195, wherein the modified sequence has 1, 2, 3, 4 or 5 amino acid changes relative to any one of SEQ ID NOs: 81 to 96, 145, 146 or 180 to 195.

[0150] In one embodiment, the light chain variable domain of the MuSK antibody-based molecule disclosed herein comprises (i) a light chain variable domain comprising: CDR-L1 of SEQ ID NO:49 or a CDR-L1 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:49, CDR-L2 of SEQ ID NO:65 or a CDR-L2 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:65, and CDR-L3 of SEQ ID NO:81 or a CDR-L3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:81; (ii) a light chain variable domain comprising: CDR-L1 of SEQ ID NO:50 or a CDR-L1 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:50, CDR-L2 of SEQ ID NO:66 or a CDR-L2 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: NO:66 has a CDR-L2 with 1, 2, 3, 4 or 5 amino acid changes, and a CDR-L3 of SEQ ID NO:82 or a CDR-L3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:82; (iii) a light chain variable domain comprising: a CDR-L1 of SEQ ID NO:51 or a CDR-L1 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:51, a CDR-L2 of SEQ ID NO:67 or a CDR-L2 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:67, and a CDR-L3 of SEQ ID NO:83 or a CDR-L3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:83; (iv) a light chain variable domain comprising: a CDR-L1 of SEQ ID NO:52 or a CDR-L3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: NO:52 has a CDR-L1 with 1, 2, 3, 4 or 5 amino acid changes, a CDR-L2 of SEQ ID NO:68 or a CDR-L2 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:68, and a CDR-L3 of SEQ ID NO:84 or a CDR-L3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:84;(v) a light chain variable domain comprising: a CDR-L1 of SEQ ID NO:53 or a CDR-L1 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:53, a CDR-L2 of SEQ ID NO:69 or a CDR-L2 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:69, and a CDR-L3 of SEQ ID NO:85 or a CDR-L3 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:85; (vi) a light chain variable domain comprising: a CDR-L1 of SEQ ID NO:54 or a CDR-L1 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:54, a CDR-L2 of SEQ ID NO:70 or a CDR-L2 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:70, and a CDR-L3 of SEQ ID NO:86 or a CDR-L3 of SEQ ID NO:87. NO:86 has a CDR-L3 with 1, 2, 3, 4 or 5 amino acid changes; (vii) a light chain variable domain comprising: CDR-L1 of SEQ ID NO:55 or a CDR-L1 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:55, CDR-L2 of SEQ ID NO:71 or a CDR-L2 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:71, and CDR-L3 of SEQ ID NO:87 or a CDR-L3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:87; (viii) a light chain variable domain comprising: CDR-L1 of SEQ ID NO:56 or a CDR-L1 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:56, CDR-L2 of SEQ ID NO:72 or a CDR-L2 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: NO:72 has a CDR-L2 with 1, 2, 3, 4 or 5 amino acid changes, and SEQ ID NO:88 or a CDR-L3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:88; (ix) a light chain variable domain comprising: SEQ ID NO:57 or a CDR-L1 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:57, SEQ ID NO:73 or a CDR-L2 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:73, and SEQ ID NO:89 or a CDR-L3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:89;(x) a light chain variable domain comprising: a CDR-L1 of SEQ ID NO:58 or a CDR-L1 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:58, a CDR-L2 of SEQ ID NO:74 or a CDR-L2 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:74, and a CDR-L3 of SEQ ID NO:90 or a CDR-L3 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:90; (xi) a light chain variable domain comprising: a CDR-L1 of SEQ ID NO:59 or a CDR-L1 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:59, a CDR-L2 of SEQ ID NO:75 or a CDR-L2 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:75, and a CDR-L3 of SEQ ID NO:91 or a CDR-L3 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: NO:91 has a CDR-L3 with 1, 2, 3, 4 or 5 amino acid changes; (xii) a light chain variable domain comprising: CDR-L1 of SEQ ID NO:60 or a CDR-L1 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:60, CDR-L2 of SEQ ID NO:76 or a CDR-L2 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:76, and CDR-L3 of SEQ ID NO:92 or a CDR-L3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:92; (xiii) a light chain variable domain comprising: CDR-L1 of SEQ ID NO:61 or a CDR-L1 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:61, CDR-L2 of SEQ ID NO:77 or a CDR-L2 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: NO:77 having a CDR-L2 with 1, 2, 3, 4 or 5 amino acid changes, and CDR-L3 of SEQ ID NO:93 or a CDR-L3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:93; (xiv) a light chain variable domain comprising: CDR-L1 of SEQ ID NO:62 or a CDR-L1 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:62, CDR-L2 of SEQ ID NO:78 or a CDR-L2 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:78, and CDR-L3 of SEQ ID NO:94 or a CDR-L3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:94;(xv) a light chain variable domain comprising: a CDR-L1 of SEQ ID NO:63 or a CDR-L1 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:63, a CDR-L2 of SEQ ID NO:79 or a CDR-L2 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:79, and a CDR-L3 of SEQ ID NO:95 or a CDR-L3 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:95; (xvi) a light chain variable domain comprising: a CDR-L1 of SEQ ID NO:64 or a CDR-L1 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:64, a CDR-L2 of SEQ ID NO:80 or a CDR-L2 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:80, and a CDR-L3 of SEQ ID NO:96 or a CDR-L3 of SEQ ID NO:97. NO:96 has a CDR-L3 with 1, 2, 3, 4 or 5 amino acid changes; (xvii) a light chain variable domain comprising: CDR-L1 of SEQ ID NO:141 or a CDR-L1 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:141, CDR-L2 of SEQ ID NO:143 or a CDR-L2 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:143, and CDR-L3 of SEQ ID NO:145 or a CDR-L3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:145; (xviii) a light chain variable domain comprising: CDR-L1 of SEQ ID NO:142 or a CDR-L1 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:142, CDR-L2 of SEQ ID NO:144 or a CDR-L2 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:145 NO: 144 has a CDR-L2 with 1, 2, 3, 4 or 5 amino acid changes, and a CDR-L3 of SEQ ID NO: 146 or a CDR-L3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 146. The sequences of the light chain CDRs are provided in Table 2 below. ;

[0151] In one embodiment, the light chain variable domain of the MuSK antibody-based molecule disclosed herein comprises (xix) a light chain variable domain comprising: a CDR-L1 of SEQ ID NO: 159 or a CDR-L1 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 159, a CDR-L2 of SEQ ID NO: 170 or a CDR-L2 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 170, and a CDR-L3 of SEQ ID NO: 180 or a CDR-L3 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 180; (xx) a light chain variable domain comprising: a CDR-L1 of SEQ ID NO: 159 or a CDR-L1 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 159, a CDR-L2 of SEQ ID NO: 171 or a CDR-L2 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 171. NO:171 has a CDR-L2 with 1, 2, 3, 4 or 5 amino acid changes, and SEQ ID NO:181 CDR-L3 or a CDR-L3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:181; (xxi) a light chain variable domain comprising: SEQ ID NO:160 CDR-L1 or a CDR-L1 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:160, SEQ ID NO:172 CDR-L2 or a CDR-L2 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:172, and SEQ ID NO:182 CDR-L3 or a CDR-L3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:182; (xxii) a light chain variable domain comprising: SEQ ID NO:159 CDR-L1 or a CDR-L1 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:159 NO:159 has a CDR-L1 with 1, 2, 3, 4 or 5 amino acid changes, a CDR-L2 of SEQ ID NO:172 or a CDR-L2 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:172, and a CDR-L3 of SEQ ID NO:183 or a CDR-L3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:183;(xxiii) a light chain variable domain comprising: a CDR-L1 of SEQ ID NO: 159 or a CDR-L1 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 159, a CDR-L2 of SEQ ID NO: 171 or a CDR-L2 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 171, and a CDR-L3 of SEQ ID NO: 184 or a CDR-L3 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 184; (xxiv) a light chain variable domain comprising: a CDR-L1 of SEQ ID NO: 159 or a CDR-L1 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 159, a CDR-L2 of SEQ ID NO: 173 or a CDR-L2 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 173, and a CDR-L3 of SEQ ID NO: 184 or a CDR-L3 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: NO: 185 or a CDR-L3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 185; (xxv) a light chain variable domain comprising: a CDR-L1 of SEQ ID NO: 159 or a CDR-L1 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 159, a CDR-L2 of SEQ ID NO: 173 or a CDR-L2 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 173, and a CDR-L3 of SEQ ID NO: 186 or a CDR-L3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 186; (xxvi) a light chain variable domain comprising: a CDR-L1 of SEQ ID NO: 161 or a CDR-L1 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 161, a CDR-L2 of SEQ ID NO: 173 or a CDR-L2 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 173 CDR-L2 of SEQ ID NO: 174 or a CDR-L2 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 174, and CDR-L3 of SEQ ID NO: 187 or a CDR-L3 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 187;(xxvii) a light chain variable domain comprising: a CDR-L1 of SEQ ID NO: 162 or a CDR-L1 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 162, a CDR-L2 of SEQ ID NO: 174 or a CDR-L2 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 174, and a CDR-L3 of SEQ ID NO: 188 or a CDR-L3 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 188; (xxviii) a light chain variable domain comprising: a CDR-L1 of SEQ ID NO: 163 or a CDR-L1 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 163, a CDR-L2 of SEQ ID NO: 174 or a CDR-L2 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 174, and a CDR-L3 of SEQ ID NO: 188 or a CDR-L3 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: NO:188 or a CDR-L3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:188; (xxix) a light chain variable domain comprising: a CDR-L1 of SEQ ID NO:164 or a CDR-L1 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:164, a CDR-L2 of SEQ ID NO:174 or a CDR-L2 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:174, and a CDR-L3 of SEQ ID NO:189 or a CDR-L3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:189; (xxx) a light chain variable domain comprising: a CDR-L1 of SEQ ID NO:165 or a CDR-L1 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:165, a CDR-L2 of SEQ ID NO:174 or a CDR-L2 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:174 CDR-L2 of SEQ ID NO: 175 or a CDR-L2 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 175, and CDR-L3 of SEQ ID NO: 190 or a CDR-L3 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 190;(xxxi) a light chain variable domain comprising: a CDR-L1 of SEQ ID NO: 166 or a CDR-L1 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 166, a CDR-L2 of SEQ ID NO: 176 or a CDR-L2 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 176, and a CDR-L3 of SEQ ID NO: 191 or a CDR-L3 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 191; (xxxi) a light chain variable domain comprising: a CDR-L1 of SEQ ID NO: 167 or a CDR-L1 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 167, a CDR-L2 of SEQ ID NO: 177 or a CDR-L2 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 177, and a CDR-L3 of SEQ ID NO: 191 or a CDR-L3 having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: NO:192 or a CDR-L3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:192; (xxxii) a light chain variable domain comprising: CDR-L1 of SEQ ID NO:168 or a CDR-L1 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:168, CDR-L2 of SEQ ID NO:178 or a CDR-L2 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:178, and CDR-L3 of SEQ ID NO:193 or a CDR-L3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:193; (xxxiii) a light chain variable domain comprising: CDR-L1 of SEQ ID NO:169 or a CDR-L1 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:169, CDR-L2 of SEQ ID NO: 179 or CDR-L2 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 179, and CDR-L3 of SEQ ID NO: 194 or CDR-L3 with 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 194. ;

[0152] In one embodiment, the light chain variable domain of the MuSK antibody-based molecule disclosed herein comprises: (i) a light chain variable domain comprising a CDR-L1 of SEQ ID NO: 49, a CDR-L2 of SEQ ID NO: 65, and a CDR-L3 of SEQ ID NO: 81; (ii) a light chain variable domain comprising a CDR-L1 of SEQ ID NO: 50, a CDR-L2 of SEQ ID NO: 66, and a CDR-L3 of SEQ ID NO: 82; (iii) a light chain variable domain comprising a CDR-L1 of SEQ ID NO: 51, a CDR-L2 of SEQ ID NO: 67, and a CDR-L3 of SEQ ID NO: 83; (iv) a light chain variable domain comprising a CDR-L1 of SEQ ID NO: 52, a CDR-L2 of SEQ ID NO: 68, and a CDR-L3 of SEQ ID NO: 84; (v) a light chain variable domain comprising a CDR-L1 of SEQ ID NO: 53, a CDR-L2 of SEQ ID NO: 69, and a CDR-L3 of SEQ ID NO: 84. SEQ ID NO:69 CDR-L2 and SEQ ID NO:85 CDR-L3; (vi) a light chain variable domain comprising CDR-L1 of SEQ ID NO:54, CDR-L2 of SEQ ID NO:70 and CDR-L3 of SEQ ID NO:86; (vii) a light chain variable domain comprising CDR-L1 of SEQ ID NO:55, CDR-L2 of SEQ ID NO:71 and CDR-L3 of SEQ ID NO:87; (viii) a light chain variable domain comprising CDR-L1 of SEQ ID NO:56, CDR-L2 of SEQ ID NO:72 and CDR-L3 of SEQ ID NO:88; (ix) a light chain variable domain comprising CDR-L1 of SEQ ID NO:57, CDR-L2 of SEQ ID NO:73 and CDR-L3 of SEQ ID NO:89; (x) a light chain variable domain comprising CDR-L1 of SEQ ID NO:57, CDR-L2 of SEQ ID NO:73 and CDR-L3 of SEQ ID NO:89 NO:58 CDR-L1, SEQ ID NO:74 CDR-L2 and SEQ ID NO:90 CDR-L3; (xi) a light chain variable domain comprising CDR-L1 of SEQ ID NO:59, CDR-L2 of SEQ ID NO:75 and CDR-L3 of SEQ ID NO:91; (xii) a light chain variable domain comprising CDR-L1 of SEQ ID NO:60, CDR-L2 of SEQ ID NO:76 and CDR-L3 of SEQ ID NO:92;(xiii) a light chain variable domain comprising CDR-L1 of SEQ ID NO:61, CDR-L2 of SEQ ID NO:77, and CDR-L3 of SEQ ID NO:93; (xiv) a light chain variable domain comprising CDR-L1 of SEQ ID NO:62, CDR-L2 of SEQ ID NO:78, and CDR-L3 of SEQ ID NO:94; (xv) a light chain variable domain comprising CDR-L1 of SEQ ID NO:63, CDR-L2 of SEQ ID NO:79, and CDR-L3 of SEQ ID NO:95; (xvi) a light chain variable domain comprising CDR-L1 of SEQ ID NO:64, CDR-L2 of SEQ ID NO:80, and CDR-L3 of SEQ ID NO:96; (xvii) a light chain variable domain comprising CDR-L1 of SEQ ID NO:141, CDR-L2 of SEQ ID NO:143, and CDR-L3 of SEQ ID NO: (xviii) a light chain variable domain comprising CDR-L1 of SEQ ID NO: 142, CDR-L2 of SEQ ID NO: 144, and CDR-L3 of SEQ ID NO: 146. The sequences of the light chain CDRs are provided in Table 2 below. ;

[0153] In one embodiment, the light chain variable domain of the MuSK antibody-based molecule disclosed herein comprises (xix) a light chain variable domain comprising CDR-L1 of SEQ ID NO: 159, CDR-L2 of SEQ ID NO: 170, and CDR-L3 of SEQ ID NO: 180; (xx) a light chain variable domain comprising CDR-L1 of SEQ ID NO: 159, CDR-L2 of SEQ ID NO: 171, and CDR-L3 of SEQ ID NO: 181; (xxi) a light chain variable domain comprising CDR-L1 of SEQ ID NO: 160, CDR-L2 of SEQ ID NO: 172, and CDR-L3 of SEQ ID NO: 182; (xxii) a light chain variable domain comprising CDR-L1 of SEQ ID NO: 159, CDR-L2 of SEQ ID NO: 172, and CDR-L3 of SEQ ID NO: 182. NO:183; (xxiii) a light chain variable domain comprising CDR-L1 of SEQ ID NO:159, CDR-L2 of SEQ ID NO:171, and CDR-L3 of SEQ ID NO:184; (xxiv) a light chain variable domain comprising CDR-L1 of SEQ ID NO:159, CDR-L2 of SEQ ID NO:173, and CDR-L3 of SEQ ID NO:185; (xxv) a light chain variable domain comprising CDR-L1 of SEQ ID NO:159, CDR-L2 of SEQ ID NO:173, and CDR-L3 of SEQ ID NO:186; (xxvi) a light chain variable domain comprising CDR-L1 of SEQ ID NO:161, CDR-L2 of SEQ ID NO:174, and CDR-L3 of SEQ ID NO:187; (xxvii) a light chain variable domain comprising CDR-L1 of SEQ ID NO:161, CDR-L2 of SEQ ID NO:174, and CDR-L3 of SEQ ID NO:187 NO:162, CDR-L1 of SEQ ID NO:174, and CDR-L3 of SEQ ID NO:188; (xxviii) a light chain variable domain comprising CDR-L1 of SEQ ID NO:163, CDR-L2 of SEQ ID NO:174, and CDR-L3 of SEQ ID NO:188; (xxix) a light chain variable domain comprising CDR-L1 of SEQ ID NO:164, CDR-L2 of SEQ ID NO:174, and CDR-L3 of SEQ ID NO:189; (xxx) a light chain variable domain comprising CDR-L1 of SEQ ID NO:165, CDR-L2 of SEQ ID NO:175, and CDR-L3 of SEQ ID NO:190;(xxxi) a light chain variable domain comprising CDR-L1 of SEQ ID NO: 166, CDR-L2 of SEQ ID NO: 176, and CDR-L3 of SEQ ID NO: 191; (xxxi) a light chain variable domain comprising CDR-L1 of SEQ ID NO: 167, CDR-L2 of SEQ ID NO: 177, and CDR-L3 of SEQ ID NO: 192; (xxxii) a light chain variable domain comprising CDR-L1 of SEQ ID NO: 168, CDR-L2 of SEQ ID NO: 178, and CDR-L3 of SEQ ID NO: 193; (xxxiii) a light chain variable domain comprising CDR-L1 of SEQ ID NO: 169, CDR-L2 of SEQ ID NO: 179, and CDR-L3 of SEQ ID NO: 194.;

[0154] In one embodiment, the light chain variable domain of a MuSK antibody-based molecule disclosed herein comprises CDR-L1 of SEQ ID NO: 159, CDR-L2 of SEQ ID NO: 172, and CDR-L3 of SEQ ID NO: 195, or a CDR-L3 having 1, 2, 3, 4 or 5 amino acid changes relative to the amino acid sequence of SEQ ID NO: 195, wherein the changes occur at residues 1, 2, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or any combination thereof.

[0155] In one embodiment, an antibody-based molecule that binds to human muscle-specific tyrosine protein kinase (MuSK) comprises a light chain variable domain, wherein the light chain variable domain contains:

[0156] - a CDR-L1 amino acid sequence comprising SEQ ID NO: 159 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 159,

[0157] - a CDR-L2 amino acid sequence comprising SEQ ID NO: 172 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 172, and

[0158] - A CDR-L3 amino acid sequence comprising SEQ ID NO: 195 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 195 (3B2g2m1).

[0159] In one embodiment, the CDR-L1, CDR-L2, CDR-L3 amino acid sequence has at least 0, 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 159, 172 or 195 (respectively).

[0160] In one embodiment, an antibody-based molecule that binds to human muscle-specific tyrosine protein kinase (MuSK) comprises a light chain variable domain, wherein the light chain variable domain contains:

[0161] - a CDR-L1 amino acid sequence comprising or consisting of SEQ ID NO: 159,

[0162] - a CDR-L2 amino acid sequence comprising or consisting of SEQ ID NO: 172, and

[0163] A CDR-L3 amino acid sequence (3B2g2m1) comprising or consisting of SEQ ID NO: 195.

[0164] The sequences of the light chain CDR sequences are provided in Table 2 below.

[0165]

[0166]

[0167] Suitable amino acid modifications to the heavy chain CDR sequences and / or light chain CDR sequences of the MuSK antibody-based molecules disclosed herein include, for example, conservative substitutions or functionally equivalent amino acid residue substitutions that result in variant CDR sequences having binding characteristics similar to or enhanced to the binding characteristics of the CDR sequences disclosed herein described above. The present invention encompasses the CDRs of Tables 1 and 2, which contain 1, 2, 3, 4, 5 or more amino acid changes (depending on the length of the CDR) that maintain or enhance the MuSK binding of the antibody. Suitable amino acid modifications to the heavy chain CDR sequences of Table 1 and / or the light chain CDR sequences of Tables 1 and 2 include, for example, conservative substitutions or functionally equivalent amino acid residue substitutions that result in variant CDR sequences having binding characteristics similar to or enhanced to the binding characteristics of the CDR sequences in Tables 1 and 2. Conservative substitutions are those that occur within a family of amino acids related in their side chains. The genetically encoded amino acids can be divided into four families: (1) acidic (aspartic acid, glutamic acid); (2) basic (lysine, arginine, histidine); (3) nonpolar (alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan); and (4) uncharged polar (glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine). Phenylalanine, tryptophan, and tyrosine are sometimes collectively classified as aromatic amino acids. Alternatively, the amino acid library can be divided into (1) acidic (aspartic acid, glutamic acid); (2) basic (lysine, arginine histidine), (3) aliphatic (glycine, alanine, valine, leucine, isoleucine, serine, threonine), wherein serine and threonine are optionally divided into aliphatic-hydroxyl alone; (4) aromatic (phenylalanine, tyrosine, tryptophan); (5) amide (asparagine, glutamine); and (6) sulfur-containing (cysteine ​​and methionine) (Stryer (ed.), Biochemistry, 2nd ed, WH Freeman and Co., 1981, which is hereby incorporated by reference in its entirety). Non-conservative substitutions can also be made to the heavy chain CDR sequences of Table 1 and the light chain CDR sequences of Table 2. Non-conservative substitutions involve replacing one or more amino acid residues of the CDR with one or more amino acid residues from a different class of amino acids to improve or enhance the binding properties of the CDR. The amino acid sequences of the heavy chain CDRs of Table 1 and / or the light chain CDRs of Table 2 may also contain one or more internal neutral amino acid insertions or deletions that maintain or enhance MuSK binding.

[0168] In one embodiment, a MuSK antibody-based molecule comprises:

[0169] (i) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 1, CDR-H2 of SEQ ID NO: 17, and CDR-H3 of SEQ ID NO: 33, and a light chain variable domain comprising CDR-L1 of SEQ ID NO: 49, CDR-L2 of SEQ ID NO: 65, and CDR-L3 of SEQ ID NO: 81;

[0170] (ii) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO:2, CDR-H2 of SEQ ID NO:18, and CDR-H3 of SEQ ID NO:34, and a light chain variable domain comprising CDR-L1 of SEQ ID NO:50, CDR-L2 of SEQ ID NO:66, and CDR-L3 of SEQ ID NO:82;

[0171] (iii) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO:3, CDR-H2 of SEQ ID NO:19, and CDR-H3 of SEQ ID NO:35, and a light chain variable domain comprising CDR-L1 of SEQ ID NO:51, CDR-L2 of SEQ ID NO:67, and CDR-L3 of SEQ ID NO:83;

[0172] (iv) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO:4, CDR-H2 of SEQ ID NO:20, and CDR-H3 of SEQ ID NO:36, and a light chain variable domain comprising CDR-L1 of SEQ ID NO:52, CDR-L2 of SEQ ID NO:68, and CDR-L3 of SEQ ID NO:84;

[0173] (v) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO:5, CDR-H2 of SEQ ID NO:21, and CDR-H3 of SEQ ID NO:37, and a light chain variable domain comprising CDR-L1 of SEQ ID NO:53, CDR-L2 of SEQ ID NO:69, and CDR-L3 of SEQ ID NO:85;

[0174] (vi) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO:6, CDR-H2 of SEQ ID NO:22, and CDR-H3 of SEQ ID NO:38, and a light chain variable domain comprising CDR-L1 of SEQ ID NO:54, CDR-L2 of SEQ ID NO:70, and CDR-L3 of SEQ ID NO:86;

[0175] (vii) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO:7, CDR-H2 of SEQ ID NO:23, and CDR-H3 of SEQ ID NO:39, and a light chain variable domain comprising CDR-L1 of SEQ ID NO:55, CDR-L2 of SEQ ID NO:71, and CDR-L3 of SEQ ID NO:87;

[0176] (viii) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO:8, CDR-H2 of SEQ ID NO:24, and CDR-H3 of SEQ ID NO:40, and a light chain variable domain comprising CDR-L1 of SEQ ID NO:56, CDR-L2 of SEQ ID NO:72, and CDR-L3 of SEQ ID NO:88;

[0177] (ix) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO:9, CDR-H2 of SEQ ID NO:25, and CDR-H3 of SEQ ID NO:41, and a light chain variable domain comprising CDR-L1 of SEQ ID NO:57, CDR-L2 of SEQ ID NO:73, and CDR-L3 of SEQ ID NO:89;

[0178] (x) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 10, CDR-H2 of SEQ ID NO: 26, and CDR-H3 of SEQ ID NO: 42, and a light chain variable domain comprising CDR-L1 of SEQ ID NO: 58, CDR-L2 of SEQ ID NO: 74, and CDR-L3 of SEQ ID NO: 90;

[0179] (xi) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 11, CDR-H2 of SEQ ID NO: 27, and CDR-H3 of SEQ ID NO: 43, and a light chain variable domain comprising CDR-L1 of SEQ ID NO: 59, CDR-L2 of SEQ ID NO: 75, and CDR-L3 of SEQ ID NO: 91;

[0180] (xii) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 12, CDR-H2 of SEQ ID NO: 28, and CDR-H3 of SEQ ID NO: 44, and a light chain variable domain comprising CDR-L1 of SEQ ID NO: 60, CDR-L2 of SEQ ID NO: 76, and CDR-L3 of SEQ ID NO: 92;

[0181] (xiii) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 13, CDR-H2 of SEQ ID NO: 29, and CDR-H3 of SEQ ID NO: 45, and a light chain variable domain comprising CDR-L1 of SEQ ID NO: 61, CDR-L2 of SEQ ID NO: 77, and CDR-L3 of SEQ ID NO: 93;

[0182] (xiv) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 14, CDR-H2 of SEQ ID NO: 30, and CDR-H3 of SEQ ID NO: 46, and a light chain variable domain comprising CDR-L1 of SEQ ID NO: 62, CDR-L2 of SEQ ID NO: 78, and CDR-L3 of SEQ ID NO: 94;

[0183] (xv) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 15, CDR-H2 of SEQ ID NO: 31, and CDR-H3 of SEQ ID NO: 47, and a light chain variable domain comprising CDR-L1 of SEQ ID NO: 63, CDR-L2 of SEQ ID NO: 79, and CDR-L3 of SEQ ID NO: 95;

[0184] (xvi) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 16, CDR-H2 of SEQ ID NO: 32, and CDR-H3 of SEQ ID NO: 48, and a light chain variable domain comprising CDR-L1 of SEQ ID NO: 64, CDR-L2 of SEQ ID NO: 80, and CDR-L3 of SEQ ID NO: 96;

[0185] (xvii) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 135, CDR-H2 of SEQ ID NO: 137, and CDR-H3 of SEQ ID NO: 139, and a light chain variable domain comprising CDR-L1 of SEQ ID NO: 141, CDR-L2 of SEQ ID NO: 143, and CDR-L3 of SEQ ID NO: 145; and

[0186] (xviii) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 136, CDR-H2 of SEQ ID NO: 138, and CDR-H3 of SEQ ID NO: 140, and a light chain variable domain comprising CDR-L1 of SEQ ID NO: 142, CDR-L2 of SEQ ID NO: 144, and CDR-L3 of SEQ ID NO: 146.

[0187] In one embodiment, a MuSK antibody-based molecule comprises:

[0188] (ii.a) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO:2, CDR-H2 of SEQ ID NO:18, and CDR-H3 of SEQ ID NO:240, and a light chain variable domain (X2m1) comprising CDR-L1 of SEQ ID NO:50, CDR-L2 of SEQ ID NO:66, and CDR-L3 of SEQ ID NO:82;

[0189] (ii.b) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO:2, CDR-H2 of SEQ ID NO:18, and CDR-H3 of SEQ ID NO:241, and a light chain variable domain (X2m2) comprising CDR-L1 of SEQ ID NO:50, CDR-L2 of SEQ ID NO:66, and CDR-L3 of SEQ ID NO:82;

[0190] (ii.c) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO:2, CDR-H2 of SEQ ID NO:18, and CDR-H3 of SEQ ID NO:242, and a light chain variable domain (X2m3) comprising CDR-L1 of SEQ ID NO:50, CDR-L2 of SEQ ID NO:66, and CDR-L3 of SEQ ID NO:82;

[0191] (ii.d) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO:2, CDR-H2 of SEQ ID NO:18, and CDR-H3 of SEQ ID NO:243, and a light chain variable domain comprising CDR-L1 of SEQ ID NO:50, CDR-L2 of SEQ ID NO:66, and CDR-L3 of SEQ ID NO:82 (X2m4);

[0192] (ii.e) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO:2, CDR-H2 of SEQ ID NO:18, and CDR-H3 of SEQ ID NO:244, and a light chain variable domain (X2m5) comprising CDR-L1 of SEQ ID NO:50, CDR-L2 of SEQ ID NO:66, and CDR-L3 of SEQ ID NO:82;

[0193] (ii.f) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO:2, CDR-H2 of SEQ ID NO:18, and CDR-H3 of SEQ ID NO:245, and a light chain variable domain comprising CDR-L1 of SEQ ID NO:50, CDR-L2 of SEQ ID NO:66, and CDR-L3 of SEQ ID NO:82 (X2m6);

[0194] (ii.g) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO:2, CDR-H2 of SEQ ID NO:18, and CDR-H3 of SEQ ID NO:246, and a light chain variable domain comprising CDR-L1 of SEQ ID NO:50, CDR-L2 of SEQ ID NO:66, and CDR-L3 of SEQ ID NO:82 (X2m7);

[0195] (ii.f) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO:2, CDR-H2 of SEQ ID NO:18, and CDR-H3 of SEQ ID NO:247, and a light chain variable domain (X2m8) comprising CDR-L1 of SEQ ID NO:50, CDR-L2 of SEQ ID NO:66, and CDR-L3 of SEQ ID NO:82.

[0196] In one embodiment, a MuSK antibody-based molecule comprises:

[0197] (xvii.a) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 135, CDR-H2 of SEQ ID NO: 137, and CDR-H3 of SEQ ID NO: 248, and a light chain variable domain comprising CDR-L1 of SEQ ID NO: 141, CDR-L2 of SEQ ID NO: 143, and CDR-L3 of SEQ ID NO: 145 (X17m1);

[0198] (xvii.b) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 135, CDR-H2 of SEQ ID NO: 137, and CDR-H3 of SEQ ID NO: 249, and a light chain variable domain comprising CDR-L1 of SEQ ID NO: 141, CDR-L2 of SEQ ID NO: 143, and CDR-L3 of SEQ ID NO: 145 (X17m2);

[0199] (xvii.c) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 135, CDR-H2 of SEQ ID NO: 137, and CDR-H3 of SEQ ID NO: 250, and a light chain variable domain comprising CDR-L1 of SEQ ID NO: 141, CDR-L2 of SEQ ID NO: 143, and CDR-L3 of SEQ ID NO: 145 (X17m3);

[0200] (xvii.d) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 135, CDR-H2 of SEQ ID NO: 137, and CDR-H3 of SEQ ID NO: 251, and a light chain variable domain comprising CDR-L1 of SEQ ID NO: 141, CDR-L2 of SEQ ID NO: 143, and CDR-L3 of SEQ ID NO: 145 (X17m6).

[0201] In one embodiment, a MuSK antibody-based molecule comprises:

[0202] (i) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 147, CDR-H2 of SEQ ID NO: 150, and CDR-H3 of SEQ ID NO: 156, and a light chain variable domain comprising CDR-L1 of SEQ ID NO: 159, CDR-L2 of SEQ ID NO: 170, and CDR-L3 of SEQ ID NO: 180 (14D10);

[0203] (ii) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 147, CDR-H2 of SEQ ID NO: 150, and CDR-H3 of SEQ ID NO: 156, and a light chain variable domain comprising CDR-L1 of SEQ ID NO: 159, CDR-L2 of SEQ ID NO: 171, and CDR-L3 of SEQ ID NO: 181 (7G4);

[0204] (iii) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 147, CDR-H2 of SEQ ID NO: 150, and CDR-H3 of SEQ ID NO: 156, and a light chain variable domain comprising CDR-L1 of SEQ ID NO: 160, CDR-L2 of SEQ ID NO: 172, and CDR-L3 of SEQ ID NO: 182 (3C4);

[0205] (iv) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 147, CDR-H2 of SEQ ID NO: 150, and CDR-H3 of SEQ ID NO: 156, and a light chain variable domain comprising CDR-L1 of SEQ ID NO: 159, CDR-L2 of SEQ ID NO: 172, and CDR-L3 of SEQ ID NO: 183 (3B2);

[0206] (v) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 147, CDR-H2 of SEQ ID NO: 150, and CDR-H3 of SEQ ID NO: 156, and a light chain variable domain comprising CDR-L1 of SEQ ID NO: 159, CDR-L2 of SEQ ID NO: 171, and CDR-L3 of SEQ ID NO: 184 (3G3);

[0207] (vi) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 147, CDR-H2 of SEQ ID NO: 150, and CDR-H3 of SEQ ID NO: 156, and a light chain variable domain comprising CDR-L1 of SEQ ID NO: 159, CDR-L2 of SEQ ID NO: 173, and CDR-L3 of SEQ ID NO: 185 (31G2);

[0208] (vii) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 147, CDR-H2 of SEQ ID NO: 150, and CDR-H3 of SEQ ID NO: 156, and a light chain variable domain comprising CDR-L1 of SEQ ID NO: 159, CDR-L2 of SEQ ID NO: 173, and CDR-L3 of SEQ ID NO: 186 (31B7);

[0209] (viii) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 148, CDR-H2 of SEQ ID NO: 151, and CDR-H3 of SEQ ID NO: 157, and a light chain variable domain comprising CDR-L1 of SEQ ID NO: 161, CDR-L2 of SEQ ID NO: 174, and CDR-L3 of SEQ ID NO: 187 (17H10);

[0210] (ix) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 148, CDR-H2 of SEQ ID NO: 151, and CDR-H3 of SEQ ID NO: 157, and a light chain variable domain comprising CDR-L1 of SEQ ID NO: 162, CDR-L2 of SEQ ID NO: 174, and CDR-L3 of SEQ ID NO: 188 (23B6);

[0211] (x) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 148, CDR-H2 of SEQ ID NO: 151, and CDR-H3 of SEQ ID NO: 157, and a light chain variable domain comprising CDR-L1 of SEQ ID NO: 163, CDR-L2 of SEQ ID NO: 174, and CDR-L3 of SEQ ID NO: 188 (30E1);

[0212] (xi) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 148, CDR-H2 of SEQ ID NO: 151, and CDR-H3 of SEQ ID NO: 157, and a light chain variable domain comprising CDR-L1 of SEQ ID NO: 164, CDR-L2 of SEQ ID NO: 174, and CDR-L3 of SEQ ID NO: 189 (30A11);

[0213] (xii) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 149, CDR-H2 of SEQ ID NO: 152, and CDR-H3 of SEQ ID NO: 158, and a light chain variable domain comprising CDR-L1 of SEQ ID NO: 165, CDR-L2 of SEQ ID NO: 175, and CDR-L3 of SEQ ID NO: 190 (16F11);

[0214] (xiii) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 149, CDR-H2 of SEQ ID NO: 152, and CDR-H3 of SEQ ID NO: 158, and a light chain variable domain comprising CDR-L1 of SEQ ID NO: 166, CDR-L2 of SEQ ID NO: 176, and CDR-L3 of SEQ ID NO: 191 (4C11);

[0215] (xiv) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 149, CDR-H2 of SEQ ID NO: 152, and CDR-H3 of SEQ ID NO: 158, and a light chain variable domain comprising CDR-L1 of SEQ ID NO: 167, CDR-L2 of SEQ ID NO: 177, and CDR-L3 of SEQ ID NO: 192 (7A12);

[0216] (xv) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 149, CDR-H2 of SEQ ID NO: 152, and CDR-H3 of SEQ ID NO: 158, and a light chain variable domain comprising CDR-L1 of SEQ ID NO: 168, CDR-L2 of SEQ ID NO: 178, and CDR-L3 of SEQ ID NO: 193 (7G12);

[0217] (xvi) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 149, CDR-H2 of SEQ ID NO: 152, and CDR-H3 of SEQ ID NO: 158, and a light chain variable domain comprising CDR-L1 of SEQ ID NO: 169, CDR-L2 of SEQ ID NO: 179, and CDR-L3 of SEQ ID NO: 194 (7B8);

[0218] (xvii) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 147, CDR-H2 of SEQ ID NO: 153, and CDR-H3 of SEQ ID NO: 156, and a light chain variable domain comprising CDR-L1 of SEQ ID NO: 159, CDR-L2 of SEQ ID NO: 172, and CDR-L3 of SEQ ID NO: 183 (3B2g1m1);

[0219] (xviii) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 147, CDR-H2 of SEQ ID NO: 154, and CDR-H3 of SEQ ID NO: 156, and a light chain variable domain comprising CDR-L1 of SEQ ID NO: 159, CDR-L2 of SEQ ID NO: 172, and CDR-L3 of SEQ ID NO: 183 (3B2g1m2);

[0220] (xvix) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 147, CDR-H2 of SEQ ID NO: 155, and CDR-H3 of SEQ ID NO: 156, and a light chain variable domain comprising CDR-L1 of SEQ ID NO: 159, CDR-L2 of SEQ ID NO: 172, and CDR-L3 of SEQ ID NO: 183 (3B2g1m4);

[0221] (xx) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 147, CDR-H2 of SEQ ID NO: 153, and CDR-H3 of SEQ ID NO: 156, and a light chain variable domain comprising CDR-L1 of SEQ ID NO: 159, CDR-L2 of SEQ ID NO: 172, and CDR-L3 of SEQ ID NO: 195 (3B2g2m1);

[0222] (xxi) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 147, CDR-H2 of SEQ ID NO: 154, and CDR-H3 of SEQ ID NO: 156, and a light chain variable domain comprising CDR-L1 of SEQ ID NO: 159, CDR-L2 of SEQ ID NO: 172, and CDR-L3 of SEQ ID NO: 195 (3B2g2m2); and

[0223] (xxii) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 147, CDR-H2 of SEQ ID NO: 155, and CDR-H3 of SEQ ID NO: 156, and a light chain variable domain comprising CDR-L1 of SEQ ID NO: 159, CDR-L2 of SEQ ID NO: 172, and CDR-L3 of SEQ ID NO: 195 (3B2g2m4).

[0224] In a preferred embodiment, the antibody-based molecule that binds to human muscle-specific tyrosine protein kinase (MuSK) comprises a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain contains:

[0225] - a CDR-H1 amino acid sequence comprising SEQ ID NO: 147 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 147,

[0226] - a CDR-H2 amino acid sequence comprising SEQ ID NO: 153 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 153, and

[0227] - comprising SEQ ID NO: 156 or a CDR-H3 amino acid sequence having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 156 (3B2g2m1) and

[0228] The light chain variable domain contains:

[0229] - a CDR-L1 amino acid sequence comprising SEQ ID NO: 159 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 159,

[0230] - a CDR-L2 amino acid sequence comprising SEQ ID NO: 172 or 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 172, and

[0231] - A CDR-L3 amino acid sequence comprising SEQ ID NO: 195 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 195 (3B2g2m1).

[0232] In one embodiment, CDR-H2 of the antibody comprises proline (P) at position 3, tryptophan (W) at position 4, and serine (S) or asparagine (N) at position 5.

[0233] In a more preferred embodiment, the antibody-based molecule that binds to human muscle-specific tyrosine protein kinase (MuSK) comprises a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain contains:

[0234] - a CDR-H1 amino acid sequence comprising or consisting of SEQ ID NO: 147,

[0235] - a CDR-H2 amino acid sequence comprising or consisting of SEQ ID NO: 153, and

[0236] - a CDR-H3 amino acid sequence (3B2g2m1) comprising or consisting of SEQ ID NO: 156 and

[0237] The light chain variable domain contains:

[0238] - a CDR-L1 amino acid sequence comprising or consisting of SEQ ID NO: 159,

[0239] - a CDR-L2 amino acid sequence comprising or consisting of SEQ ID NO: 172, and

[0240] - a CDR-L3 amino acid sequence comprising or consisting of SEQ ID NO: 195 (3B2g2m1).

[0241] The MuSK antibody-based molecules described herein may comprise a variable light (VL) chain, a variable heavy (VH) chain, or a combination of VL and VH chains. In some embodiments, the VH chain of the MuSK antibody-based molecule comprises any one of the VH amino acid sequences provided in Table 3 below, or comprises a VH amino acid sequence that is at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 100%, at least 101%, at least 102%, at least 103%, at least 104%, at least 105%, at least 106%, at least 107%, at least 108%, at least 109%, at least 110%, at least 111%, at least 112%, at least 113%, at least 114%, at least 115%, at least 116%, at least 117%, at least 118%, at least 119%, at least 120%, at least 121%, at least 122%, In some embodiments, the VL chain of the MuSK antibody-based molecule comprises any one of the VL amino acid sequences provided in Table 3 below, or comprises an amino acid sequence having at least 60% identity or similarity to any one of the VL amino acid sequences listed in Table 3. In some embodiments, the identity or similarity is at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%.

[0242]

[0243]

[0244]

[0245]

[0246]

[0247]

[0248]

[0249]

[0250] In one embodiment, a MuSK antibody-based molecule disclosed herein contains: a heavy chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO: 97 and a light chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO: 98; (ii) a heavy chain variable domain comprising an amino acid sequence at least 80% identical to any one of SEQ ID NOs: 99 and 252 to 259 and a light chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO: 100; (iii) a heavy chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO: 101 and a light chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO: 102; (iv) a heavy chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO: 103 and a light chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO: 104; (v) a heavy chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO: 105; NO: 105 having at least 80% identity and a light chain variable domain comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 106; (vi) a heavy chain variable domain comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 107 and a light chain variable domain comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 108; or (vii) a heavy chain variable domain comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 109 and a light chain variable domain comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 110; (viii) a heavy chain variable domain comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 111 and a light chain variable domain comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 112; (ix) a heavy chain variable domain comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 113 and a light chain variable domain comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 114. NO:114; (x) a heavy chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO:115 and a light chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO:116; (xi) a heavy chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO:117 and a light chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO:118;(xii) a heavy chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO: 119 and a light chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO: 120; (xiii) a heavy chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO: 121 and a light chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO: 122; (xiv) a heavy chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO: 123 and a light chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO: 124; (xv) a heavy chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO: 125 and a light chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO: 126; (xvi) a heavy chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO: 127 and a light chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO: 128; NO:127 having at least 80% identity to a heavy chain variable domain and a light chain variable domain comprising an amino acid sequence having at least 80% identity to SEQ ID NO:128; (xvii) a heavy chain variable domain comprising an amino acid sequence having at least 80% identity to any one of SEQ ID NOs:131 and 260 to 263, and a light chain variable domain comprising an amino acid sequence having at least 80% identity to SEQ ID NO:132; and (xviii) a heavy chain variable domain comprising an amino acid sequence having at least 80% identity to SEQ ID NO:133 and a light chain variable domain comprising an amino acid sequence having at least 80% identity to SEQ ID NO:134. ;

[0251] In some embodiments, the MuSK antibody-based molecules disclosed herein contain: (i) a heavy chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO: 196 and a light chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO: 197; (ii) a heavy chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO: 198 and a light chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO: 199; (iii) a heavy chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO: 200 and a light chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO: 201; (iv) a heavy chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO: 202 and a light chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO: 203; (v) a heavy chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO: 204 and a light chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO: 205; NO:204 having at least 80% identity, and a light chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO:205; (vi) a heavy chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO:206 and a light chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO:207; (vii) a heavy chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO:208 and a light chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO:209; (viii) a heavy chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO:210 and a light chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO:211; (vix) a heavy chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO:212 and a light chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO:213. NO:213; (x) a heavy chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO:214 and a light chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO:215; (xi) a heavy chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO:216 and a light chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO:217;(xii) a heavy chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO: 218 and a light chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO: 219; (xiii) a heavy chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO: 220 and a light chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO: 221; (xiv) a heavy chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO: 222 and a light chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO: 223; (xv) a heavy chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO: 224 and a light chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO: 225; (xvi) a heavy chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO: 226 and a light chain variable domain comprising an amino acid sequence at least 80% identical to SEQ ID NO: 227; NO:226 having at least 80% identity, and a light chain variable domain comprising an amino acid sequence having at least 80% identity to SEQ ID NO:227; (xvii) a heavy chain variable domain comprising an amino acid sequence having at least 80% identity to SEQ ID NO:228, and a light chain variable domain comprising an amino acid sequence having at least 80% identity to SEQ ID NO:229; (xviii) a heavy chain variable domain comprising an amino acid sequence having at least 80% identity to SEQ ID NO:230, and a light chain variable domain comprising an amino acid sequence having at least 80% identity to SEQ ID NO:231; (xix) a heavy chain variable domain comprising an amino acid sequence having at least 80% identity to SEQ ID NO:232, and a light chain variable domain comprising an amino acid sequence having at least 80% identity to SEQ ID NO:233; (xx) a heavy chain variable domain comprising an amino acid sequence having at least 80% identity to SEQ ID NO:234, and a light chain variable domain comprising an amino acid sequence having at least 80% identity to SEQ ID NO:235; ID NO: 235 having at least 80% identity to the light chain variable domain; (xxi) comprising a heavy chain variable domain having at least 80% identity to the amino acid sequence of SEQ ID NO: 236 and a light chain variable domain having at least 80% identity to the amino acid sequence of SEQ ID NO: 237; (xxii) comprising a heavy chain variable domain having at least 80% identity to the amino acid sequence of SEQ ID NO: 238 and a light chain variable domain having at least 80% identity to the amino acid sequence of SEQ ID NO: 239. ;

[0252] In a preferred embodiment, the MuSK antibody-based molecule (or anti-MuSK antibody or antigen-binding fragment thereof) disclosed herein comprises a heavy chain variable domain (VH) comprising an amino acid sequence having at least 80% identity or similarity to SEQ ID NO:234 ​​and a light chain variable domain (VL) comprising an amino acid sequence having at least 80% identity or similarity to SEQ ID NO:235.

[0253] In one embodiment, the identity or similarity is at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%.

[0254] In a preferred embodiment, the MuSK antibody-based molecule disclosed herein comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:234 ​​and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:235.

[0255] In a preferred embodiment, the antibody-based molecule that binds to human muscle-specific tyrosine protein kinase (MuSK) comprises a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain comprises an amino acid sequence having at least 80% identity or similarity to SEQ ID NO: 234 and the light chain variable domain comprises an amino acid sequence having at least 80% identity or similarity to SEQ ID NO: 235, and

[0256] The heavy chain variable domain contains:

[0257] - a CDR-H1 amino acid sequence comprising SEQ ID NO: 147 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 147,

[0258] - a CDR-H2 amino acid sequence comprising SEQ ID NO: 153 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 153, and

[0259] - comprising SEQ ID NO: 156 or a CDR-H3 amino acid sequence having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 156 (3B2g2m1) and

[0260] The light chain variable domain contains:

[0261] - a CDR-L1 amino acid sequence comprising SEQ ID NO: 159 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 159,

[0262] - a CDR-L2 amino acid sequence comprising SEQ ID NO: 172 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 172, and

[0263] - A CDR-L3 amino acid sequence comprising SEQ ID NO: 195 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 195 (3B2g2m1).

[0264] In a more preferred embodiment, the antibody-based molecule that binds to human muscle-specific tyrosine protein kinase (MuSK) comprises a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain comprises an amino acid sequence having at least 80% identity or similarity to SEQ ID NO: 234 and the light chain variable domain comprises an amino acid sequence having at least 80% identity or similarity to SEQ ID NO: 235, and

[0265] The heavy chain variable domain contains:

[0266] - a CDR-H1 amino acid sequence comprising or consisting of SEQ ID NO: 147,

[0267] - a CDR-H2 amino acid sequence comprising or consisting of SEQ ID NO: 153, and

[0268] - a CDR-H3 amino acid sequence (3B2g2m1) comprising or consisting of SEQ ID NO: 156 and

[0269] The light chain variable domain contains:

[0270] - a CDR-L1 amino acid sequence comprising or consisting of SEQ ID NO: 159,

[0271] - a CDR-L2 amino acid sequence comprising or consisting of SEQ ID NO: 172, and

[0272] - a CDR-L3 amino acid sequence comprising or consisting of SEQ ID NO: 195 (3B2g2m1).

[0273] In one embodiment, an antibody-based molecule that binds to human muscle-specific tyrosine protein kinase (MuSK) comprises a wild-type human IgG constant Fc region, a heavy chain variable domain, and a light chain variable domain, wherein the wild-type human IgG constant Fc region comprises at least 80% sequence identity to SEQ ID NO: 266 or SEQ ID NO: 267, wherein the heavy chain variable domain comprises an amino acid sequence at least 80% identical or similar to SEQ ID NO: 234 and the light chain variable domain comprises an amino acid sequence at least 80% identical or similar to SEQ ID NO: 235, and wherein the heavy chain variable domain contains:

[0274] - a CDR-H1 amino acid sequence comprising SEQ ID NO: 147 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 147,

[0275] - a CDR-H2 amino acid sequence comprising SEQ ID NO: 153 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 153, and

[0276] - comprising SEQ ID NO: 156 or a CDR-H3 amino acid sequence having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 156 (3B2g2m1) and

[0277] The light chain variable domain contains:

[0278] - a CDR-L1 amino acid sequence comprising SEQ ID NO: 159 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 159,

[0279] - a CDR-L2 amino acid sequence comprising SEQ ID NO: 172 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 172, and

[0280] - A CDR-L3 amino acid sequence comprising SEQ ID NO: 195 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 195 (3B2g2m1).

[0281] In one embodiment, the identity or similarity is at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%.

[0282] In one embodiment, CDR-H2 of the antibody comprises proline (P) at position 3, tryptophan (W) at position 4, and serine (S) or asparagine (N) at position 5.

[0283] In one embodiment, an antibody-based molecule that binds to human muscle-specific tyrosine protein kinase (MuSK) comprises a wild-type human IgG constant Fc region, a heavy chain variable domain, and a light chain variable domain, wherein the wild-type human IgG constant Fc region comprises SEQ ID NO: 266 or SEQ ID NO: 267, wherein the heavy chain variable domain comprises an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 234, and the light chain variable domain comprises an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 235, and

[0284] The heavy chain variable domain contains:

[0285] - a CDR-H1 amino acid sequence comprising SEQ ID NO: 147 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 147,

[0286] - a CDR-H2 amino acid sequence comprising SEQ ID NO: 153 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 153, and

[0287] - comprising SEQ ID NO: 156 or a CDR-H3 amino acid sequence having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 156 (3B2g2m1) and

[0288] The light chain variable domain contains:

[0289] - a CDR-L1 amino acid sequence comprising SEQ ID NO: 159 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 159,

[0290] - a CDR-L2 amino acid sequence comprising SEQ ID NO: 172 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 172, and

[0291] - A CDR-L3 amino acid sequence comprising SEQ ID NO: 195 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 195 (3B2g2m1).

[0292] In one embodiment, the identity or similarity is at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%.

[0293] In one embodiment, CDR-H2 of the antibody comprises proline (P) at position 3, tryptophan (W) at position 4, and serine (S) or asparagine (N) at position 5.

[0294] In one embodiment, the antibody-based molecule that binds to human muscle-specific tyrosine protein kinase (MuSK) comprises a wild-type human IgG constant Fc region, a heavy chain variable domain, and a light chain variable domain, wherein the wild-type human IgG constant Fc region comprises SEQ ID NO: 266 or SEQ ID NO: 267, wherein the heavy chain variable domain comprises SEQ ID NO: 234 and the light chain variable domain comprises SEQ ID NO: 235, and

[0295] The heavy chain variable domain contains:

[0296] - a CDR-H1 amino acid sequence comprising SEQ ID NO: 147 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 147,

[0297] - a CDR-H2 amino acid sequence comprising SEQ ID NO: 153 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 153, and

[0298] - comprising SEQ ID NO: 156 or a CDR-H3 amino acid sequence having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 156 (3B2g2m1) and

[0299] The light chain variable domain contains:

[0300] - a CDR-L1 amino acid sequence comprising SEQ ID NO: 159 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 159,

[0301] - a CDR-L2 amino acid sequence comprising SEQ ID NO: 172 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 172, and

[0302] - A CDR-L3 amino acid sequence comprising SEQ ID NO: 195 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 195 (3B2g2m1).

[0303] In one embodiment, CDR-H2 of the antibody comprises proline (P) at position 3, tryptophan (W) at position 4, and serine (S) or asparagine (N) at position 5.

[0304] In one embodiment, the antibody-based molecule that binds to human muscle-specific tyrosine protein kinase (MuSK) comprises a wild-type human IgG constant Fc region, a heavy chain variable domain, and a light chain variable domain, wherein the wild-type human IgG constant Fc region comprises SEQ ID NO: 266 or SEQ ID NO: 267, wherein the heavy chain variable domain comprises SEQ ID NO: 234 and the light chain variable domain comprises SEQ ID NO: 235, and

[0305] The heavy chain variable domain contains:

[0306] - a CDR-H1 amino acid sequence comprising or consisting of SEQ ID NO: 147,

[0307] - a CDR-H2 amino acid sequence comprising or consisting of SEQ ID NO: 153, and

[0308] - a CDR-H3 amino acid sequence (3B2g2m1) comprising or consisting of SEQ ID NO: 156 and

[0309] The light chain variable domain comprises:

[0310] - a CDR-L1 amino acid sequence comprising or consisting of SEQ ID NO: 159,

[0311] - a CDR-L2 amino acid sequence comprising or consisting of SEQ ID NO: 172, and

[0312] - a CDR-L3 amino acid sequence comprising or consisting of SEQ ID NO: 195 (3B2g2m1).

[0313] - A CDR-L3 amino acid sequence comprising SEQ ID NO: 195 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 195 (3B2g2m1).

[0314] In one embodiment, the antibody-based molecule that binds to human muscle-specific tyrosine protein kinase (MuSK) comprises a wild-type human IgG constant Fc region, a heavy chain variable domain, and a light chain variable domain,

[0315] The wild-type human IgG constant Fc region is identical to SEQ ID NO: 266 or SEQ ID NO:267 comprises at least 80% sequence identity, wherein a), wherein one or more of the following mutations (all numbered according to the EU numbering system) have been introduced into the full-length heavy chain: N297A substitution; N297Q substitution; L234A substitution; L234D substitution; L234E substitution; L234G substitution; L234H substitution; L234F substitution; L234K substitution; L234Q substitution; L234R substitution; L234S substitution; L234T substitution; L235A substitution; L235D substitution; L235E substitution; L235F substitution; L235G substitution; L235V substitution; L235H substitution; L235I substitution; L235K substitution; L235R substitution; L235S substitution; L235T substitution; L235Q substitution; L237A substitution; S239D substitution; E233 P substitution; L234V substitution; C236 deletion; G236E substitution; G236R substitution; G236K substitution; G237A substitution; P238A substitution; F243L substitution; D265A substitution; S267E substitution; H268A substitution; R292P substitution; Y300L substitution; K322A substitution; K322Q substitution; A327Q substitution; L328F substitution; L328R substitution; P329A substitution; P329G substitution; A330L substitution; A330S substitution; P331S substitution; I332E substitution; P396L substitution; or each of the combinations of the mutations described above in the fourth embodiment of the present application, preferably the mutation is L234A or L235A, more preferably the mutation is L234A and L235A, and wherein the heavy chain variable domain comprises the residue corresponding to SEQ ID NO:234 ​​has an amino acid sequence that is at least 80% identical or similar to SEQ ID NO:234 ​​and the light chain variable domain comprises an amino acid sequence that is at least 80% identical or similar to SEQ ID NO:235, and

[0316] The heavy chain variable domain contains:

[0317] - a CDR-H1 amino acid sequence comprising SEQ ID NO: 147 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 147,

[0318] - a CDR-H2 amino acid sequence comprising SEQ ID NO: 153 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 153, and

[0319] - comprising SEQ ID NO: 156 or a CDR-H3 amino acid sequence having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 156 (3B2g2m1) and

[0320] The light chain variable domain contains:

[0321] - a CDR-L1 amino acid sequence comprising SEQ ID NO: 159 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 159,

[0322] - a CDR-L2 amino acid sequence comprising SEQ ID NO: 172 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 172, and

[0323] - A CDR-L3 amino acid sequence comprising SEQ ID NO: 195 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 195 (3B2g2m1).

[0324] In one embodiment, the identity or similarity is at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%.

[0325] In one embodiment, the antibody-based molecule that binds to human muscle-specific tyrosine protein kinase (MuSK) comprises a wild-type human IgG constant Fc region, a heavy chain variable domain, and a light chain variable domain,

[0326] wherein the wild-type human IgG constant Fc region comprises SEQ ID NO: 266 or SEQ ID NO: 267, wherein L234A and / or L235A substitutions numbered according to the EU numbering system are introduced into said Fc region, and

[0327] wherein the heavy chain variable domain comprises an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 234 and the light chain variable domain comprises an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 235, and

[0328] The heavy chain variable domain contains:

[0329] - a CDR-H1 amino acid sequence comprising SEQ ID NO: 147 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 147,

[0330] - a CDR-H2 amino acid sequence comprising SEQ ID NO: 153 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 153, and

[0331] - comprising SEQ ID NO: 156 or a CDR-H3 amino acid sequence having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 156 (3B2g2m1) and

[0332] The light chain variable domain contains:

[0333] - a CDR-L1 amino acid sequence comprising SEQ ID NO: 159 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 159,

[0334] - a CDR-L2 amino acid sequence comprising SEQ ID NO: 172 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 172, and

[0335] - A CDR-L3 amino acid sequence comprising SEQ ID NO: 195 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 195 (3B2g2m1).

[0336] In one embodiment, the identity or similarity is at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%.

[0337] In one embodiment, an antibody-based molecule that binds to human muscle-specific tyrosine protein kinase (MuSK) comprises a wild-type human IgG constant Fc region, a heavy chain variable domain, and a light chain variable domain, wherein the wild-type human IgG constant Fc region comprises SEQ ID NO: 266 or SEQ ID NO: 267, wherein L234A and / or L235A numbered according to the EU numbering system are introduced into the Fc region, and wherein the heavy chain variable domain comprises SEQ ID NO: 234 and the light chain variable domain comprises SEQ ID NO: 235, and

[0338] The heavy chain variable domain contains:

[0339] - a CDR-H1 amino acid sequence comprising or consisting of SEQ ID NO: 147,

[0340] - a CDR-H2 amino acid sequence comprising or consisting of SEQ ID NO: 153, and

[0341] - a CDR-H3 amino acid sequence (3B2g2m1) comprising or consisting of SEQ ID NO: 156 and

[0342] The light chain variable domain contains:

[0343] - a CDR-L1 amino acid sequence comprising or consisting of SEQ ID NO: 159,

[0344] - a CDR-L2 amino acid sequence comprising or consisting of SEQ ID NO: 172, and

[0345] - a CDR-L3 amino acid sequence comprising or consisting of SEQ ID NO: 195 (3B2g2m1).

[0346] - A CDR-L3 amino acid sequence comprising SEQ ID NO: 195 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 195 (3B2g2m1).

[0347] In one embodiment, the anti-MuSK antibody or antigen-binding fragment thereof comprises:

[0348] a) a full-length heavy chain comprising an amino acid sequence having at least 80% identity or similarity to SEQ ID NO: 268, and

[0349] b) a full-length light chain comprising an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 269, and

[0350] c) in which one or more of the following mutations (all numbered according to the EU numbering system) have been introduced into the full-length heavy chain: N297A substitution; N297Q substitution; L234A substitution; L234D substitution; L234E substitution; L234G substitution; L234H substitution; L234F substitution; L234K substitution; L234Q substitution; L234R substitution; L234S substitution; L234T substitution; L235A substitution; L235D substitution; L235E substitution; L235F substitution; L235G substitution; L235V substitution; L235H substitution; L235I substitution; L235K substitution; L235R substitution; L235S substitution; L235T substitution; L235Q substitution; L237A substitution; S239D substitution; E233P substitution replacement; L234V replacement; C236 deletion; G236E replacement; G236R replacement; G236K replacement; G237A replacement; P238A replacement; F243L replacement; D265A replacement; S267E replacement; H268A replacement; R292P replacement; Y300L replacement; K322A replacement; K322Q replacement; A327Q replacement; L328F replacement; L328R replacement; P329A replacement; P329G replacement; A330L replacement; A330S replacement; P331S replacement; I332E replacement; P396L replacement; or each of the combinations of the mutations described above in the fourth embodiment of the present application, preferably the mutation is L234A or L235A, more preferably the mutation is L234A and L235A.

[0351] In one embodiment, the identity or similarity is at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%.

[0352] In one embodiment, the anti-MuSK antibody or antigen-binding fragment thereof comprises:

[0353] a) a full-length heavy chain comprising SEQ ID NO: 268 and

[0354] b) a full-length light chain comprising SEQ ID NO: 269, and

[0355] c) wherein the full length heavy chain comprises L234A and L235A mutations numbered according to the EU numbering system.

[0356] In one embodiment, the anti-MuSK antibody or antigen-binding fragment thereof comprises:

[0357] a) a full-length heavy chain comprising an amino acid sequence having at least 80% identity or similarity to SEQ ID NO: 270 and

[0358] b) a full-length light chain comprising an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 271, and

[0359] c) in which one or more of the following mutations (all numbered according to the EU numbering system) have been introduced into the full-length heavy chain: N297A substitution; N297Q substitution; L234A substitution; L234D substitution; L234E substitution; L234G substitution; L234H substitution; L234F substitution; L234K substitution; L234Q substitution; L234R substitution; L234S substitution; L234T substitution; L235A substitution; L235D substitution; L235E substitution; L235F substitution; L235G substitution; L235V substitution; L235H substitution; L235I substitution; L235K substitution; L235R substitution; L235S substitution; L235T substitution; L235Q substitution; L237A substitution; S239D substitution; E233P Replacement; L234V replacement; C236 deletion; G236E replacement; G236R replacement; G236K replacement; G237A replacement; P238A replacement; F243L replacement; D265A replacement; S267E replacement; H268A replacement; R292P replacement; Y300L replacement; K322A replacement; K322Q replacement; A327Q replacement; L328F replacement; L328R replacement; P329A replacement; P329G replacement; A330L replacement; A330S replacement; P331S replacement; I332E replacement; P396L replacement; or each of the combinations of the mutations described above in the fourth embodiment of the present application, preferably the mutation is L234A or L235A, more preferably the mutation is L234A and L235A.

[0360] In one embodiment, the identity or similarity is at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%.

[0361] In one embodiment, the anti-MuSK antibody or antigen-binding fragment thereof comprises:

[0362] a) a full-length heavy chain comprising SEQ ID NO: 270 and

[0363] b) a full-length light chain comprising SEQ ID NO: 271, and

[0364] c) wherein the full length heavy chain comprises L234A and L235A mutations numbered according to the EU numbering system.

[0365] Polynucleotide

[0366] Another aspect of the present invention relates to isolated polynucleotides encoding the molecules based on the MuSK antibodies described herein. In one embodiment, the polynucleotide encoding the MuSK antibody of the present invention comprises a nucleotide sequence encoding any one, any two, any three, any four, any five or any six of the above CDRs, including the heavy chain CDRs of SEQ ID NOs: 1 to 48, 135 to 140, 147 to 158, 240 to 251 and the light chain CDRs of SEQ ID NOs: 49 to 96, 141 to 146 and 159 to 195.

[0367] Thus, the present invention provides a polynucleotide for treating a neuromuscular disease in a human subject, the polynucleotide comprising a nucleotide sequence encoding an anti-MuSK antibody or antigen-binding fragment thereof, or a VH, VL or CDR domain thereof.

[0368] In one embodiment, the polynucleotide comprises a nucleotide sequence encoding a VH domain, wherein the VH domain comprises: (i) a heavy chain variable domain comprising a CDR-H1 of SEQ ID NO: 1, a CDR-H2 of SEQ ID NO: 17, and a CDR-H3 of SEQ ID NO: 33; (ii) a heavy chain variable domain comprising a CDR-H1 of SEQ ID NO: 2, a CDR-H2 of SEQ ID NO: 18, and a CDR-H3 of SEQ ID NO: 34; (iii) a heavy chain variable domain comprising a CDR-H1 of SEQ ID NO: 3, a CDR-H2 of SEQ ID NO: 19, and a CDR-H3 of SEQ ID NO: 35; (iv) a heavy chain variable domain comprising a CDR-H1 of SEQ ID NO: 4, a CDR-H2 of SEQ ID NO: 20, and a CDR-H3 of SEQ ID NO: 36; (v) a heavy chain variable domain comprising a CDR-H1 of SEQ ID NO: 5, a CDR-H2 of SEQ ID NO: 6, and a CDR-H3 of SEQ ID NO: 7. NO:21 and CDR-H2 of SEQ ID NO:37; (vi) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO:6, CDR-H2 of SEQ ID NO:22 and CDR-H3 of SEQ ID NO:38; (vii) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO:7, CDR-H2 of SEQ ID NO:23 and CDR-H3 of SEQ ID NO:39; (viii) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO:8, CDR-H2 of SEQ ID NO:24 and CDR-H3 of SEQ ID NO:40; (ix) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO:9, CDR-H2 of SEQ ID NO:25 and CDR-H3 of SEQ ID NO:41; (x) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO:9, CDR-H2 of SEQ ID NO:25 and CDR-H3 of SEQ ID NO:41 NO:10, CDR-H1 of SEQ ID NO:26, and CDR-H3 of SEQ ID NO:42; (xi) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO:11, CDR-H2 of SEQ ID NO:27, and CDR-H3 of SEQ ID NO:43; (xii) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO:12, CDR-H2 of SEQ ID NO:28, and CDR-H3 of SEQ ID NO:44;(xiii) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 13, CDR-H2 of SEQ ID NO: 29, and CDR-H3 of SEQ ID NO: 45; (xiv) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 14, CDR-H2 of SEQ ID NO: 30, and CDR-H3 of SEQ ID NO: 46; (xv) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 15, CDR-H2 of SEQ ID NO: 31, and CDR-H3 of SEQ ID NO: 47; (xvi) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 16, CDR-H2 of SEQ ID NO: 32, and CDR-H3 of SEQ ID NO: 48; (xvii) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 135, CDR-H2 of SEQ ID NO: 137, and CDR-H3 of SEQ ID NO: and (xviii) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 136, CDR-H2 of SEQ ID NO: 138, and CDR-H3 of SEQ ID NO: 140.

[0369] In some embodiments, the polynucleotide comprises a nucleotide sequence encoding a VH domain, wherein the VH domain comprises: (ii.a) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 2, CDR-H2 of SEQ ID NO: 18, and CDR-H3 (X2m1) of SEQ ID NO: 240; (ii.b) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 2, CDR-H2 of SEQ ID NO: 18, and CDR-H3 (X2m2) of SEQ ID NO: 241; (ii.c) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 2, CDR-H2 of SEQ ID NO: 18, and CDR-H3 (X2m3) of SEQ ID NO: 242; (ii.d) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 2, CDR-H2 of SEQ ID NO: 18, and CDR-H3 (X2m4) of SEQ ID NO: 243. NO:243 CDR-H3 (X2m4); (ii.e) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO:2, CDR-H2 of SEQ ID NO:18, and CDR-H3 of SEQ ID NO:244 (X2m5); (ii.f) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO:2, CDR-H2 of SEQ ID NO:18, and CDR-H3 of SEQ ID NO:245 (X2m6); (ii.g) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO:2, CDR-H2 of SEQ ID NO:18, and CDR-H3 of SEQ ID NO:246 (X2m7); (ii.h) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO:2, CDR-H2 of SEQ ID NO:18, and CDR-H3 of SEQ ID NO:247; CDR-H3 of NO:247 (X2m8).

[0370] In some embodiments, the polynucleotide comprises a nucleotide sequence encoding a VH domain, wherein the VH domain comprises: (xvii.a) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 135, CDR-H2 of SEQ ID NO: 137, and CDR-H3 (X17m1) of SEQ ID NO: 248; (xvii.b) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 135, CDR-H2 of SEQ ID NO: 137, and CDR-H3 (X17m2) of SEQ ID NO: 249; (xvii.c) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 135, CDR-H2 of SEQ ID NO: 137, and CDR-H3 (X17m3) of SEQ ID NO: 250; (xvii.d) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 135, CDR-H2 of SEQ ID NO: 137, and CDR-H3 (X17m3) of SEQ ID NO: 251. CDR-H2 of SEQ ID NO:137 and CDR-H3 of SEQ ID NO:251 (X17m6).

[0371] In one embodiment, the polynucleotide comprises a nucleotide sequence encoding a VH domain, wherein the VH domain comprises: (xix) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 147, CDR-H2 of SEQ ID NO: 150, and CDR-H3 of SEQ ID NO: 156; (xx) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 148, CDR-H2 of SEQ ID NO: 151, and CDR-H3 of SEQ ID NO: 157; (xxi) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 149, CDR-H2 of SEQ ID NO: 152, and CDR-H3 of SEQ ID NO: 158.

[0372] In one embodiment, the polynucleotide comprises a nucleotide sequence encoding a VH domain, wherein the VH domain comprises: (xxii) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 147, CDR-H2 of SEQ ID NO: 153, and CDR-H3 of SEQ ID NO: 156; (xxiii) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 147, CDR-H2 of SEQ ID NO: 154, and CDR-H3 of SEQ ID NO: 156; (xxiv) a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 147, CDR-H2 of SEQ ID NO: 155, and CDR-H3 of SEQ ID NO: 156.

[0373] In one embodiment, the polynucleotide comprises a nucleotide sequence encoding a VL domain, wherein the VL domain comprises: (i) a light chain variable domain comprising a CDR-L1 of SEQ ID NO: 49, a CDR-L2 of SEQ ID NO: 65, and a CDR-L3 of SEQ ID NO: 81; (ii) a light chain variable domain comprising a CDR-L1 of SEQ ID NO: 50, a CDR-L2 of SEQ ID NO: 66, and a CDR-L3 of SEQ ID NO: 82; (iii) a light chain variable domain comprising a CDR-L1 of SEQ ID NO: 51, a CDR-L2 of SEQ ID NO: 67, and a CDR-L3 of SEQ ID NO: 83; (iv) a light chain variable domain comprising a CDR-L1 of SEQ ID NO: 52, a CDR-L2 of SEQ ID NO: 68, and a CDR-L3 of SEQ ID NO: 84; (v) a light chain variable domain comprising a CDR-L1 of SEQ ID NO: 52, a CDR-L2 of SEQ ID NO: 68, and a CDR-L3 of SEQ ID NO: 84 NO:53 CDR-L1, SEQ ID NO:69 CDR-L3, and SEQ ID NO:85 CDR-L1; (vi) a light chain variable domain comprising CDR-L1 of SEQ ID NO:54, CDR-L2 of SEQ ID NO:70, and CDR-L3 of SEQ ID NO:86; (vii) a light chain variable domain comprising CDR-L1 of SEQ ID NO:55, CDR-L2 of SEQ ID NO:71, and CDR-L3 of SEQ ID NO:87; (viii) a light chain variable domain comprising CDR-L1 of SEQ ID NO:56, CDR-L2 of SEQ ID NO:72, and CDR-L3 of SEQ ID NO:88; (ix) a light chain variable domain comprising CDR-L1 of SEQ ID NO:57, CDR-L2 of SEQ ID NO:73, and CDR-L3 of SEQ ID NO:89; NO:89; (x) a light chain variable domain comprising CDR-L1 of SEQ ID NO:58, CDR-L2 of SEQ ID NO:74, and CDR-L3 of SEQ ID NO:90; (xi) a light chain variable domain comprising CDR-L1 of SEQ ID NO:59, CDR-L2 of SEQ ID NO:75, and CDR-L3 of SEQ ID NO:91; (xii) a light chain variable domain comprising CDR-L1 of SEQ ID NO:60, CDR-L2 of SEQ ID NO:76, and CDR-L3 of SEQ ID NO:92;(xiii) a light chain variable domain comprising CDR-L1 of SEQ ID NO:61, CDR-L2 of SEQ ID NO:77, and CDR-L3 of SEQ ID NO:93; (xiv) a light chain variable domain comprising CDR-L1 of SEQ ID NO:62, CDR-L2 of SEQ ID NO:78, and CDR-L3 of SEQ ID NO:94; (xv) a light chain variable domain comprising CDR-L1 of SEQ ID NO:63, CDR-L2 of SEQ ID NO:79, and CDR-L3 of SEQ ID NO:95; (xvi) a light chain variable domain comprising CDR-L1 of SEQ ID NO:64, CDR-L2 of SEQ ID NO:80, and CDR-L3 of SEQ ID NO:96; (xvii) a light chain variable domain comprising CDR-L1 of SEQ ID NO:141, CDR-L2 of SEQ ID NO:143, and CDR-L3 of SEQ ID NO: and (xviii) a light chain variable domain comprising CDR-L1 of SEQ ID NO: 142, CDR-L2 of SEQ ID NO: 144, and CDR-L3 of SEQ ID NO: 146.

[0374] In one embodiment, the polynucleotide comprises a nucleotide sequence encoding a VL domain, wherein the VL domain comprises: (xix) a light chain variable domain comprising a CDR-L1 of SEQ ID NO: 159, a CDR-L2 of SEQ ID NO: 170, and a CDR-L3 of SEQ ID NO: 180; (xx) a light chain variable domain comprising a CDR-L1 of SEQ ID NO: 159, a CDR-L2 of SEQ ID NO: 171, and a CDR-L3 of SEQ ID NO: 181; (xxi) a light chain variable domain comprising a CDR-L1 of SEQ ID NO: 160, a CDR-L2 of SEQ ID NO: 172, and a CDR-L3 of SEQ ID NO: 182; (xxii) a light chain variable domain comprising a CDR-L1 of SEQ ID NO: 159, a CDR-L2 of SEQ ID NO: 172, and a CDR-L3 of SEQ ID NO: NO:183; (xxiii) a light chain variable domain comprising CDR-L1 of SEQ ID NO:159, CDR-L2 of SEQ ID NO:171, and CDR-L3 of SEQ ID NO:184; (xxiv) a light chain variable domain comprising CDR-L1 of SEQ ID NO:159, CDR-L2 of SEQ ID NO:173, and CDR-L3 of SEQ ID NO:185; (xxv) a light chain variable domain comprising CDR-L1 of SEQ ID NO:159, CDR-L2 of SEQ ID NO:173, and CDR-L3 of SEQ ID NO:186; (xxvi) a light chain variable domain comprising CDR-L1 of SEQ ID NO:161, CDR-L2 of SEQ ID NO:174, and CDR-L3 of SEQ ID NO:187; (xxvii) a light chain variable domain comprising CDR-L1 of SEQ ID NO:161, CDR-L2 of SEQ ID NO:174, and CDR-L3 of SEQ ID NO:187 NO:162, CDR-L1 of SEQ ID NO:174, and CDR-L3 of SEQ ID NO:188; (xxviii) a light chain variable domain comprising CDR-L1 of SEQ ID NO:163, CDR-L2 of SEQ ID NO:174, and CDR-L3 of SEQ ID NO:188; (xxix) a light chain variable domain comprising CDR-L1 of SEQ ID NO:164, CDR-L2 of SEQ ID NO:174, and CDR-L3 of SEQ ID NO:189; (xxx) a light chain variable domain comprising CDR-L1 of SEQ ID NO:165, CDR-L2 of SEQ ID NO:175, and CDR-L3 of SEQ ID NO:190;(xxxi) a light chain variable domain comprising CDR-L1 of SEQ ID NO: 166, CDR-L2 of SEQ ID NO: 176, and CDR-L3 of SEQ ID NO: 191; (xxxi) a light chain variable domain comprising CDR-L1 of SEQ ID NO: 167, CDR-L2 of SEQ ID NO: 177, and CDR-L3 of SEQ ID NO: 192; (xxxii) a light chain variable domain comprising CDR-L1 of SEQ ID NO: 168, CDR-L2 of SEQ ID NO: 178, and CDR-L3 of SEQ ID NO: 193; (xxxiii) a light chain variable domain comprising CDR-L1 of SEQ ID NO: 169, CDR-L2 of SEQ ID NO: 179, and CDR-L3 of SEQ ID NO: 194.;

[0375] In one embodiment, the polynucleotide comprises a nucleotide sequence encoding a VL domain, wherein the VL domain comprises: (xxxiv) a light chain variable domain comprising CDR-L1 of SEQ ID NO: 159, CDR-L2 of SEQ ID NO: 172, and CDR-L3 of SEQ ID NO: 183; (xxxv) a light chain variable domain comprising CDR-L1 of SEQ ID NO: 159, CDR-L2 of SEQ ID NO: 172, and CDR-L3 of SEQ ID NO: 195.

[0376] In one embodiment, the isolated polynucleotide encoding the MuSK antibody-based molecule encodes any one of the VH and / or VL domain sequences provided below in Table 3. The nucleic acid molecules described herein include isolated polynucleotides, portions of expression vectors, or portions of linear DNA sequences, including linear DNA sequences for in vitro transcription / translation, and vectors compatible with prokaryotic, eukaryotic or filamentous phage expression, secretion and / or display of the antibodies or binding fragments thereof described herein.

[0377] In a preferred embodiment, the polynucleotide comprises a nucleotide sequence encoding a VH comprising an amino acid sequence having at least 80% identity or similarity to SEQ ID NO: 234. In another more preferred embodiment, the polynucleotide comprises a nucleotide sequence encoding a VL comprising an amino acid sequence having at least 80% identity or similarity to SEQ ID NO: 235.

[0378] In a preferred embodiment, the polynucleotide comprises a nucleotide sequence encoding an antibody-based molecule that binds to human muscle-specific tyrosine protein kinase (MuSK), the molecule comprising a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain comprises an amino acid sequence having at least 80% identity or similarity to SEQ ID NO: 234 and the light chain variable domain comprises an amino acid sequence having at least 80% identity or similarity to SEQ ID NO: 235, and

[0379] The heavy chain variable domain contains:

[0380] - a CDR-H1 amino acid sequence comprising SEQ ID NO: 147 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 147,

[0381] - a CDR-H2 amino acid sequence comprising SEQ ID NO: 153 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 153, and

[0382] - comprising SEQ ID NO: 156 or a CDR-H3 amino acid sequence having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 156 (3B2g2m1) and

[0383] The light chain variable domain contains:

[0384] - a CDR-L1 amino acid sequence comprising SEQ ID NO: 159 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 159,

[0385] - a CDR-L2 amino acid sequence comprising SEQ ID NO: 172 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 172, and

[0386] - A CDR-L3 amino acid sequence comprising SEQ ID NO: 195 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 195 (3B2g2m1).

[0387] In one embodiment, the identity or similarity is at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%.

[0388] In a more preferred embodiment, the polynucleotide comprises a nucleotide sequence encoding an antibody-based molecule that binds to human muscle-specific tyrosine protein kinase (MuSK), comprising a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain comprises an amino acid sequence having at least 80% identity or similarity to SEQ ID NO: 234 and the light chain variable domain comprises an amino acid sequence having at least 80% identity or similarity to SEQ ID NO: 235, and wherein the heavy chain variable domain contains:

[0389] - a CDR-H1 amino acid sequence comprising or consisting of SEQ ID NO: 147,

[0390] - a CDR-H2 amino acid sequence comprising or consisting of SEQ ID NO: 153, and

[0391] - a CDR-H3 amino acid sequence (3B2g2m1) comprising or consisting of SEQ ID NO: 156 and

[0392] The light chain variable domain contains:

[0393] - a CDR-L1 amino acid sequence comprising or consisting of SEQ ID NO: 159,

[0394] - a CDR-L2 amino acid sequence comprising or consisting of SEQ ID NO: 172, and

[0395] - a CDR-L3 amino acid sequence comprising or consisting of SEQ ID NO: 195 (3B2g2m1).

[0396] In one embodiment, the identity or similarity is at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%.

[0397] In a more preferred embodiment, the polynucleotide comprises or consists of a nucleotide sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO: 264. In an even more preferred embodiment, the polynucleotide comprises or consists of SEQ ID NO: 264.

[0398] In another more preferred embodiment, the polynucleotide comprises or consists of a nucleotide sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 265. In an even more preferred embodiment, the polynucleotide comprises or consists of SEQ ID NO: 265.

[0399] In a more preferred embodiment, the polynucleotide comprises a nucleotide sequence encoding an antibody-based molecule that binds to human muscle-specific tyrosine protein kinase (MuSK), comprising a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain is encoded by a nucleotide sequence that is at least 80% identical to SEQ ID NO: 264 and the light chain variable domain is encoded by a nucleotide sequence that is at least 80% identical to SEQ ID NO: 265. In one embodiment, the identity is at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%.

[0400] In one embodiment, the polynucleotide comprises:

[0401] a) a nucleotide sequence having at least 80% identity to SEQ ID NO: 276 encoding the full length heavy chain, and

[0402] b) a nucleotide sequence that is at least 80% identical to SEQ ID NO: 278 encoding the full length light chain.

[0403] In one embodiment, the identity is at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%.

[0404] In one embodiment, the polynucleotide comprises:

[0405] a) a nucleotide sequence that is at least 80% identical to SEQ ID NO: 277 encoding the heavy chain variable domain, and

[0406] b) a nucleotide sequence that is at least 80% identical to SEQ ID NO: 279 encoding the light chain variable domain.

[0407] In one embodiment, the identity is at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%.

[0408] In one embodiment, the polynucleotide comprises:

[0409] a) a nucleotide sequence that is at least 80% identical to SEQ ID NO: 276 encoding the full-length heavy chain, wherein the nucleotide sequence comprises a nucleotide sequence that is at least 80% identical to SEQ ID NO: 277 encoding the heavy chain variable domain, and

[0410] b) a nucleotide sequence that is at least 80% identical to SEQ ID NO: 278 encoding the full-length light chain, wherein the nucleotide sequence comprises a nucleotide sequence that is at least 80% identical to SEQ ID NO: 279 encoding the light chain variable domain.

[0411] In one embodiment, the identity is at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%.

[0412] In one embodiment, the polynucleotide comprises:

[0413] a) the nucleotide sequence SEQ ID NO: 276, and

[0414] b) Nucleotide sequence SEQ ID NO: 278.

[0415] The polynucleotides of the present invention can be produced and assembled into complete single-stranded or double-stranded molecules by chemical synthesis, such as solid phase polynucleotide synthesis on an automated polynucleotide synthesizer. Alternatively, the polynucleotides can be produced by other techniques such as PCR, followed by conventional cloning. The techniques for producing or obtaining polynucleotides of a given sequence are well known in the art.

[0416] The polynucleotide may comprise at least one non-coding sequence, such as a promoter or enhancer sequence, an intron, a polyadenylation signal, a cis sequence that promotes RepA binding, etc. The polynucleotide sequence may also comprise additional sequences encoding, for example, a linker sequence, a marker or tag sequence (e.g., a histidine tag or an HA tag) to facilitate purification or detection of the protein, a signal sequence, a fusion protein partner (e.g., RepA, an Fc portion), or a phage coat protein (e.g., pIX or pill).

[0417] Carrier

[0418] In another aspect, a vector (preferably an expression vector) for treating a neuromuscular disorder in a human subject is provided, comprising a polynucleotide encoding a MuSK antibody-based molecule (or an anti-MuSK antibody or antigen-binding fragment thereof) described herein.

[0419] Such vectors include, but are not limited to, plasmid vectors, viral vectors, including, but not limited to, vaccinia vectors, lentiviral vectors, adenoviral vectors, adeno-associated viral vectors, vectors for baculovirus expression, transposon-based vectors, or any other vectors suitable for introducing the polynucleotides described herein into a given organism or genetic background by any means to promote the expression of the encoded antibody polypeptides. In one embodiment, the polynucleotides encoding the heavy chain variable domains, alone or together with the polynucleotides encoding the light chain variable domains as described herein, are combined with a promoter, a translation initiation segment (e.g., a ribosome binding sequence and a start codon), a 3' untranslated region, a polyadenylation signal, a stop codon, and a sequence for transcription termination to form one or more expression vector constructs.

[0420] In one embodiment, the vector is an adenovirus-associated viral (AAV) vector. Many therapeutic AAV vectors suitable for delivering polynucleotides encoding antibodies described herein to the central nervous system are known in the art. See, for example, Deverman et al., "Gene Therapy for Neurological Disorders: Progress and Prospects," Nature Rev. 17: 641-659 (2018), Nature Rev. 17: 641-659 (2018), which are incorporated herein by reference in their entirety. Suitable AAV vectors include serotypes AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, or AAV11 modified in natural form or for enhanced tropism. AAV vectors known to have tropism for the CNS that are particularly suitable for therapeutic expression of the MuSK antibodies described herein include AAV1, AAV2, AAV4, AAV5, AAV8, and AAV9 modified in natural form or for enhanced tropism. In one embodiment, the AAV vector is an AAV2 vector. In another embodiment, the AAV vector is an AAV5 vector (Vitale et al., "Anti-tau Conformational scFv MC1 Antibody Efficiently Reduces Pathological Tau Species in Adult JNPL3 Mice," Acta Neuropathol. Commun. 6: 82 (2018), which is hereby incorporated by reference in its entirety). In another embodiment, the AAV vector is an AAV9 vector (Haiyan et al., “Targeting Root Cause by Systemic scAAV9-hIDS Gene Delivery: Functional Correction and Reversal of Severe MPSII in Mice,” Mol. Ther. Methods Clin. Dev. 10:327-340 (2018), which is hereby incorporated by reference in its entirety).In another embodiment, the AAV vector is an AAVrh10 vector (Liu et al., “Vectored Intracerebral Immunizations with the Anti-Tau Monoclonal Antibody PHF1 Markedly Reduces Tau Pathology in Mutant Transgenic Mice,” J. Neurosci. 36(49): 12425-35 (2016), which is hereby incorporated by reference in its entirety).

[0421] In another embodiment, the AAV vector is a hybrid vector comprising a genome of one serotype (e.g., AAV2) and a capsid protein of another serotype (e.g., AAV1 or AAV3 to 9) to control tropism. See, for example, Broekman et al., "Adeno-associated Virus Vectors Serotyped with AAV8 Capsid are More Efficient than AAV-1 or -2 Serotypes for Widespread Gene Delivery to the Neonatal Mouse Brain," Neuroscience 138:501-510 (2006), which is incorporated herein by reference in its entirety. In one embodiment, the AAV vector is an AAV2 / 8 hybrid vector (Ising et al., "AAV-mediated Expression of Anti-Tau ScFv Decreases Tau Accumulation in a Mouse Model of Tauopathy," J. Exp. Med. 214 (5): 1227 (2017), which is incorporated herein by reference in its entirety). In another embodiment, the AAV vector is an AAV2 / 9 hybrid vector (Simon et al., “A Rapid Gene Delivery-Based Mouse Model for Early-Stage Alzheimer Disease-Type Tauopathy,” J. Neuropath. Exp. Neurol. 72(11): 1062-71 (2013), which is hereby incorporated by reference in its entirety).

[0422] In another embodiment, the AAV vector is an AAV vector that has been engineered or selected for its: enhanced CNS transduction following intraparenchymal administration, such as AAV-DJ (Grimm et al., J. Viol. 82:5887-5911 (2008), which is hereby incorporated by reference in its entirety); improved transduction of neural stem and progenitor cells, such as SCH9 and AAV4.18 (Murlidharan et al., J. Virol. 89:3976-3987 (2015) and Ojala et al., Mol. Ther. 26:304-319 (2018), which are hereby incorporated by reference in their entirety); enhanced retrograde transduction, such as rAAV2-retro (Muller et al., J. Viol. 89:3976-3987 (2015) and Ojala et al., Mol. Ther. 26:304-319 (2018), which are hereby incorporated by reference in their entirety); et al., Nat. Biotechnol. 21: 1040-1046 (2003), which is hereby incorporated by reference in its entirety); selective transduction into brain endothelial cells, such as AAV-BRI (Korbelin et al., EMBO Mol. Med. 8: 609-625 (2016), which is hereby incorporated by reference in its entirety); or enhanced transduction of the adult CNS after IV administration, such as AAV-PHP.B and AAVPHP.eB (Deverman et al., Nat. Biotechnol. 34: 204-209 (2016) and Chan et al., Nat. Neurosci. 20: 1172-1179 (2017), which are hereby incorporated by reference in their entirety.

[0423] According to this embodiment, the expression vector construct encoding the MuSK antibody-based molecule comprises a polynucleotide encoding a heavy chain polypeptide, a functional fragment thereof, a variant thereof, or a combination thereof. The expression construct may alternatively comprise a nucleic acid sequence encoding a light chain polypeptide, a functional fragment thereof, a variant thereof, or a combination thereof. In one embodiment, the expression vector construct comprises a nucleic acid sequence encoding a heavy chain polypeptide, a functional fragment thereof, or a variant thereof and a light chain polypeptide, a functional fragment thereof, or a variant thereof.

[0424] In one embodiment, the expression construct further comprises a promoter sequence suitable for driving the expression of a molecule based on the MuSK antibody. Suitable promoter sequences include, but are not limited to, elongation factor 1-alpha promoter (EF1a) promoter, phosphoglycerate kinase-1 promoter (PGK) promoter, cytomegalovirus immediate early gene promoter (CMV), chimeric liver-specific promoter (liver-specific promoter, LSP), cytomegalovirus enhancer / chicken β-actin promoter (CAG), tetracycline responsive promoter (TRE), thyroxine transporter promoter (TTR), simian virus 40 promoter (SV40) and CK6 promoter. Other promoters suitable for driving gene expression in mammalian cells known in the art are also suitable for incorporation into the expression construct disclosed herein.

[0425] In one embodiment, the expression construct (or expression vector) also encodes a linker sequence. The linker sequence may encode an amino acid sequence that spatially separates and / or connects one or more components of the expression construct (the heavy and light chain components of the encoded antibody).

[0426] In a preferred embodiment, the expression vector comprises: a polynucleotide encoding an antibody-based molecule that binds to human muscle-specific tyrosine protein kinase (MuSK) and comprises a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain comprises an amino acid sequence having at least 80% identity or similarity to SEQ ID NO: 234 and the light chain variable domain comprises an amino acid sequence having at least 80% identity or similarity to SEQ ID NO: 235, and wherein the heavy chain variable domain comprises:

[0427] - a CDR-H1 amino acid sequence comprising SEQ ID NO: 147 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 147,

[0428] - a CDR-H2 amino acid sequence comprising SEQ ID NO: 153 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 153, and

[0429] - comprising SEQ ID NO: 156 or a CDR-H3 amino acid sequence having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 156 (3B2g2m1) and

[0430] The light chain variable domain contains:

[0431] - a CDR-L1 amino acid sequence comprising SEQ ID NO: 159 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 159,

[0432] - a CDR-L2 amino acid sequence comprising SEQ ID NO: 172 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 172, and

[0433] - A CDR-L3 amino acid sequence comprising SEQ ID NO: 195 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 195 (3B2g2m1).

[0434] In one embodiment, the identity or similarity is at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%.

[0435] In a more preferred embodiment, the expression vector comprises nucleotides encoding an antibody-based molecule that binds to human muscle-specific tyrosine protein kinase (MuSK) and comprises a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain comprises an amino acid sequence having at least 80% identity or similarity to SEQ ID NO: 234 and the light chain variable domain comprises an amino acid sequence having at least 80% identity or similarity to SEQ ID NO: 235, and wherein the heavy chain variable domain comprises:

[0436] - a CDR-H1 amino acid sequence comprising or consisting of SEQ ID NO: 147,

[0437] - a CDR-H2 amino acid sequence comprising or consisting of SEQ ID NO: 153, and

[0438] - a CDR-H3 amino acid sequence (3B2g2m1) comprising or consisting of SEQ ID NO: 156 and

[0439] The light chain variable domain contains:

[0440] - a CDR-L1 amino acid sequence comprising or consisting of SEQ ID NO: 159,

[0441] - a CDR-L2 amino acid sequence comprising or consisting of SEQ ID NO: 172, and

[0442] - a CDR-L3 amino acid sequence comprising or consisting of SEQ ID NO: 195 (3B2g2m1).

[0443] In one embodiment, the identity or similarity is at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%.

[0444] In one embodiment, the expression vector comprises a polynucleotide encoding an antibody-based molecule that binds to human muscle-specific tyrosine protein kinase (MuSK) and comprises:

[0445] a) a nucleotide sequence having at least 80% identity to SEQ ID NO: 276 encoding the full length heavy chain, and

[0446] b) a nucleotide sequence that is at least 80% identical to SEQ ID NO: 278 encoding the full length light chain.

[0447] In one embodiment, the identity is at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%.

[0448] In one embodiment, the expression vector comprises a polynucleotide encoding an antibody-based molecule that binds to human muscle-specific tyrosine protein kinase (MuSK) and comprises:

[0449] a) a nucleotide sequence that is at least 80% identical to SEQ ID NO: 277 encoding the heavy chain variable domain, and

[0450] b) a nucleotide sequence that is at least 80% identical to SEQ ID NO: 279 encoding the light chain variable domain.

[0451] In one embodiment, the identity is at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%.

[0452] In a more preferred embodiment, the expression vector comprises a polynucleotide encoding an antibody-based molecule that binds to human muscle-specific tyrosine protein kinase (MuSK) and comprises:

[0453] c) a nucleotide sequence that is at least 80% identical to SEQ ID NO: 276 encoding the full-length heavy chain, wherein the nucleotide sequence comprises a nucleotide sequence that is at least 80% identical to SEQ ID NO: 277 encoding the heavy chain variable domain, and

[0454] d) a nucleotide sequence that is at least 80% identical to SEQ ID NO: 278 encoding the full-length light chain, wherein the nucleotide sequence comprises a nucleotide sequence that is at least 80% identical to SEQ ID NO: 279 encoding the light chain variable domain.

[0455] In one embodiment, the identity is at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%.

[0456] In a more preferred embodiment, the expression vector comprises a polynucleotide encoding an antibody-based molecule that binds to human muscle-specific tyrosine protein kinase (MuSK) and comprises:

[0457] a) the nucleotide sequence SEQ ID NO: 276, and

[0458] b) Nucleotide sequence SEQ ID NO: 278.

[0459] Host cells

[0460] Another aspect of the invention is a host cell or cell-free expression system for treating a neuromuscular disease in a human subject, wherein the cell contains an expression vector encoding a MuSK antibody (or an antigen-binding fragment thereof) and optionally produces the MuSK antibody described herein.

[0461] The MuSK antibody-based molecules described herein can optionally be produced by a cell line, a mixed cell line, an immortalized cell, or a clonal population of immortalized cells, as is known in the art (see, e.g.,

[0462] Ausubel et al., ed., Current Protocols in Molecular Biology, John Wiley & Sons, Inc., NY, NY (1987-2001); Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor, NY (1989); Harlow and Lane, Antibodies, a Laboratory Manual, Cold Spring Harbor, NY (1989); Colligan et al. al., eds., Current Protocols in Immunology, John Wiley&Sons, lnc., NY (1994-2001); Colligan et al., Current Protocols in Protein Science, John Wiley&Sons, NY, NY, (1997-2001),

[0463] which is hereby incorporated by reference in its entirety).

[0464] In some embodiments, the host cell selected for expression can be of mammalian origin. Suitable mammalian host cells include but are not limited to COS-1 cells, COS-7 cells, HEK293 cells, BHK21 cells, CHO cells, BSC-1 cells, HeG2 cells, SP2 / 0 cells, HeLa cells, mammalian myeloma cells, mammalian lymphoma cells or any derived, immortalized or transformed cells thereof. Other suitable host cells include but are not limited to yeast cells, insect cells and plant cells. Alternatively, host cells can be selected to be species or organisms that cannot make polypeptide glycosylation, such as prokaryotic cells or organisms, such as BL21, BL21 (DE3), BL21-GOLD (DE3), XL1-Blue, JM109, HMS174, HMS174 (DE3), and any natural or modified Escherichia coli (E.coli spp), Klebsiella (Klebsiellaspp) or Pseudomonas (Pseudomonas spp) strains.

[0465] The molecules based on MuSK antibodies described herein can be prepared by any of a variety of techniques using the isolated polynucleotides, vectors and host cells described above. In general, antibodies can be produced by cell culture techniques, including the production of monoclonal antibodies by conventional techniques, or by transfecting antibody genes, heavy chains and / or light chains into suitable bacteria or mammalian cell hosts to allow the production of antibodies, wherein the antibodies can be recombinant. In one embodiment, the molecules based on MuSK antibodies described herein are monoclonal antibodies or functional binding fragments thereof. Standard molecular biology techniques are used to prepare recombinant expression vectors, transfect host cells, select transformants, culture host cells and recover antibodies from culture medium. Transfection of host cells can be performed using a variety of techniques commonly used to introduce exogenous DNA into prokaryotic or eukaryotic host cells, such as by electroporation, calcium phosphate precipitation, DEAE-dextran transfection, etc. Although the antibodies described herein can be expressed in prokaryotic or eukaryotic host cells, it is sometimes preferred to express antibodies in eukaryotic cells, particularly in mammalian cells, because such eukaryotic cells (and particularly mammalian cells) are more likely to assemble and secrete antibodies that are properly folded and immunologically active than prokaryotic cells.

[0466] As described above, exemplary mammalian host cells for expressing the recombinant antibodies of the present invention include Chinese hamster ovary (CHO cells) (including dhfr-CHO cells, described in Urlaub and Chasin, Proc. Natl. Acad. Sci. USA, 77: 4216-4220 (1980), which is hereby incorporated by reference in its entirety). Other suitable mammalian host cells include, but are not limited to, NSO myeloma cells, COS cells, and SP2 cells. When a recombinant expression vector encoding an antibody gene is introduced into a mammalian host cell, the antibody is produced by culturing the host cell for a period of time sufficient to allow the antibody to be expressed in the host cell or, more preferably, to allow the antibody to be secreted into the culture medium in which the host cell is cultured.

[0467] Host cells can also be used to produce functional antibody fragments, such as Fab fragments or scFv molecules.It is understood that variations of the above operations are also within the scope of the present invention.For example, it is desirable to transfect host cells with DNA encoding the functional fragments of the light chain and / or heavy chain of the antibody described herein.Recombinant DNA technology can also be used to remove some or all of the DNA encoding either or both of the light chain and the heavy chain that are not necessary for combining with the target antigen.Molecules expressed from such truncated DNA molecules are also encompassed in antibodies described herein.

[0468] Antibodies and antibody binding fragments are recovered and purified from recombinant cell cultures by known methods, including but not limited to protein A purification, ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxyapatite chromatography, and lectin chromatography. High performance liquid chromatography ("HPLC") can also be used for purification.

[0469] In a preferred embodiment, the host cell expresses an antibody-based molecule that binds to human muscle-specific tyrosine protein kinase (MuSK) comprising a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain comprises an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 234 and the light chain variable domain comprises an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 235, and

[0470] The heavy chain variable domain contains:

[0471] - a CDR-H1 amino acid sequence comprising SEQ ID NO: 147 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 147,

[0472] - a CDR-H2 amino acid sequence comprising SEQ ID NO: 153 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 153, and

[0473] - comprising SEQ ID NO: 156 or a CDR-H3 amino acid sequence having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 156 (3B2g2m1) and

[0474] The light chain variable domain contains:

[0475] - a CDR-L1 amino acid sequence comprising SEQ ID NO: 159 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 159,

[0476] - a CDR-L2 amino acid sequence comprising SEQ ID NO: 172 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 172, and

[0477] - A CDR-L3 amino acid sequence comprising SEQ ID NO: 195 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 195 (3B2g2m1).

[0478] In one embodiment, the identity or similarity is at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%.

[0479] In a more preferred embodiment, the host cell expresses an antibody-based molecule that binds to human muscle-specific tyrosine protein kinase (MuSK) comprising a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain comprises an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 234 and the light chain variable domain comprises an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 235, and

[0480] The heavy chain variable domain contains:

[0481] - a CDR-H1 amino acid sequence comprising or consisting of SEQ ID NO: 147,

[0482] - a CDR-H2 amino acid sequence comprising or consisting of SEQ ID NO: 153, and

[0483] - a CDR-H3 amino acid sequence (3B2g2m1) comprising or consisting of SEQ ID NO: 156 and

[0484] The light chain variable domain contains:

[0485] - a CDR-L1 amino acid sequence comprising or consisting of SEQ ID NO: 159,

[0486] - a CDR-L2 amino acid sequence comprising or consisting of SEQ ID NO: 172, and

[0487] - a CDR-L3 amino acid sequence comprising or consisting of SEQ ID NO: 195 (3B2g2m1).

[0488] In one embodiment, the identity or similarity is at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%.

[0489] In one embodiment, the host cell expresses an antibody-based molecule that binds to human muscle-specific tyrosine protein kinase (MuSK) comprising:

[0490] a) a nucleotide sequence having at least 80% identity to SEQ ID NO: 276 encoding the full length heavy chain, and

[0491] b) a nucleotide sequence that is at least 80% identical to SEQ ID NO: 278 encoding the full length light chain.

[0492] In one embodiment, the identity is at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%.

[0493] In one embodiment, the host cell expresses an antibody-based molecule that binds to human muscle-specific tyrosine protein kinase (MuSK) comprising:

[0494] a) a nucleotide sequence that is at least 80% identical to SEQ ID NO: 277 encoding the heavy chain variable domain, and

[0495] b) a nucleotide sequence that is at least 80% identical to SEQ ID NO: 279 encoding the light chain variable domain.

[0496] In one embodiment, the identity is at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%.

[0497] In one embodiment, the host cell expresses an antibody-based molecule that binds to human muscle-specific tyrosine protein kinase (MuSK) comprising:

[0498] a) a nucleotide sequence that is at least 80% identical to SEQ ID NO: 276 encoding the full-length heavy chain, wherein the nucleotide sequence comprises a nucleotide sequence that is at least 80% identical to SEQ ID NO: 277 encoding the heavy chain variable domain, and

[0499] b) a nucleotide sequence that is at least 80% identical to SEQ ID NO: 278 encoding the full-length light chain, wherein the nucleotide sequence comprises a nucleotide sequence that is at least 80% identical to SEQ ID NO: 279 encoding the light chain variable domain.

[0500] In one embodiment, the identity is at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%.

[0501] In one embodiment, the host cell expresses an antibody-based molecule that binds to human muscle-specific tyrosine protein kinase (MuSK) comprising:

[0502] a) the nucleotide sequence SEQ ID NO: 276, and

[0503] b) Nucleotide sequence SEQ ID NO: 278.

[0504] Compositions comprising MuSK antibody-based molecules

[0505] The MuSK antibody-based molecules or polynucleotides encoding MuSK antibody-based molecules of the present invention may be advantageously administered as a composition.

[0506] Thus, in another aspect, there is provided a composition for treating a neuromuscular disorder in a human subject, the composition comprising an antibody or antigen-binding fragment, a polynucleotide, an expression vector or a host cell or a cell-free expression system as defined herein.

[0507] In one embodiment, the composition is a pharmaceutical composition. In one embodiment, the pharmaceutical composition comprises at least one pharmaceutically acceptable carrier or excipient.

[0508] In one embodiment, such a composition is a pharmaceutical composition comprising an active therapeutic agent (ie, a MuSK antibody) and one or more of a variety of other pharmaceutically acceptable components. See Remington: The Science and Practice of Pharmacy (21 stEdition) (2005) (Troy, DB et al. (Eds.) Lippincott Williams & Wilkins (Publs.), Baltimore MD), which is hereby incorporated by reference in its entirety. The preferred form depends on the intended mode of administration and therapeutic application. Depending on the desired formulation, the composition may also include a pharmaceutically acceptable non-toxic carrier, excipient, diluent, filler, salt, buffer, detergent (e.g., non-ionic detergent, such as Tween-20 or Tween-80), stabilizer (e.g., sugar or protein-free amino acids), preservative, tissue fixative, solubilizer and / or other substances suitable for inclusion in a pharmaceutical composition, and they are carriers commonly used to formulate pharmaceutical compositions for animal or human administration. The diluent is selected so as not to affect the biological activity of the combination. Some examples of such diluents are distilled water, physiological phosphate buffered saline, Ringer's solution, dextrose solution and Hank's solution. In addition, the pharmaceutical composition or formulation may also include other carriers, or non-toxic, non-therapeutic, non-immunogenic stabilizers, etc. Examples of suitable aqueous and non-aqueous carriers that can be used in the pharmaceutical compositions of the present invention include water, saline, phosphate buffered saline, ethanol, dextrose, polyols (e.g., glycerol, propylene glycol, polyethylene glycol, etc.) and suitable mixtures thereof, vegetable oils (e.g., olive oil, corn oil, peanut oil, cottonseed oil, and sesame oil), carboxymethylcellulose colloid solutions, tragacanth gum, and injectable organic esters (e.g., ethyl oleate), and / or various buffers. Other carriers are well known in the pharmaceutical art.

[0509] Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. The use of such media and agents for pharmaceutically active substances is known in the art. Unless any conventional media or agents are incompatible with the active compound, their use in the pharmaceutical compositions of the present invention is contemplated.

[0510] The composition may also include large, slowly metabolized macromolecules such as proteins, polysaccharides (e.g., chitosan), polylactic acid, polyglycolic acid and copolymers (e.g., latex functionalized agarose, agarose, cellulose, etc.), polymeric amino acids, amino acid copolymers, and lipid aggregates (e.g., oil droplets or liposomes). The suitability of the carrier and other components of the pharmaceutical composition is determined based on the absence of a significant negative impact on the desired biological properties of the active antibody-based molecules of the invention (e.g., less than a significant effect on antigen binding (e.g., 10% or less relative inhibition, 5% or less relative inhibition, etc.)).

[0511] The pharmaceutical composition of the present invention may also contain pharmaceutically acceptable antioxidants, such as (1) water-soluble antioxidants, such as ascorbic acid, cysteine ​​hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite, etc.; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, α-tocopherol, etc.; and (3) metal chelators, such as citric acid, ethylenediaminetetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, etc.

[0512] The pharmaceutical compositions of the present invention may also include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, glycerol, or sodium chloride in the composition.

[0513] The pharmaceutical composition of the present invention may also include one or more adjuvants suitable for the selected route of administration, such as preservatives, wetting agents, emulsifiers, dispersants, preservatives or buffers, which can improve the shelf life or effectiveness of the pharmaceutical composition. The antibody of the present invention can be prepared with a carrier that protects the antibody from rapid release, such as a controlled release formulation, including implants, transdermal patches and microencapsulated delivery systems. Such a carrier may include gelatin, glyceryl monostearate, glyceryl distearate, biodegradable, biocompatible polymers, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters and polylactic acid, alone or with wax, or other substances well known in the art. The method for preparing such a preparation is generally known to those skilled in the art. See, for example, SUSTAINED AND CONTROLLED RELEASE DRUG DELIVERY SYSTEMS, JR Robinson, ed., Marcel Dekker, Inc., New York, 1978.

[0514] In one embodiment, the antibodies of the invention can be formulated to ensure proper distribution in vivo. Pharmaceutically acceptable carriers for parenteral administration include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. The use of such media and agents for pharmaceutically active substances is known in the art.

[0515] Pharmaceutical compositions for injection must usually be sterile and stable under preparation and storage conditions. Compositions can be formulated into solutions, microemulsions, liposomes or other ordered structures suitable for achieving high drug concentrations. The carrier can be an aqueous or non-aqueous solvent or dispersion medium, containing, for example, water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, etc.) and suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters, such as ethyl oleate. Appropriate fluidity can be maintained, for example, by using a coating (such as lecithin), by maintaining the required particle size in the case of a dispersion, and by using a surfactant to maintain. In many cases, it will be preferred to include an isotonic agent, such as sugar, polyols (such as glycerol, mannitol, sorbitol) or sodium chloride in the composition. By including a medicament that delays absorption in the composition, such as monostearate and gelatin, extended absorption of injectable compositions can be achieved. Sterile injectable solutions can be prepared by incorporating the desired amount of active compound with, for example, one of the ingredients listed above or a combination (as required) into a suitable solvent, followed by sterilization microfiltration. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the desired other ingredients. In the case of sterile powders for the preparation of sterile injectable solutions, examples of preparation methods are vacuum drying and freeze drying (lyophilization), which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

[0516] For parenteral administration, the medicament of the present invention is usually formulated into a solution or suspension of an injectable dose of a substance in a physiologically acceptable diluent together with a pharmaceutical carrier, and the pharmaceutical carrier can be a sterile liquid, such as water, oil, saline, glycerol or ethanol. In addition, auxiliary substances, such as wetting agents or emulsifiers, surfactants, pH buffer substances, etc., can be present in the composition. Other components of the pharmaceutical composition are components of petroleum, animal, plant or synthetic origin. Peanut oil, soybean oil and mineral oil are all examples of available materials. In general, glycols (such as propylene glycol or polyethylene glycol) are preferred liquid carriers, particularly for injectable solutions. The medicament of the present invention can be used in the form of a reservoir injection or an implant preparation, which can be formulated in such a way that the active ingredient is allowed to be continuously released.

[0517] Typically, the composition is prepared as an injectable, as a liquid solution or suspension; solid forms suitable for dissolution or suspension in a liquid carrier prior to injection may also be prepared. The formulation may also be emulsified or encapsulated in liposomes or microparticles, such as polylactide, polyglycolide or copolymers, to enhance the effect of the adjuvant (Langer, et al., Science 249: 1527 (1990); Hanes, et al., Advanced Drug Delivery Reviews 28: 97-119 (1997), which are hereby incorporated by reference in their entirety). Additional formulations suitable for other modes of administration include oral, intranasal and pulmonary formulations, suppositories and transdermal applications.

[0518] In one embodiment, the composition comprises an anti-MuSK antibody (or antigen-binding fragment) comprising a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 147, CDR-H2 of SEQ ID NO: 153, and CDR-H3 of SEQ ID NO: 156, and a light chain variable domain (3B2g2m1) comprising CDR-L1 of SEQ ID NO: 159, CDR-L2 of SEQ ID NO: 172, and CDR-L3 of SEQ ID NO: 195.

[0519] In one embodiment, the composition comprises an anti-MuSK antibody (or antigen-binding fragment) comprising a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 147, CDR-H2 of SEQ ID NO: 153, and CDR-H3 of SEQ ID NO: 156, and a light chain variable domain (3B2g1m1) comprising CDR-L1 of SEQ ID NO: 159, CDR-L2 of SEQ ID NO: 172, and CDR-L3 of SEQ ID NO: 183.

[0520] In one embodiment, the anti-MuSK antibody (or antigen-binding fragment) contains: a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 147, CDR-H2 of SEQ ID NO: 154, and CDR-H3 of SEQ ID NO: 156, and a light chain variable domain (3B2g1m2) comprising CDR-L1 of SEQ ID NO: 159, CDR-L2 of SEQ ID NO: 172, and CDR-L3 of SEQ ID NO: 183.

[0521] In one embodiment, the anti-MuSK antibody (or antigen-binding fragment) contains: a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 147, CDR-H2 of SEQ ID NO: 154, and CDR-H3 of SEQ ID NO: 156, and a light chain variable domain (3B2g2m2) comprising CDR-L1 of SEQ ID NO: 159, CDR-L2 of SEQ ID NO: 172, and CDR-L3 of SEQ ID NO: 195.

[0522] In one embodiment, the anti-MuSK antibody (or antigen-binding fragment) contains: a heavy chain variable domain comprising CDR-H1 of SEQ ID NO: 147, CDR-H2 of SEQ ID NO: 150, and CDR-H3 of SEQ ID NO: 156, and a light chain variable domain (3B2) comprising CDR-L1 of SEQ ID NO: 159, CDR-L2 of SEQ ID NO: 172, and CDR-L3 of SEQ ID NO: 183.

[0523] In a preferred embodiment, the composition comprises an antibody or antigen-binding fragment that binds to human muscle-specific tyrosine protein kinase (MuSK), comprising a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain comprises an amino acid sequence having at least 80% identity or similarity to SEQ ID NO: 234 and the light chain variable domain comprises an amino acid sequence having at least 80% identity or similarity to SEQ ID NO: 235, and

[0524] The heavy chain variable domain contains:

[0525] - a CDR-H1 amino acid sequence comprising SEQ ID NO: 147 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 147,

[0526] - a CDR-H2 amino acid sequence comprising SEQ ID NO: 153 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 153, and

[0527] - comprising SEQ ID NO: 156 or a CDR-H3 amino acid sequence having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 156 (3B2g2m1) and

[0528] The light chain variable domain contains:

[0529] - a CDR-L1 amino acid sequence comprising SEQ ID NO: 159 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 159,

[0530] - a CDR-L2 amino acid sequence comprising SEQ ID NO: 172 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 172, and

[0531] - A CDR-L3 amino acid sequence comprising SEQ ID NO: 195 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 195 (3B2g2m1).

[0532] In one embodiment, the identity or similarity is at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%.

[0533] In a more preferred embodiment, the composition comprises an antibody or antigen-binding fragment that binds to human muscle-specific tyrosine protein kinase (MuSK), comprising a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain comprises an amino acid sequence having at least 80% identity or similarity to SEQ ID NO: 234 and the light chain variable domain comprises an amino acid sequence having at least 80% identity or similarity to SEQ ID NO: 235, and

[0534] The heavy chain variable domain contains:

[0535] - a CDR-H1 amino acid sequence comprising or consisting of SEQ ID NO: 147,

[0536] - a CDR-H2 amino acid sequence comprising or consisting of SEQ ID NO: 153, and

[0537] - a CDR-H3 amino acid sequence (3B2g2m1) comprising or consisting of SEQ ID NO: 156 and

[0538] The light chain variable domain contains:

[0539] - a CDR-L1 amino acid sequence comprising or consisting of SEQ ID NO: 159,

[0540] - a CDR-L2 amino acid sequence comprising or consisting of SEQ ID NO: 172, and

[0541] - a CDR-L3 amino acid sequence comprising or consisting of SEQ ID NO: 195 (3B2g2m1).

[0542] In one embodiment, the identity or similarity is at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%.

[0543] In a preferred embodiment, the composition comprises an antibody or antigen-binding fragment that binds to human muscle-specific tyrosine protein kinase (MuSK), comprising a wild-type human IgG constant Fc region, a heavy chain variable domain, and a light chain variable domain, wherein the wild-type human IgG constant Fc region comprises SEQ ID NO: 266 or SEQ ID NO: 267, a heavy chain variable domain, and a light chain variable domain, wherein the heavy chain variable domain comprises an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 234 and the light chain variable domain comprises an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 235, and

[0544] The heavy chain variable domain contains:

[0545] - a CDR-H1 amino acid sequence comprising SEQ ID NO: 147 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 147,

[0546] - a CDR-H2 amino acid sequence comprising SEQ ID NO: 153 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 153, and

[0547] - comprising SEQ ID NO: 156 or a CDR-H3 amino acid sequence having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 156 (3B2g2m1) and

[0548] The light chain variable domain contains:

[0549] - a CDR-L1 amino acid sequence comprising SEQ ID NO: 159 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 159,

[0550] - a CDR-L2 amino acid sequence comprising SEQ ID NO: 172 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 172, and

[0551] - A CDR-L3 amino acid sequence comprising SEQ ID NO: 195 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 195 (3B2g2m1).

[0552] In one embodiment, the identity or similarity is at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%.

[0553] In a more preferred embodiment, the composition comprises an antibody or antigen-binding fragment that binds to human muscle-specific tyrosine protein kinase (MuSK), comprising a wild-type human IgG constant Fc region, a heavy chain variable domain, and a light chain variable domain, wherein the wild-type human IgG constant Fc region comprises SEQ ID NO: 266 or SEQ ID NO: 267, a heavy chain variable domain, and a light chain variable domain, wherein the heavy chain variable domain comprises an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 234 and the light chain variable domain comprises an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 235, and

[0554] The heavy chain variable domain contains:

[0555] - a CDR-H1 amino acid sequence comprising or consisting of SEQ ID NO: 147,

[0556] - a CDR-H2 amino acid sequence comprising or consisting of SEQ ID NO: 153, and

[0557] - a CDR-H3 amino acid sequence (3B2g2m1) comprising or consisting of SEQ ID NO: 156 and

[0558] The light chain variable domain contains:

[0559] - a CDR-L1 amino acid sequence comprising or consisting of SEQ ID NO: 159,

[0560] - a CDR-L2 amino acid sequence comprising or consisting of SEQ ID NO: 172, and

[0561] - a CDR-L3 amino acid sequence comprising or consisting of SEQ ID NO: 195 (3B2g2m1).

[0562] In one embodiment, the identity or similarity is at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%.

[0563] In a preferred embodiment, the composition comprises an antibody or antigen-binding fragment that binds to human muscle-specific tyrosine protein kinase (MuSK), comprising a wild-type human IgG constant Fc region (wherein L234A and / or L235A substitutions numbered according to the EU numbering system are introduced into the Fc region), a heavy chain variable domain, and a light chain variable domain, wherein the wild-type human IgG constant Fc region comprises SEQ ID NO: 266 or SEQ ID NO: 267, a heavy chain variable domain, and a light chain variable domain, wherein the heavy chain variable domain comprises an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 234 and the light chain variable domain comprises an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 235, and

[0564] The heavy chain variable domain contains:

[0565] - a CDR-H1 amino acid sequence comprising SEQ ID NO: 147 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 147,

[0566] - a CDR-H2 amino acid sequence comprising SEQ ID NO: 153 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 153, and

[0567] - comprising SEQ ID NO: 156 or a CDR-H3 amino acid sequence having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 156 (3B2g2m1) and

[0568] The light chain variable domain contains:

[0569] - a CDR-L1 amino acid sequence comprising SEQ ID NO: 159 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 159,

[0570] - a CDR-L2 amino acid sequence comprising SEQ ID NO: 172 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 172, and

[0571] - A CDR-L3 amino acid sequence comprising SEQ ID NO: 195 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 195 (3B2g2m1).

[0572] In one embodiment, the identity or similarity is at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%.

[0573] In a more preferred embodiment, the composition comprises an antibody or antigen-binding fragment that binds to human muscle-specific tyrosine protein kinase (MuSK), comprising a wild-type human IgG constant Fc region (wherein L234A and / or L235A substitutions numbered according to the EU numbering system are introduced into the Fc region), a heavy chain variable domain, and a light chain variable domain, wherein the wild-type human IgG constant Fc region comprises SEQ ID NO: 266 or SEQ ID NO: 267, a heavy chain variable domain, and a light chain variable domain, wherein the heavy chain variable domain comprises an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 234 and the light chain variable domain comprises an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 235, and

[0574] The heavy chain variable domain contains:

[0575] - a CDR-H1 amino acid sequence comprising or consisting of SEQ ID NO: 147,

[0576] - a CDR-H2 amino acid sequence comprising or consisting of SEQ ID NO: 153, and

[0577] - a CDR-H3 amino acid sequence (3B2g2m1) comprising or consisting of SEQ ID NO: 156 and

[0578] The light chain variable domain contains:

[0579] - a CDR-L1 amino acid sequence comprising or consisting of SEQ ID NO: 159,

[0580] - a CDR-L2 amino acid sequence comprising or consisting of SEQ ID NO: 172, and

[0581] - a CDR-L3 amino acid sequence comprising or consisting of SEQ ID NO: 195 (3B2g2m1).

[0582] In one embodiment, the identity or similarity is at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%.

[0583] In one embodiment, the composition comprises an antibody or antigen-binding fragment that binds to human muscle-specific tyrosine protein kinase (MuSK) comprising:

[0584] a) a full length heavy chain comprising an amino acid sequence having at least 80% identity or similarity to SEQ ID NO: 268 and

[0585] b) a full-length light chain comprising an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 269, and

[0586] c) in which one or more of the following mutations (all numbered according to the EU numbering system) have been introduced into the full-length heavy chain: N297A substitution; N297Q substitution; L234A substitution; L234D substitution; L234E substitution; L234G substitution; L234H substitution; L234F substitution; L234K substitution; L234Q substitution; L234R substitution; L234S substitution; L234T substitution; L235A substitution; L235D substitution; L235E substitution; L235F substitution; L235G substitution; L235V substitution; L235H substitution; L235I substitution; L235K substitution; L235R substitution; L235S substitution; L235T substitution; L235Q substitution; L237A substitution; S239D substitution; E233P substitution replacement; L234V replacement; C236 deletion; G236E replacement; G236R replacement; G236K replacement; G237A replacement; P238A replacement; F243L replacement; D265A replacement; S267E replacement; H268A replacement; R292P replacement; Y300L replacement; K322A replacement; K322Q replacement; A327Q replacement; L328F replacement; L328R replacement; P329A replacement; P329G replacement; A330L replacement; A330S replacement; P331S replacement; I332E replacement; P396L replacement; or each of the combinations of the mutations described above in the fourth embodiment of the present application, preferably the mutation is L234A or L235A, more preferably the mutation is L234A and L235A.

[0587] In one embodiment, the composition comprises an antibody or antigen-binding fragment that binds to human muscle-specific tyrosine protein kinase (MuSK) comprising:

[0588] a) a full-length heavy chain comprising SEQ ID NO: 268, and

[0589] b) a full-length light chain comprising SEQ ID NO: 269, and

[0590] c) wherein the full length heavy chain comprises L234A and L235A mutations numbered according to the EU numbering system.

[0591] In one embodiment, binding to an effector ligand is reduced by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or is no longer detectable, compared to binding of an antibody without any amino acid substitutions in its human IgG constant Fc region to the same ligand.

[0592] In one embodiment, the composition comprises an antibody or antigen-binding fragment that binds to human muscle-specific tyrosine protein kinase (MuSK) comprising:

[0593] a) a full-length heavy chain comprising an amino acid sequence having at least 80% identity or similarity to SEQ ID NO: 270, and

[0594] b) a full-length light chain comprising an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 271, and

[0595] c) in which one or more of the following mutations (all numbered according to the EU numbering system) have been introduced into the full-length heavy chain: N297A substitution; N297Q substitution; L234A substitution; L234D substitution; L234E substitution; L234G substitution; L234H substitution; L234F substitution; L234K substitution; L234Q substitution; L234R substitution; L234S substitution; L234T substitution; L235A substitution; L235D substitution; L235E substitution; L235F substitution; L235G substitution; L235V substitution; L235H substitution; L235I substitution; L235K substitution; L235R substitution; L235S substitution; L235T substitution; L235Q substitution; L237A substitution; S239D substitution; E233P substitution replacement; L234V replacement; C236 deletion; G236E replacement; G236R replacement; G236K replacement; G237A replacement; P238A replacement; F243L replacement; D265A replacement; S267E replacement; H268A replacement; R292P replacement; Y300L replacement; K322A replacement; K322Q replacement; A327Q replacement; L328F replacement; L328R replacement; P329A replacement; P329G replacement; A330L replacement; A330S replacement; P331S replacement; I332E replacement; P396L replacement; or each of the combinations of the mutations described above in the fourth embodiment of the present application, preferably the mutation is L234A or L235A, more preferably the mutation is L234A and L235A.

[0596] In one embodiment, the composition comprises an antibody or antigen-binding fragment that binds to human muscle-specific tyrosine protein kinase (MuSK) comprising:

[0597] a) a full-length heavy chain comprising SEQ ID NO: 270, and

[0598] b) a full-length light chain comprising SEQ ID NO: 271, and

[0599] c) wherein the full length heavy chain comprises L234A and L235A mutations numbered according to the EU numbering system.

[0600] In one embodiment, binding to an effector ligand is reduced by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or is no longer detectable, compared to binding of an antibody without any amino acid substitutions in its human IgG constant Fc region to the same ligand.

[0601] The MuSK antibody-based molecules of the invention can be administered parenterally, topically, orally or intranasally for therapeutic treatment. Intramuscular injection (e.g., injection into an arm or leg muscle) and intravenous infusion are preferred methods of administration for the molecules of the invention. In some methods, such molecules are administered as a slow release composition or device, such as a Medipad TM Device (Elan Pharm. Technologies, Dublin, Ireland). In some methods, the antibodies disclosed herein are injected directly into a specific tissue, such as intracranial injection.

[0602] In one embodiment, the pharmaceutical composition of the present invention is administered parenterally. As used herein, the phrase "parenteral administration" and variations thereof refer to modes of administration other than enteral and topical administration, usually by injection, and include epidermal, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intracranial, intraorbital, intracardiac, intradermal, intraperitoneal, intratendinous, transtracheal, subcutaneous, subcutaneous, intraarticular, subcapsular, subarachnoid, intraspinal, intracranial, intrathoracic, epidural, and intrasternal injection, subcutaneous, and infusion. In one embodiment, the pharmaceutical composition is administered by intravenous or subcutaneous injection or infusion.

[0603] In one embodiment, the anti-MuSK antibody or antigen-binding fragment thereof (or polynucleotide, expression vector, host cell or composition) used according to the present invention is administered in combination with an anticholinergic compound. Anticholinergic compounds are compounds that can inhibit the action of the neurotransmitter acetylcholine at synapses or neuroeffector junctions (e.g., neuromuscular junctions). Preferably, the anticholinergic compound is a compound that can inhibit the activity of muscarinic acetylcholine receptors.

[0604] Anticholinergic compounds can also be formulated in compositions that are anti-MuSK antibodies or antigen-binding fragments. Compositions of the type disclosed herein for anti-MuSK antibodies or antigen-binding fragments can also be used in compositions comprising anticholinergic compounds. The two compounds can be present in a single composition. Alternatively, they can be formulated in separate compositions.

[0605] The use of compounds that lead to activation, induction of mechanisms that promote NMJ (neuromuscular junction) stability and / or repair is attractive for the treatment of any neuromuscular disease, especially when such NMJ is affected. In a preferred embodiment, two different compounds are used, each of which activates, induces mechanisms that promote NMJ stability and / or repair, even more attractive, because such combination treatments have been shown to be synergistic. Therefore, the combination is highly beneficial for the treatment of neuromuscular diseases, particularly for neuromuscular diseases or disorders with affected NMJs, such as ALS.

[0606] In one embodiment, the anti-MuSK antibody or antigen-binding fragment thereof, polynucleotide, expression vector, host cell or composition for use according to any of the preceding claims, wherein the neuromuscular disorder is characterized by impaired neuromuscular transmission and / or NMJ denervation.

[0607] Impaired neuromuscular transmission is characterized by at least one of the following:

[0608] a. Muscarinic overexcitation,

[0609] b. Death of motor neurons,

[0610] c. NMJ denervation and

[0611] d. Impaired synaptic transmission.

[0612] In one embodiment, impaired neuromuscular transmission or impaired synaptic transmission may be characterized by insufficient MuSK signaling, insufficient MuSK dimerization, insufficient MuSK phosphorylation, insufficient MuSK signaling, and / or insufficient acetylcholine receptor clustering.

[0613] In one embodiment, impaired neuromuscular transmission or impaired synaptic transmission may be characterized by poorer motor performance, reduced grip strength, poorer contractile properties of the muscle at the NMJ, poorer resistance to muscle fatigue, reduced muscle weight.

[0614] In one embodiment, a neuromuscular disorder is analyzed, evaluated, or diagnosed by electrophysiological assessment; pharmacodynamic assessment; levels of neurofilaments (e.g., neurofilament light chain (NFL)) in serum, plasma, and / or cerebrospinal fluid (CSF); or NMJ biopsy.

[0615] The neuromuscular disorder may be selected from the group consisting of amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), myasthenia gravis (MG), congenital myasthenia, Lambert-Eaton myasthenic syndrome (LEMS), Lyme disease, poliomyelitis, post-poliomyelitis, heavy metal poisoning, Kennedy syndrome, adult-onset Tay-Sachs disease, hereditary spastic paraplegia, multifocal neuropathy, cervical spondylosis, extramedullary tumors with compressive radiculopathy and myelopathy, inclusion body myositis, progressive bulbar palsy, progressive muscular atrophy, motor neuron syndrome, and thyrotoxic myopathy. A preferred neuromuscular disorder is ALS.

[0616] In one embodiment, an anti-MuSK antibody or antigen-binding fragment thereof as defined herein may be administered to an asymptomatic ALS subject. This means that such an antibody or antigen-binding fragment may be administered prior to the onset of ALS in the subject. The same applies to other neuromuscular disorders.

[0617] In this context, an asymptomatic ALS subject may be a subject that has been diagnosed as being susceptible to a neuromuscular disorder or disease (e.g., ALS). Identifying an individual (or subject) suffering from a neuromuscular disorder may mean identifying using a diagnostic method. Such a subject may be a symptomatic subject diagnosed at the onset of the disease or after the onset of the disease, or susceptible to a neuromuscular disorder or disease (i.e., an asymptomatic subject diagnosed before the onset of the disease, which is synonymous with before the onset of the disease).

[0618] Neuromuscular disorders can be caused by genetic defects. Genetic defects are caused in whole or in part by changes in the genomic DNA sequence relative to the genomic DNA sequence of a corresponding individual or object that does not suffer from the genetic defect. Genetic defects can be caused by mutations in one gene (single gene disorder), mutations in multiple genes (multifactorial genetic disorders), a combination of genetic mutations and environmental factors, or chromosome damage (changes in the number or structure of the entire chromosome, the structure that carries the gene). Types of genetic mutations include base substitutions, deletions, and insertions.

[0619] In one embodiment, the human subject is identified as suffering from (or being prone to) a neuromuscular disease caused by a genetic defect. In one embodiment, the neuromuscular disease is ALS, and the genetic defect is in the SOD1 gene. Individuals or human subjects susceptible to ALS include those with one or more ALS risk factors (including age increase, personal or family history, or genetic predisposition to one or more SOD-1 related diseases) or human subjects. A potential genetic cause or tendency of ALS is a mutation in the human SOD1 gene. Therefore, the SOD1 gene of the object can be genetically tested using a determination known in the art (such as gene sequencing) to identify an object suffering from ALS, being susceptible to ALS, or being prone to ALS. At least 180 mutations in human SOD1 known in the art are associated with ALS. In one embodiment, the SOD1 mutation is one or more mutations selected from the following:

[0620] A4V, H46R, G93S, A4T, G141X, D133A, V148G, N139K, G85R, G93A, V14G, C6S, I113T, D49K, G37R,

[0621] A89V, E100G, D90A, T137A, E100K, G41A, G41D, G41S, G13R, G72S, L8V, F20C, Q22L, H48R, T54R,

[0622] S591, V87A, T88ΔTAD, A89T, V97M, S105ΔSL, VI 18L, D124G, LI 14F, D90A, G12RG147R and G37R

[0623] In one embodiment, the mutation in the SOD1 gene is G37R.

[0624] Thus, asymptomatic individuals or subjects may be identified (before disease onset) when the subject has a SOD1 mutation selected from the following:

[0625] A4V, H46R, G93S, A4T, G141X, D133A, V148G, N139K, G85R, G93A, V14G, C6S, I 113T, D49K, G37R, A89V, E100G, D90A, T137A, E100K, G41A, G41D, G41S, G13R, G7 2S, L8V, F20C, Q22L, H48R, T54R, S591, V87A, T88δTAD, A89T, V97M, S105δSL, VI 18L, D124G, LI 14F, D90A, G12RG147R and G37R.

[0626] Analysis of a subject's susceptibility to ALS disease (i.e., an asymptomatic subject susceptible to developing ALS) can be performed by analyzing the subject's family history of ALS. Family history analysis may include recording a three-generation pedigree for ALS, review of family members' medical records and autopsy reports, and identification of an autosomal dominant pattern of SOD1 mutations.

[0627] Identification of individuals or subjects who are asymptomatic for ALS (but are susceptible to developing such a disease) can also be analyzed by ALS markers. For example, ALS-specific markers can be circulating microRNAs, circular RNAs (circRNAs) or messenger RNAs (mRNAs), TDP-42 aggregates, 8-oxo-deoxyguanosine (8-oxodG), 15-F2t-isoprostane (IsoP), plasma TNF-a, IL-10, TRAIL, plasma IL-1b, CSF TRAIL, proinflammatory T helper (Th) 17 cells, Th1 cells, anti-inflammatory Th2, regulatory T cells (Treg), proinflammatory IL-1b, IL-6, IFN-g, anti-inflammatory IL-10, cholesterol, LDL cholesterol, apolipoprotein B, HDL cholesterol, apolipoprotein AI, plasma creatinine (PCr), plasma ferritin, transferrin, hepcidin, chitotriosidase-1 (CHIT1), chitinase-3-like protein 2 (CHI3L2 / YKL39), total tau (tTu), phosphorylated tau (pTau), amyloid beta (Ab), novel INHAT repressor (NIR), ubiquitin C-terminal hydrolase L1 (UCHL1), microtubule-associated protein 2, capped actin, gelsolin (CAPG), or glycoprotein nonmetastatic melanoma protein B (GPNMB). A human subject may be considered susceptible to ALS disease when at least one of such marker measurements deviates by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% from a normal human subject of the same age but without ALS. Analysis of a subject's susceptibility to ALS disease may also be analyzed by imaging. For example, such imaging analysis may be MRI assessment of skeletal muscle, imaging-derived functional muscle scores, or tongue ultrasound predicted bulbar progression with or without MRI.

[0628] In one embodiment, the anticholinergic compound and the anti-MuSK antibody or antigen-binding fragment thereof, polynucleotide, expression vector, host cell, cell-free expression system, or composition are administered separately, sequentially or simultaneously.

[0629] In one embodiment, the anticholinergic compound is administered within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 days or 1, 2, 3, 4, 5, 6, 7 weeks after the onset of the disease; or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 months. In one embodiment, the anticholinergic compound is administered within one week of the onset of the disease or after the onset of the disease. Unexpectedly, attractive results were obtained when the anticholinergic compound was administered as soon as possible at the onset of the disease or after the onset of the disease. It should be understood by those skilled in the art that anticholinergic compounds are preferably not used to reduce or alleviate symptoms associated with neuromuscular disorders (such as ALS). In one embodiment, anticholinergic compounds are not used to reduce or alleviate urinary urgency. In one embodiment, anticholinergic compounds are not used to reduce or alleviate urinary urgency in neuromuscular diseases (such as ALS).

[0630] In one embodiment, the anticholinergic compound is administered at the onset of the disease, or within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 days after the onset of the disease; within 1, 2, 3, 4, 5, 6, or 7 weeks; or within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months, but before the diagnosis of the disease. In some preferred embodiments, the administration is between diagnosis and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 days; within 1, 2, 3, 4, 5, 6, or 7 weeks; or within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months before diagnosis.

[0631] In one embodiment, an anti-MuSK antibody or antigen-binding fragment thereof, polynucleotide, expression vector, host cell or composition is administered before or at the onset of the disease. Before the onset of the disease can mean 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 days before the onset of the disease, or 1, 2, 3, 4, 5, 6, 7, 8 weeks before the onset of the disease, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 months before the onset of the disease. In this context, a human subject before the onset can mean a human subject who has no symptoms for the neuromuscular disorder (e.g., ALS).

[0632] Therefore, in another aspect of the present invention, an anti-MuSK antibody or antigen-binding fragment thereof (polynucleotide, expression vector, host cell, cell-free expression system or composition) for treating ALS in a human subject is provided, wherein the antibody or antigen-binding fragment is administered before the onset of the disease, preferably within 1, 2, 3, 4, 5 or 6 months before the onset of the disease. In this context, a human subject before onset may mean a human subject who has no symptoms for ALS. In one embodiment, the subject is diagnosed as being susceptible to a neuromuscular disorder or disease, such as ALS.

[0633] In one embodiment, the antibody or antigen-binding fragment binds to the MuSK Frizzled (Fz)-like domain sequence of SEQ ID NO:129.

[0634] In one embodiment, the antibody or antigen-binding fragment thereof comprises a wild-type human IgG constant Fc region comprising at least 80% sequence identity to SEQ ID NO:266 or SEQ ID NO:267.

[0635] In one embodiment, the antibody or antigen-binding fragment is an agonist MuSK antibody and / or effector function has been reduced or abolished.

[0636] In one embodiment, the reduction or elimination of effector function is achieved by introducing one or more of the following mutations (all numbered according to the EU numbering system) into the human IgG constant Fc region of an antibody-based molecule described herein, SEQ ID NO: 266 or SEQ ID NO: 267: N297A substitution; N297Q substitution; L234A substitution; L234D substitution; L234E substitution; L234G substitution; L234H substitution; L234F substitution; L234K substitution; L234Q substitution; L234R substitution; L234S substitution; L234T substitution; L235A substitution; L235D substitution; L235E substitution; L235F substitution; L235G substitution; L235V substitution; L235H substitution; L235I substitution; L235K substitution; L235R substitution; L235S substitution; L235T substitution; L235Q substitution; L235 37A replacement; S239D replacement; E233P replacement; L234V replacement; C236 deletion; G236E replacement; G236R replacement; G236K replacement; G237A replacement; P238A replacement; F243L replacement; D265A replacement; S267E replacement; H268A replacement; R292P replacement; Y300L replacement; K322A replacement; K322Q replacement; A327Q replacement; L328F replacement; L328R replacement; P329A replacement; P329G replacement; A330L replacement; A330S replacement; P331S replacement; I332E replacement or P396L replacement.

[0637] In a preferred embodiment, L234A or L235A substitutions are introduced into the human IgG constant Fc region of the antibody-based molecules described herein. In a more preferred embodiment, L234A and L235A substitutions are introduced into the human IgG constant Fc region of the antibody-based molecules described herein. This embodiment produces an antibody-based molecule having a heavy chain represented by SEQ ID NO: 268 or SEQ ID NO: 270.

[0638] In one embodiment, the antibody or antigen-binding fragment comprises:

[0639] a) a heavy chain variable domain (VH) comprising an amino acid sequence having at least 80% identity or similarity to SEQ ID NO: 234 and

[0640] b) a light chain variable domain (VL) comprising an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 235.

[0641] In one embodiment, the antibody or antigen-binding fragment comprises a heavy chain variable domain (VH) and a light chain variable domain (VL):

[0642] wherein the VH comprises:

[0643] - a CDR-H1 amino acid sequence comprising SEQ ID NO: 147 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 147,

[0644] - a CDR-H2 amino acid sequence comprising SEQ ID NO: 153 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 153, and

[0645] - comprising SEQ ID NO: 156 or a CDR-H3 amino acid sequence having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 156 (3B2g2m1) and

[0646] wherein the VL comprises:

[0647] - a CDR-L1 amino acid sequence comprising SEQ ID NO: 159 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 159,

[0648] - a CDR-L2 amino acid sequence comprising SEQ ID NO: 172 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 172, and

[0649] - A CDR-L3 amino acid sequence comprising SEQ ID NO: 195 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 195 (3B2g2m1).

[0650] In one embodiment, the antibody or antigen-binding fragment comprises a heavy chain variable domain (VH) and a light chain variable domain (VL):

[0651] - wherein the VH comprises an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 234, and the VL comprises an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 235, and

[0652] - wherein said VH comprises:

[0653] o a CDR-H1 amino acid sequence comprising SEQ ID NO: 147 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 147,

[0654] o comprising SEQ ID NO: 153 or a CDR-H2 amino acid sequence having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 153, and

[0655] o comprising SEQ ID NO: 156 or a CDR-H3 amino acid sequence (3B2g2m1) having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 156 and - wherein the VL comprises:

[0656] o a CDR-L1 amino acid sequence comprising SEQ ID NO: 159 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 159,

[0657] o comprising SEQ ID NO: 172 or a CDR-L2 amino acid sequence having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 172, and

[0658] ○ A CDR-L3 amino acid sequence comprising SEQ ID NO: 195 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 195 (3B2g2m1).

[0659] In one embodiment, the antibody or antigen-binding fragment comprises:

[0660] a) a heavy chain variable domain (VH) comprising an amino acid sequence having at least 80% identity or similarity to SEQ ID NO: 234, and

[0661] b) a light chain variable domain (VL) comprising an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 235.

[0662] In one embodiment, the antibody or antigen-binding fragment comprises:

[0663] a) a full-length heavy chain comprising SEQ ID NO: 268, and

[0664] b) a full-length light chain comprising SEQ ID NO: 269, and

[0665] c) wherein the full length heavy chain comprises L234A and L235A mutations numbered according to the EU numbering system.

[0666] Unexpectedly, attractive results were obtained when anti-MuSK antibodies (expression vectors or polynucleotides or antigen-binding fragments of host cells) were administered before the onset of the disease. In one embodiment, the human subject therefore has no symptoms for the neuromuscular disorder (e.g., ALS). In such an embodiment, the human subject has been diagnosed as being susceptible to a neuromuscular disorder (e.g., ALS) based on his / her family history, genetic background, or based on an increased level of neurofilaments (e.g., neurofilament light chain (NFL)) as determined in his / her serum or cerebrospinal fluid (CSF), or based on a positive genetic test for an ALS-related gene mutation, or based on a change in the level of a biomarker for ALS, or a combination thereof. However, he / she has not yet developed any obvious symptoms; he / she is asymptomatic. In a preferred embodiment, administration to a human subject is as early as possible after being diagnosed with a genetic defect or a genetic mutation associated with ALS but having not yet developed any visible symptoms (i.e., an asymptomatic subject). In a more preferred embodiment, the human subject is administered as soon as possible after being diagnosed with a genetic defect or genetic mutation associated with ALS but before any visible symptoms occur (and the human subject has a family history of ALS). In this context, "immediately" can mean within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 hours, or within 1, 2, 3, 4, 5, 6 or 7 days, or within 1, 2, 3 or 4 weeks. In this context, such treatment ultimately shows limited or no toxicity and / or side effects, or any harmful effects, without a confirmed diagnosis of ALS.

[0667] In another aspect of the present invention, a combination comprising an anti-MuSK antibody or antigen-binding fragment thereof as described herein and an anticholinergic compound is provided. The combination is preferably used to treat a neuromuscular disease in a human subject.

[0668] The neuromuscular disorder is characterized by impaired neuromuscular transmission and / or denervation at the NMJ (neuromuscular junction). The neuromuscular disorder is characterized by at least one of the following:

[0669] a. Muscarinic overexcitation,

[0670] b. Death of motor neurons,

[0671] c. Neuromuscular junction (NMJ) denervation and

[0672] d. Impaired synaptic transmission.

[0673] In one embodiment, the neuromuscular disorder is selected from the group consisting of amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), myasthenia gravis (MG), myasthenia gravis, Lambert-Eaton myasthenic syndrome (LEMS), Lyme disease, poliomyelitis, post-polio, heavy metal poisoning, Kennedy syndrome, adult-onset Tay-Sachs disease, hereditary spastic paraplegia, multifocal neuropathy, cervical spondylosis, extramedullary tumors with compressive radiculopathy and myelopathy, inclusion body myositis, progressive bulbar palsy, progressive muscular atrophy, motor neuron syndrome, and thyrotoxic myopathy. In a preferred embodiment, the neuromuscular disease is ALS.

[0674] In this context, the combination does not require the anti-MuSK antibody or antigen-binding fragment thereof and the anticholinergic compound described herein to be physically present together in one composition.

[0675] In one embodiment, the anticholinergic compound is administered singly, sequentially or simultaneously. In one embodiment, the antibody or antigen-binding fragment is administered before the onset of the disease, or within 1, 2, 3, 4, 5 or 6 months before the onset of the disease. In one embodiment, the antibody or antigen-binding fragment is administered before the onset of the disease, or preferably within 1, 2, 3, 4, 5 or 6 months before the onset of the disease, and / or wherein the anticholinergic compound is administered at the onset of the disease or within 1, 2, 3, 4, 5, 6 or 7 weeks after the onset of the disease. In this context, a human subject before the onset may mean a human subject without symptoms for the neuromuscular disorder. In one embodiment, the subject treated with the antibody has first been diagnosed as being susceptible to a neuromuscular disorder or disease.

[0676] In one embodiment, the anti-MuSK antibody or antigen-binding fragment thereof binds to the MuSK Frizzled (Fz)-like domain sequence of SEQ ID NO:129.

[0677] In one embodiment, the antibody or antigen-binding fragment thereof comprises a wild-type human IgG constant Fc region comprising at least 80% sequence identity to SEQ ID NO:266 or SEQ ID NO:267.

[0678] In one embodiment, the antibody or antigen-binding fragment is an agonist MuSK antibody and / or effector function has been reduced or abolished.

[0679] In one embodiment, the reduction or elimination of effector function is achieved by introducing one or more of the following mutations (all numbered according to the EU numbering system) into the human IgG constant Fc region of an antibody-based molecule described herein, SEQ ID NO: 266 or SEQ ID NO: 267: N297A substitution; N297Q substitution; L234A substitution; L234D substitution; L234E substitution; L234G substitution; L234H substitution; L234F substitution; L234K substitution; L234Q substitution; L234R substitution; L234S substitution; L234T substitution; L235A substitution; L235D substitution; L235E substitution; L235F substitution; L235G substitution; L235V substitution; L235H substitution; L235I substitution; L235K substitution; L235R substitution; L235S substitution; L235T substitution; L235Q substitution; L235 37A replacement; S239D replacement; E233P replacement; L234V replacement; C236 deletion; G236E replacement; G236R replacement; G236K replacement; G237A replacement; P238A replacement; F243L replacement; D265A replacement; S267E replacement; H268A replacement; R292P replacement; Y300L replacement; K322A replacement; K322Q replacement; A327Q replacement; L328F replacement; L328R replacement; P329A replacement; P329G replacement; A330L replacement; A330S replacement; P331S replacement; I332E replacement or P396L replacement.

[0680] In a preferred embodiment, L234A or L235A substitutions are introduced into the human IgG constant Fc region of the antibody-based molecules described herein. In a more preferred embodiment, L234A and L235A substitutions are introduced into the human IgG constant Fc region of the antibody-based molecules described herein. This embodiment produces an antibody-based molecule having a heavy chain represented by SEQ ID NO: 268 or SEQ ID NO: 270.

[0681] In one embodiment, the antibody or antigen-binding fragment comprises:

[0682] a) a heavy chain variable domain (VH) comprising an amino acid sequence having at least 80% identity or similarity to SEQ ID NO: 234, and

[0683] b) a light chain variable domain (VL) comprising an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 235.

[0684] In one embodiment, the antibody or antigen-binding fragment comprises a heavy chain variable domain (VH) and a light chain variable domain (VL):

[0685] wherein the VH comprises:

[0686] - a CDR-H1 amino acid sequence comprising SEQ ID NO: 147 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 147,

[0687] - a CDR-H2 amino acid sequence comprising SEQ ID NO: 153 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 153, and

[0688] - comprising SEQ ID NO: 156 or a CDR-H3 amino acid sequence having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 156 (3B2g2m1) and

[0689] wherein the VL comprises:

[0690] - a CDR-L1 amino acid sequence comprising SEQ ID NO: 159 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 159,

[0691] - a CDR-L2 amino acid sequence comprising SEQ ID NO: 172 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 172, and

[0692] - A CDR-L3 amino acid sequence comprising SEQ ID NO: 195 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 195 (3B2g2m1).

[0693] In one embodiment, the antibody or antigen-binding fragment comprises a heavy chain variable domain (VH) and a light chain variable domain (VL):

[0694] - wherein the VH comprises an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 234, and the VL comprises an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 235, and

[0695] - wherein said VH comprises:

[0696] o a CDR-H1 amino acid sequence comprising SEQ ID NO: 147 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 147,

[0697] o comprising SEQ ID NO: 153 or a CDR-H2 amino acid sequence having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 153, and

[0698] o A CDR-H3 amino acid sequence comprising SEQ ID NO: 156 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 156 (3B2g2m1) and - wherein the VL comprises:

[0699] o a CDR-L1 amino acid sequence comprising SEQ ID NO: 159 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 159,

[0700] o comprising SEQ ID NO: 172 or a CDR-L2 amino acid sequence having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 172, and

[0701] ○ A CDR-L3 amino acid sequence comprising SEQ ID NO: 195 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 195 (3B2g2m1).

[0702] In one embodiment, the antibody or antigen-binding fragment comprises:

[0703] a) a full-length heavy chain comprising SEQ ID NO: 268, and

[0704] b) a full-length light chain comprising SEQ ID NO: 269, and

[0705] c) wherein the full length heavy chain comprises L234A and L235A mutations numbered according to the EU numbering system.

[0706] In one embodiment, the antibody or antigen-binding fragment comprises:

[0707] a) a full-length heavy chain comprising SEQ ID NO: 270, and

[0708] b) a full-length light chain comprising SEQ ID NO: 271, and

[0709] c) wherein the full length heavy chain comprises L234A and L235A mutations numbered according to the EU numbering system.

[0710] In one embodiment, the anti-MuSK antibody or antigenic fragment thereof (polynucleotide, expression vector, host cell, cell-free expression system or composition) is administered prior to disease onset (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 days prior to disease onset or 1, 2, 3, 4, 5, 6, or 7 weeks prior to disease onset), and the anticholinergic compound is administered at disease onset (e.g., within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 days or within 1, 2, 3, 4, 5, 6, or 7 weeks after disease onset). In this context, a human subject prior to onset may refer to a human subject who has no symptoms for the neuromuscular disorder (e.g., ALS).

[0711] In a preferred embodiment, the disease episodes include at least one symptom selected from the group consisting of muscle twitches, muscle cramps, spasms, muscle weakness, slurred speech and / or nasal voice, difficulty chewing or swallowing, dysphagia, dysarthria, and dyspnea. In a more preferred embodiment, the disease is ALS and the disease episodes include at least one symptom selected from the group consisting of muscle twitches, muscle cramps, spasms, muscle weakness, slurred speech and / or nasal voice, difficulty chewing or swallowing, dysphagia, dysarthria, and dyspnea.

[0712] The onset of disease can be assessed by a physician or veterinarian. In one embodiment, the onset of weight loss is considered the onset of disease.

[0713] In a preferred embodiment, the neuromuscular disorder is ALS and the anti-MuSK antibody or antigen-binding fragment comprises a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain comprises an amino acid sequence having at least 80% identity or similarity to SEQ ID NO: 234 and the light chain variable domain comprises an amino acid sequence having at least 80% identity or similarity to SEQ ID NO: 235, and

[0714] The heavy chain variable domain contains:

[0715] - a CDR-H1 amino acid sequence comprising SEQ ID NO: 147 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 147,

[0716] - a CDR-H2 amino acid sequence comprising SEQ ID NO: 153 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 153, and

[0717] - comprising SEQ ID NO: 156 or a CDR-H3 amino acid sequence having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 156 (3B2g2m1) and

[0718] The light chain variable domain contains:

[0719] - a CDR-L1 amino acid sequence comprising SEQ ID NO: 159 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 159,

[0720] - a CDR-L2 amino acid sequence comprising SEQ ID NO: 172 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 172, and

[0721] - A CDR-L3 amino acid sequence comprising SEQ ID NO: 195 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 195 (3B2g2m1).

[0722] In one embodiment, the identity or similarity is at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%.

[0723] In a more preferred embodiment, the neuromuscular disorder is ALS and the anti-MuSK antibody or antigen-binding fragment comprises a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain comprises an amino acid sequence having at least 80% identity or similarity to SEQ ID NO: 234 and the light chain variable domain comprises an amino acid sequence having at least 80% identity or similarity to SEQ ID NO: 235, and

[0724] The heavy chain variable domain contains:

[0725] - a CDR-H1 amino acid sequence comprising or consisting of SEQ ID NO: 147,

[0726] - a CDR-H2 amino acid sequence comprising or consisting of SEQ ID NO: 153, and

[0727] - a CDR-H3 amino acid sequence (3B2g2m1) comprising or consisting of SEQ ID NO: 156 and

[0728] The light chain variable domain contains:

[0729] - a CDR-L1 amino acid sequence comprising or consisting of SEQ ID NO: 159,

[0730] - a CDR-L2 amino acid sequence comprising or consisting of SEQ ID NO: 172, and

[0731] - a CDR-L3 amino acid sequence comprising or consisting of SEQ ID NO: 195 (3B2g2m1).

[0732] In one embodiment, the identity or similarity is at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%.

[0733] In a preferred embodiment, the neuromuscular disorder is ALS and the anti-MuSK antibody or antigen-binding fragment comprises a wild-type human IgG constant Fc region, a heavy chain variable domain, and a light chain variable domain, wherein the wild-type human IgG constant Fc region comprises SEQ ID NO: 266 or SEQ ID NO: 267, a heavy chain variable domain, and a light chain variable domain, wherein the heavy chain variable domain comprises an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 234 and the light chain variable domain comprises an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 235, and

[0734] The heavy chain variable domain contains:

[0735] - a CDR-H1 amino acid sequence comprising SEQ ID NO: 147 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 147,

[0736] - a CDR-H2 amino acid sequence comprising SEQ ID NO: 153 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 153, and

[0737] - comprising SEQ ID NO: 156 or a CDR-H3 amino acid sequence having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 156 (3B2g2m1) and

[0738] The light chain variable domain contains:

[0739] - a CDR-L1 amino acid sequence comprising SEQ ID NO: 159 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 159,

[0740] - a CDR-L2 amino acid sequence comprising SEQ ID NO: 172 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 172, and

[0741] - A CDR-L3 amino acid sequence comprising SEQ ID NO: 195 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 195 (3B2g2m1).

[0742] In one embodiment, the identity or similarity is at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%.

[0743] In a more preferred embodiment, the neuromuscular disorder is ALS and the anti-MuSK antibody or antigen-binding fragment comprises a wild-type human IgG constant Fc region, a heavy chain variable domain, and a light chain variable domain, wherein the wild-type human IgG constant Fc region comprises SEQ ID NO: 266 or SEQ ID NO: 267, a heavy chain variable domain, and a light chain variable domain, wherein the heavy chain variable domain comprises an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 234 and the light chain variable domain comprises an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 235, and

[0744] The heavy chain variable domain contains:

[0745] - a CDR-H1 amino acid sequence comprising or consisting of SEQ ID NO: 147,

[0746] - a CDR-H2 amino acid sequence comprising or consisting of SEQ ID NO: 153, and

[0747] - a CDR-H3 amino acid sequence (3B2g2m1) comprising or consisting of SEQ ID NO: 156 and

[0748] The light chain variable domain contains:

[0749] - a CDR-L1 amino acid sequence comprising or consisting of SEQ ID NO: 159,

[0750] - a CDR-L2 amino acid sequence comprising or consisting of SEQ ID NO: 172, and

[0751] - a CDR-L3 amino acid sequence comprising or consisting of SEQ ID NO: 195 (3B2g2m1).

[0752] In one embodiment, the identity or similarity is at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%.

[0753] In a preferred embodiment, the neuromuscular disorder is ALS and the anti-MuSK antibody or antigen-binding fragment comprises a wild-type human IgG constant Fc region (wherein L234A and / or L235A substitutions numbered according to the EU numbering system are introduced into said Fc region), a heavy chain variable domain, and a light chain variable domain, wherein the wild-type human IgG constant Fc region comprises SEQ ID NO: 266 or SEQ ID NO: 267, a heavy chain variable domain, and a light chain variable domain, wherein the heavy chain variable domain comprises an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 234 and the light chain variable domain comprises an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 235, and

[0754] The heavy chain variable domain contains:

[0755] - a CDR-H1 amino acid sequence comprising SEQ ID NO: 147 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 147,

[0756] - a CDR-H2 amino acid sequence comprising SEQ ID NO: 153 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 153, and

[0757] - comprising SEQ ID NO: 156 or a CDR-H3 amino acid sequence having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 156 (3B2g2m1) and

[0758] The light chain variable domain contains:

[0759] - a CDR-L1 amino acid sequence comprising SEQ ID NO: 159 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 159,

[0760] - a CDR-L2 amino acid sequence comprising SEQ ID NO: 172 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 172, and

[0761] - A CDR-L3 amino acid sequence comprising SEQ ID NO: 195 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 195 (3B2g2m1).

[0762] In one embodiment, the identity or similarity is at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%.

[0763] In a more preferred embodiment, the neuromuscular disorder is ALS and the anti-MuSK antibody or antigen-binding fragment comprises a wild-type human IgG constant Fc region (wherein L234A and / or L235A substitutions numbered according to the EU numbering system are introduced into said Fc region), a heavy chain variable domain, and a light chain variable domain, wherein the wild-type human IgG constant Fc region comprises SEQ ID NO: 266 or SEQ ID NO: 267, a heavy chain variable domain, and a light chain variable domain, wherein the heavy chain variable domain comprises an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 234 and the light chain variable domain comprises an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 235, and

[0764] The heavy chain variable domain contains:

[0765] - a CDR-H1 amino acid sequence comprising or consisting of SEQ ID NO: 147,

[0766] - a CDR-H2 amino acid sequence comprising or consisting of SEQ ID NO: 153, and

[0767] - a CDR-H3 amino acid sequence (3B2g2m1) comprising or consisting of SEQ ID NO: 156 and

[0768] The light chain variable domain contains:

[0769] - a CDR-L1 amino acid sequence comprising or consisting of SEQ ID NO: 159,

[0770] - a CDR-L2 amino acid sequence comprising or consisting of SEQ ID NO: 172, and

[0771] - a CDR-L3 amino acid sequence comprising or consisting of SEQ ID NO: 195 (3B2g2m1).

[0772] In one embodiment, the identity or similarity is at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%.

[0773] In one embodiment, the neuromuscular disorder is ALS and the anti-MuSK antibody or antigen-binding fragment comprises:

[0774] a) a full-length heavy chain comprising an amino acid sequence having at least 80% identity or similarity to SEQ ID NO: 268, and

[0775] b) a full-length light chain comprising an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 269, and

[0776] c) in which one or more of the following mutations (all numbered according to the EU numbering system) have been introduced into the full-length heavy chain: N297A substitution; N297Q substitution; L234A substitution; L234D substitution; L234E substitution; L234G substitution; L234H substitution; L234F substitution; L234K substitution; L234Q substitution; L234R substitution; L234S substitution; L234T substitution; L235A substitution; L235D substitution; L235E substitution; L235F substitution; L235G substitution; L235V substitution; L235H substitution; L235I substitution; L235K substitution; L235R substitution; L235S substitution; L235T substitution; L235Q substitution; L237A substitution; S239D substitution; E233P substitution replacement; L234V replacement; C236 deletion; G236E replacement; G236R replacement; G236K replacement; G237A replacement; P238A replacement; F243L replacement; D265A replacement; S267E replacement; H268A replacement; R292P replacement; Y300L replacement; K322A replacement; K322Q replacement; A327Q replacement; L328F replacement; L328R replacement; P329A replacement; P329G replacement; A330L replacement; A330S replacement; P331S replacement; I332E replacement; P396L replacement; or each of the combinations of the mutations described above in the fourth embodiment of the present application, preferably the mutation is L234A or L235A, more preferably the mutation is L234A and L235A.

[0777] In one embodiment, the neuromuscular disorder is ALS and the anti-MuSK antibody or antigen-binding fragment comprises:

[0778] a) a full-length heavy chain comprising SEQ ID NO: 268, and

[0779] b) a full-length light chain comprising SEQ ID NO: 269, and

[0780] c) wherein the full length heavy chain comprises L234A and L235A mutations numbered according to the EU numbering system.

[0781] In one embodiment, the neuromuscular disorder is ALS and the anti-MuSK antibody or antigen-binding fragment comprises:

[0782] a) a full-length heavy chain comprising an amino acid sequence having at least 80% identity or similarity to SEQ ID NO: 270, and

[0783] b) a full-length light chain comprising an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 271, and

[0784] c) in which one or more of the following mutations (all numbered according to the EU numbering system) have been introduced into the full-length heavy chain: N297A substitution; N297Q substitution; L234A substitution; L234D substitution; L234E substitution; L234G substitution; L234H substitution; L234F substitution; L234K substitution; L234Q substitution; L234R substitution; L234S substitution; L234T substitution; L235A substitution; L235D substitution; L235E substitution; L235F substitution; L235G substitution; L235V substitution; L235H substitution; L235I substitution; L235K substitution; L235R substitution; L235S substitution; L235T substitution; L235Q substitution; L237A substitution; S239D substitution; E233P substitution replacement; L234V replacement; C236 deletion; G236E replacement; G236R replacement; G236K replacement; G237A replacement; P238A replacement; F243L replacement; D265A replacement; S267E replacement; H268A replacement; R292P replacement; Y300L replacement; K322A replacement; K322Q replacement; A327Q replacement; L328F replacement; L328R replacement; P329A replacement; P329G replacement; A330L replacement; A330S replacement; P331S replacement; I332E replacement; P396L replacement; or each of the combinations of the mutations described above in the fourth embodiment of the present application, preferably the mutation is L234A or L235A, more preferably the mutation is L234A and L235A.

[0785] In one embodiment, the neuromuscular disorder is ALS and the anti-MuSK antibody or antigen-binding fragment comprises:

[0786] a) a full-length heavy chain comprising SEQ ID NO: 270, and

[0787] b) a full-length light chain comprising SEQ ID NO: 271, and

[0788] c) wherein the full length heavy chain comprises L234A and L235A mutations numbered according to the EU numbering system.

[0789] In some embodiments, the anticholinergic compound is a muscarinic receptor antagonist. Muscarinic receptors, also known as muscarinic acetylcholine receptors or mAchRs, are acetylcholine receptors that form G protein receptor complexes in the cell membranes of certain neurons and other cells. Muscarinic receptors play several roles in mediating the effects of the neurotransmitter acetylcholine. For example, muscarinic receptors are contained in the presynaptic membrane of somatic neurons at the neuromuscular junction, where they are involved in the regulation of acetylcholine release.

[0790] Five subtypes of muscarinic receptors, M1 to M5, are generally recognized. This classification stems from their different selectivity for certain agonists and antagonists. M1, M3, and M5 receptors are coupled to Gq proteins in the cell membrane, while M2 and M4 receptors are coupled to Gi / o proteins in the cell membrane. Without being bound by this theory, the genes CHRM1-5 encode M1 to M5 receptors, respectively.

[0791] The basal or constitutive activity of a muscarinic receptor is defined as the physical, biological and / or chemical activity of the receptor in the absence of acetylcholine, muscarinic receptor agonists and muscarinic receptor antagonists.

[0792] An agonist of a muscarinic receptor, also known as a muscarinic receptor agonist, is defined as a compound that increases the physical, biological and / or chemical activity of a receptor when it contacts the receptor. Increased activity means an activity similar to that caused by contacting the receptor with acetylcholine.

[0793] An antagonist of a muscarinic receptor, also known as a muscarinic receptor antagonist, is defined as a muscarinic receptor neutral antagonist or a muscarinic negative antagonist.

[0794] Muscarinic receptor neutral antagonists are compounds that compete with a muscarinic receptor neutral agonist or with a muscarinic receptor negative antagonist for binding to the receptor, thereby blocking the effect of the agonist or negative antagonist (i.e., increasing or decreasing the activity), whereas the neutral antagonist, when bound alone, does not significantly alter the basal activity of the receptor.

[0795] In some embodiments, the anticholinergic compound is a neutral antagonist of a muscarinic receptor.

[0796] Muscarinic receptor negative antagonists are compounds that, when contacted with a receptor, reduce the physical, biological and / or chemical activity of the receptor, even in the absence of a muscarinic receptor agonist. Reduced activity means an activity that is opposite to the activity caused by contacting the receptor with acetylcholine.

[0797] In some embodiments, the anticholinergic compound is a muscarinic receptor negative antagonist.

[0798] A muscarinic receptor antagonist is defined as being selective for one or more muscarinic receptor subtypes M1, M2, M3, M4 and / or M5 if the effect of the antagonist (blocking agonists, blocking negative antagonists or reducing activity) is only significant upon contact with one or more subtypes of muscarinic receptors, and has a significantly smaller effect or no effect upon contact with another subtype of muscarinic receptors. Thus, a muscarinic receptor antagonist is said to be selective for muscarinic receptor M3, with the understanding that a significantly smaller effect or no effect is obtained when the antagonist is contacted with muscarinic receptors of subtypes M1, M2, M4 or M5. In this context, significantly smaller can be at most 1 / 10, 1 / 20, 1 / 30, 1 / 40, 1 / 50, 1 / 60, 1 / 70, 1 / 80, 1 / 90, 1 / 100, 1 / 200, 1 / 300, 1 / 400, 1 / 500, 1 / 600, 1 / 700, 1 / 800, 1 / 900, 1 / 1000, 1 / 10000, 1 / 1000000, or 1 / 1000000 smaller, or at least smaller.

[0799] 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 120%, 140%, 160%, 180%, 200%, 220%, 240%, 260%, 280%, 300%, 320%, 340%, 360%, 380%, 400%, 420%, 440%, 460%, 480%, 500%, 600%, 700%, 800%, 900%, 1000%, 1500%, 2000%, 2500%, 3000%, 3500%, 4000%, 4500%, 5000%, 5500%, 6000%, 6500%, 7000%, 7500%, 8000%, 8500%, 9000%, 9500%, 10000%, 20000%, 30000%, 40000%, 50000%, 60000%, 70000%, 80000%, 90000%, 100000%, 10000000%, 10000000% or 1000000000%.

[0800] The activity of muscarinic receptors (preferably M1, M3 and M5 subtypes) can be measured using dynamic Ca2+ imaging. These receptors regulate the levels of IP3, which then controls the release of Ca2+ from internal stores [7].

[0801] In some embodiments, the anticholinergic compound is a muscarinic receptor antagonist that:

[0802] - is selective for the muscarinic receptor M1, or

[0803] - is selective for the muscarinic receptor M3, or

[0804] - is selective for the muscarinic receptor M5, or

[0805] - is selective for muscarinic receptor M1 and muscarinic receptor M3, or

[0806] - is selective for muscarinic receptor M1 and muscarinic receptor M5, or

[0807] - is selective for muscarinic receptor M3 and muscarinic receptor M5, or

[0808] -Selective for muscarinic receptor M1, muscarinic receptor M3 and muscarinic receptor M5.

[0809] In some embodiments, the anticholinergic compound is a muscarinic receptor antagonist that:

[0810] - is selective for the muscarinic receptor M3, or

[0811] - is selective for muscarinic receptor M1 and muscarinic receptor M3, or

[0812] - is selective for muscarinic receptor M3 and muscarinic receptor M5, or

[0813] -Selective for muscarinic receptor M1, muscarinic receptor M3 and muscarinic receptor M5.

[0814] In some embodiments, the anticholinergic compound is darifenacin, ipratropium bromide, tiotropium bromide, trospium, glycopyrronium, aclidinium, umeclidinium, solifenacin, dicylomine, fesoterodine, fiavoxate, glycopyrrolate, propantheline, 1R,2R,4S,5S,7S)-7-[({4-fluoro-2-(thien-2-yl)phenyl}carbamoyl)oxy]-9,9-dimethyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonane-9-carboxylic acid (BS46 in

[38] ), N-(2-[3-([3R]-1-(cyclohexylmethyl)-3-piperidinyl]methylamino)-3-oxopropyl]amino-2-oxoethyl)-3,3,3-triphenyl-propionamide (J-115311 in

[39] ), 3,3,3-triphenylpropionamide derivatives having one or two amino acid residues between the triphenylpropionic acid part and the piperidinylmethylamine part (

[40] ), OrM3 (

[41] ) or (3R)-3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino]carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azinobicyclo[2.2.2]octane bromide (CHF 5407 in

[41] ). Without being bound by this theory, these compounds may be considered muscarinic receptor antagonists.

[0815] In some embodiments, the anticholinergic compound is darifenacin, ipratropium bromide, tiotropium bromide, trospium chloride, glycopyrrolate, aclidinium bromide, ruxolitinium bromide, solifenacin, dicyclomine, fesoterodine, flavoxate, glycopyrrolate or propantheline. Without being bound by this theory, darifenacin, ipratropium bromide and tiotropium bromide can be considered muscarinic receptor antagonists.

[0816] In some embodiments, the anticholinergic compound is darifenacin, ipratropium bromide, tiotropium bromide, or trospium chloride. Without being bound by this theory, darifenacin, ipratropium bromide, and tiotropium bromide can be considered muscarinic receptor antagonists.

[0817] In a preferred embodiment, the anticholinergic compound is darifenacin. Darifenacin can be represented by the following structure:

[0818]

[0819] Preferably, darifenacin is darifenacin hydrobromide. Darifenacin hydrobromide can be represented by the following structure:

[0820]

[0821] In some embodiments, any anticholinergic compound disclosed in the above embodiments may be present as a pharmaceutically acceptable salt thereof. In particular, the anticholinergic compound is darifenacin or a pharmaceutically acceptable salt thereof.

[0822] Examples of pharmaceutically acceptable salts include, but are not limited to, alkali metal (e.g., sodium, potassium or lithium) salts or alkaline earth metal (e.g., calcium) salts; however, any salt that is generally nontoxic and effective when administered to the subject being treated is acceptable. Other salts may include, but are not limited to: (1) acid addition salts, which may be obtained by reacting the free base of the parent compound with an inorganic acid (e.g., hydrochloric acid, hydrobromic acid, nitric acid, phosphoric acid, sulfuric acid, and perchloric acid, etc.) or an organic acid (e.g., acetic acid, oxalic acid, (D) or (L) malic acid, maleic acid, carbamate sulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, tartaric acid, citric acid, succinic acid, or malonic acid, etc.); or (2) salts formed when an acidic proton present in the parent compound is replaced by a metal ion (e.g., an alkali metal ion, an alkaline earth metal ion, or an aluminum ion), or coordinated with an organic base (e.g., ethanolamine, diethanolamine, triethanolamine, trimethylamine, N-methylglucamine, etc.). Pharmaceutically acceptable salts are well known to those skilled in the art, and any such pharmaceutically acceptable salts are contemplated in conjunction with the embodiments described herein.

[0823] Acceptable salts can be obtained using standard procedures known in the art including, but not limited to, reacting a sufficiently acidic compound with a suitable base affording a physiologically acceptable anion. Suitable acid addition salts are formed from acids which form non-toxic salts. Illustrative but non-limiting examples include acetate, aspartate, benzoate, benzenesulfonate, bicarbonate / carbonate, bisulfate / sulfate, borate, camphorsulfonate, citrate, edisylate, ethanesulfonate, formate, fumarate, glucoheptonate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride / chloride, hydrobromide / bromide, hydroiodide / iodide, lactate, malate, maleate, malonate, methanesulfonate, methylsulfate, naphthoate, 2-naphthalenesulfonate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate / hydrogenphosphate / dihydrogenphosphate, sucrose, stearate, succinate, tartrate, toluenesulfonate, and trifluoroacetate. Suitable base salts of the compounds described herein are formed from bases which form non-toxic salts, illustrative but non-limiting examples of which include arginine, benzathine, calcium, choline, diethylamine, diethanolamine, glycine, lysine, magnesium, meglumine, ethanolamine, potassium, sodium, tromethamine, and zinc salts. Hemi-salts of acids and bases can also be formed, for example, hemisulphate and hemicalcium salts.

[0824] The anticholinergic compounds disclosed in the above embodiments can be administered as a composition, preferably as a therapeutic composition. In some embodiments, the composition is formulated as a once-a-day extended release tablet for oral use, the extended release tablet comprising darifenacin, preferably darifenacin hydrobromide. Preferably, the composition comprises one or more of the following excipients: anhydrous calcium hydrogen phosphate, hypromellose, magnesium stearate, titanium dioxide, yellow iron oxide, red iron oxide, PEG 400 and / or talc. In one embodiment, the composition is referred to as ENABLEX TM ENABLEX TM It is formulated as 7.5 mg or 15 mg darifenacin (darifenacin hydrobromide).

[0825] In a preferred embodiment, the neuromuscular disorder is ALS, the anti-MuSK antibody or antigen-binding fragment comprises a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain comprises an amino acid sequence having at least 80% identity or similarity to SEQ ID NO: 234 and the light chain variable domain comprises an amino acid sequence having at least 80% identity or similarity to SEQ ID NO: 235, and

[0826] The heavy chain variable domain contains:

[0827] - a CDR-H1 amino acid sequence comprising SEQ ID NO: 147 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 147,

[0828] - a CDR-H2 amino acid sequence comprising SEQ ID NO: 153 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 153, and

[0829] - comprising SEQ ID NO: 156 or a CDR-H3 amino acid sequence having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 156 (3B2g2m1) and

[0830] The light chain variable domain contains:

[0831] - a CDR-L1 amino acid sequence comprising SEQ ID NO: 159 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 159,

[0832] - a CDR-L2 amino acid sequence comprising SEQ ID NO: 172 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 172, and

[0833] - A CDR-L3 amino acid sequence comprising SEQ ID NO: 195 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 195 (3B2g2m1)

[0834] and anticholinergic compounds were used.

[0835] In one embodiment, the identity or similarity is at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%.

[0836] In a more preferred embodiment, the neuromuscular disorder is ALS, the anti-MuSK antibody or antigen-binding fragment comprises a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain comprises an amino acid sequence having at least 80% identity or similarity to SEQ ID NO: 234 and the light chain variable domain comprises an amino acid sequence having at least 80% identity or similarity to SEQ ID NO: 235, and

[0837] The heavy chain variable domain contains:

[0838] - a CDR-H1 amino acid sequence comprising or consisting of SEQ ID NO: 147,

[0839] - a CDR-H2 amino acid sequence comprising or consisting of SEQ ID NO: 153, and

[0840] - a CDR-H3 amino acid sequence (3B2g2m1) comprising or consisting of SEQ ID NO: 156 and

[0841] The light chain variable domain contains:

[0842] - a CDR-L1 amino acid sequence comprising or consisting of SEQ ID NO: 159,

[0843] - a CDR-L2 amino acid sequence comprising or consisting of SEQ ID NO: 172, and

[0844] - A CDR-L3 amino acid sequence comprising or consisting of SEQ ID NO: 195 (3B2g2m1)

[0845] and anticholinergic compounds were used.

[0846] In one embodiment, the identity or similarity is at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%.

[0847] In a preferred embodiment, the neuromuscular disorder is ALS and the anti-MuSK antibody or antigen-binding fragment comprises a wild-type human IgG constant Fc region, a heavy chain variable domain, and a light chain variable domain, wherein the wild-type human IgG constant Fc region comprises SEQ ID NO: 266 or SEQ ID NO: 267, a heavy chain variable domain, and a light chain variable domain, wherein the heavy chain variable domain comprises an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 234 and the light chain variable domain comprises an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 235, and

[0848] The heavy chain variable domain contains:

[0849] - a CDR-H1 amino acid sequence comprising SEQ ID NO: 147 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 147,

[0850] - a CDR-H2 amino acid sequence comprising SEQ ID NO: 153 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 153, and

[0851] - comprising SEQ ID NO: 156 or a CDR-H3 amino acid sequence having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 156 (3B2g2m1) and

[0852] The light chain variable domain contains:

[0853] - a CDR-L1 amino acid sequence comprising SEQ ID NO: 159 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 159,

[0854] - a CDR-L2 amino acid sequence comprising SEQ ID NO: 172 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 172, and

[0855] - A CDR-L3 amino acid sequence comprising SEQ ID NO: 195 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 195 (3B2g2m1).

[0856] In a more preferred embodiment, the neuromuscular disorder is ALS and the anti-MuSK antibody or antigen-binding fragment comprises a wild-type human IgG constant Fc region, a heavy chain variable domain, and a light chain variable domain, wherein the wild-type human IgG constant Fc region comprises SEQ ID NO: 266 or SEQ ID NO: 267, a heavy chain variable domain, and a light chain variable domain, wherein the heavy chain variable domain comprises an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 234 and the light ch...

Claims

1. An anti-MuSK antibody or antigen-binding fragment thereof for use in treating a neuromuscular disorder in a human subject.

2. The anti-MuSK antibody or antigen-binding fragment thereof for use according to claim 1, wherein the antibody or antigen-binding fragment binds to the MuSK frizzled (Fz)-like domain sequence of SEQ ID NO:

129.

3. The anti-MuSK antibody or antigen-binding fragment thereof for use according to claim 1 or 2, wherein the antibody or antigen-binding fragment thereof comprises a wild-type human IgG constant Fc region, and the wild-type human IgG constant Fc region comprises at least 80% sequence identity with SEQ ID NO: 266 or SEQ ID NO:

267.

4. An anti-MuSK antibody or antigen-binding fragment thereof for use according to any one of the preceding claims, which is an agonist MuSK antibody and / or whose effector function has been reduced or abolished.

5. An anti-MuSK antibody or antigen-binding fragment thereof, preferably for use according to any of the preceding claims, wherein the reduction or elimination of effector function is achieved by introducing one or more of the following mutations (all numbered according to the EU numbering system) into the constant region of the antibody-based molecule: SEQ ID NO: 266 or SEQ ID NO:267 obtained: N297A replacement; N297Q replacement; L234A replacement; L234D replacement; L234E replacement; L234G replacement; L234H replacement; L234F replacement; L234K replacement; L234Q replacement; L234R replacement; L234S replacement; L234T replacement; L235A replacement; L235D replacement; L235E replacement; L235F replacement; L235G replacement; L235V replacement; L235H replacement; L235I replacement; L235K replacement; L235R replacement; L235S replacement; L235T replacement; L235Q replacement; L237A replacement; S239D replacement; E233P replacement; L234V replacement; C236 missing Loss; G236E replacement; G236R replacement; G236K replacement; G237A replacement; P238A replacement; F243L replacement; D265A replacement; S267E replacement; H268A replacement; R292P replacement; Y300L replacement; K322A replacement; K322Q replacement; A327Q replacement; L328F replacement; L328R replacement; P329A replacement; P329G replacement; A330L replacement; A330S replacement; P331S replacement; I332E replacement; P396L replacement; or each of the combinations of the mutations described above in the fourth embodiment of the present application, preferably the mutation is L234A or L235A, more preferably the mutation is L234A and L235A.

6. An anti-MuSK antibody or antigen-binding fragment thereof for use, preferably according to any of the preceding claims, wherein the antibody or antigen-binding fragment thereof comprises a wild-type human IgG constant Fc region SEQ ID NO: 266 or SEQ ID NO: 267, and wherein L234A and L235A mutations numbered according to the EU numbering system are introduced into the Fc region.

7. An anti-MuSK antibody or antigen-binding fragment thereof for use according to any one of the preceding claims, wherein the antibody or antigen-binding fragment comprises: a) a heavy chain variable domain (VH) comprising an amino acid sequence having at least 80% identity or similarity to SEQ ID NO: 234, and b) a light chain variable domain (VL) comprising an amino acid sequence that is at least 80% identical or similar to SEQ ID NO:

235.

8. An anti-MuSK antibody or antigen-binding fragment thereof for use according to any one of the preceding claims, wherein the antibody or antigen-binding fragment comprises a heavy chain variable domain (VH) and a light chain variable domain (VL): wherein the VH comprises: - a CDR-H1 amino acid sequence comprising SEQ ID NO: 147 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 147, - a CDR-H2 amino acid sequence comprising SEQ ID NO: 153 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 153, and - comprising SEQ ID NO: 156 or a CDR-H3 amino acid sequence having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 156 (3B2g2m1) and wherein the VL comprises: - a CDR-L1 amino acid sequence comprising SEQ ID NO: 159 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 159, - a CDR-L2 amino acid sequence comprising SEQ ID NO: 172 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 172, and - A CDR-L3 amino acid sequence comprising SEQ ID NO: 195 or having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 195 (3B2g2m1).

9. An anti-MuSK antibody or antigen-binding fragment thereof for use according to any one of the preceding claims, wherein the antibody or antigen-binding fragment comprises a heavy chain variable domain (VH) and a light chain variable domain (VL): - wherein the VH comprises an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 234, and the VL comprises an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 235, and - wherein said VH comprises: o comprising SEQ ID NO: 147 or a CDR-H1 amino acid sequence having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 147, o comprising SEQ ID NO: 153 or a CDR-H2 amino acid sequence having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 153, and o comprising SEQ ID NO: 156 or a CDR-H3 amino acid sequence (3B2g2m1) having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 156 and - wherein said VL contains: o comprising SEQ ID NO: 159 or a CDR-L1 amino acid sequence having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 159, o comprising SEQ ID NO: 172 or a CDR-L2 amino acid sequence having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO: 172, and o comprises SEQ ID NO: 195 or a CDR-L3 amino acid sequence (3B2g2m1) having 1, 2, 3, 4 or 5 amino acid changes relative to SEQ ID NO:

195.

10. An anti-MuSK antibody or antigen-binding fragment thereof for use according to any one of the preceding claims, wherein the antibody or antigen-binding fragment comprises: - a heavy chain variable domain (VH) comprising SEQ ID NO: 234, and - a light chain variable domain (VL) comprising SEQ ID NO:

235.

11. An anti-MuSK antibody or antigen-binding fragment thereof for use in treating a neuromuscular disorder in a human subject, wherein the antibody or antigen-binding fragment comprises a heavy chain variable domain (VH) and a light chain variable domain (VL) as determined in Table 3 and / or CDRs as determined in Table 1 or 2.

12. An anti-MuSK antibody or antigen-binding fragment thereof, preferably for use in treating a neuromuscular disorder in a human subject, wherein the antibody or antigen-binding fragment comprises: - a full-length heavy chain comprising an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 270 and a full-length light chain comprising an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 271, or - a full length heavy chain comprising an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 268 and a full length light chain comprising an amino acid sequence that is at least 80% identical or similar to SEQ ID NO: 269, - wherein one or more of the following mutations (all numbered according to the EU numbering system) have been introduced into the full-length heavy chain: N297A substitution; N297Q substitution; L234A substitution; L234D substitution; L234E substitution; L234G substitution; L234H substitution; L234F substitution; L234K substitution; L234Q substitution; L234R substitution; L234S substitution; L234T substitution; L235A substitution; L235D substitution; L235E substitution; L235F substitution; L235G substitution; L235V substitution; L235H substitution; L235I substitution; L235K substitution; L235R substitution; L235S substitution; L235T substitution; L235Q substitution; L237A substitution; S239D substitution; E233P substitution ; L234V replacement; C236 deletion; G236E replacement; G236R replacement; G236K replacement; G237A replacement; P238A replacement; F243L replacement; D265A replacement; S267E replacement; H268A replacement; R292P replacement; Y300L replacement; K322A replacement; K322Q replacement; A327Q replacement; L328F replacement; L328R replacement; P329A replacement; P329G replacement; A330L replacement; A330S replacement; P331S replacement; I332E replacement; P396L replacement; or each of the combinations of the mutations described above in the fourth embodiment of the present application, preferably the mutation is L234A or L235A, more preferably the mutation is L234A and L235A.

13. An anti-MuSK antibody or an antigen-binding fragment thereof, which is preferably used for the use according to claim 12, wherein the antibody or antigen-binding fragment comprises: - a full-length heavy chain comprising SEQ ID NO: 270, and - a full-length light chain comprising SEQ ID NO: 271, and - wherein the full length heavy chain comprises the L234A and L235A mutations numbered according to the EU numbering system.

14. An anti-MuSK antibody or an antigen-binding fragment thereof, which is preferably used for the use according to claim 12, wherein the antibody or antigen-binding fragment comprises: a) a full-length heavy chain comprising SEQ ID NO: 268, and b) a full-length light chain comprising SEQ ID NO: 269, and c) wherein the full length heavy chain comprises L234A and L235A mutations numbered according to the EU numbering system.

15. A polynucleotide for use in treating a neuromuscular disorder in a human subject, the polynucleotide comprising a nucleotide sequence encoding the antibody or antigen-binding fragment thereof, or VH or VL or CDR thereof, according to any one of claims 1 to 14.

16. An expression vector for treating a neuromuscular disorder in a human subject, comprising the polynucleotide of claim 15, preferably operably linked to a regulatory region that allows expression of the antibody or antigen-binding fragment thereof, or VH or VL or CDR thereof, in a host cell or a cell-free expression system.

17. A host cell or cell-free expression system for treating a neuromuscular disorder in a human subject, comprising the expression vector of claim 16.

18. A composition for treating a neuromuscular disorder in a human subject, comprising an antibody or antigen-binding fragment thereof as defined in any one of claims 1 to 14, a polynucleotide as defined in claim 15, an expression vector as defined in claim 16, or a host cell or cell-free expression system as defined in claim 17.

19. The composition according to claim 18, for use in treating a neuromuscular disorder in a human subject, which is a pharmaceutical composition comprising at least one pharmaceutically acceptable carrier or excipient.

20. An anti-MuSK antibody or antigen-binding fragment thereof, polynucleotide, expression vector, host cell, cell-free expression system or composition for use according to any of the preceding claims, wherein the antibody or antigen-binding fragment, polynucleotide, expression vector, host cell, cell-free expression system or composition is administered in combination with an anticholinergic compound.

21. The anti-MuSK antibody or antigen-binding fragment thereof, polynucleotide, expression vector, host cell, cell-free expression system or composition for use according to claim 20, wherein the anticholinergic compound is administered alone, sequentially or simultaneously.

22. The anti-MuSK antibody or antigen-binding fragment thereof, polynucleotide, expression vector, host cell, cell-free expression system or composition for use according to any one of claims 20 or 21, wherein the anticholinergic compound is a muscarinic receptor antagonist, preferably a muscarinic receptor antagonist selective for muscarinic receptor M1 and / or muscarinic receptor M3 and / or muscarinic receptor M5.

23. The anti-MuSK antibody or antigen-binding fragment thereof, polynucleotide, expression vector, host cell, cell-free expression system or composition for use according to any one of claim 22, wherein the muscarinic receptor antagonist is selective for muscarinic receptor M3, preferably wherein the anticholinergic compound is darifenacin, ipratropium bromide, tiotropium bromide or trospium chloride.

24. An anti-MuSK antibody or antigen-binding fragment thereof, a polynucleotide, an expression vector, a host cell, a cell-free expression system or a composition for use according to any of the preceding claims, wherein the neuromuscular disorder is characterized by impaired neuromuscular transmission and / or denervation at the NMJ (neuromuscular junction).

25. An anti-MuSK antibody or antigen-binding fragment thereof, a polynucleotide, an expression vector, a host cell, a cell-free expression system or a composition for use according to any one of the preceding claims, wherein the neuromuscular disorder is characterized by at least one of the following: a. Muscarinic overexcitation, b. Death of motor neurons, c. Neuromuscular junction (NMJ) denervation and d. Impaired synaptic transmission.

26. An anti-MuSK antibody or antigen-binding fragment thereof, a polynucleotide, an expression vector, a host cell, a cell-free expression system or a composition for use according to any of the preceding claims, wherein the neuromuscular disorder is selected from the group consisting of amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), myasthenia gravis (MG), myasthenia gravis, Lambert-Eaton myasthenic syndrome (LEMS), Lyme disease, poliomyelitis, post-poliomyelitis, heavy metal poisoning, Kennedy syndrome, adult-onset Tay-Sachs disease, hereditary spastic paraplegia, multifocal neuropathy, cervical spondylosis, extramedullary tumors with compressive radiculopathy and myelopathy, inclusion body myositis, progressive bulbar palsy, progressive muscular atrophy, motor neuron syndrome and thyrotoxic myopathy.

27. An anti-MuSK antibody or antigen-binding fragment for use according to any one of claims 1 to 14 or any one of claims 15 to 26 when referring back to any one of claims 1 to 14, wherein the disorder is ALS.

28. An anti-MuSK antibody or antigen-binding fragment thereof for use in treating ALS in a human subject, wherein the antibody or antigen-binding fragment is administered to an asymptomatic human subject, preferably within 1, 2, 3, 4, 5 or 6 months prior to disease onset.

29. The anti-MuSK antibody or antigen-binding fragment thereof of claim 28, wherein the asymptomatic human subject is diagnosed as being susceptible to a neuromuscular disorder or disease.

30. The anti-MuSK antibody or antigen-binding fragment thereof for use according to claim 28 or 29, wherein the antibody or antigen-binding fragment binds to the MuSK frizzled (Fz)-like domain sequence of SEQ ID NO:

129.

31. An anti-MuSK antibody or antigen-binding fragment thereof for use according to claims 28 to 30, wherein the antibody or antigen-binding fragment comprises: c) a heavy chain variable domain (VH) comprising an amino acid sequence having at least 80% identity or similarity to SEQ ID NO: 234, and d) a light chain variable domain (VL) comprising an amino acid sequence that is at least 80% identical or similar to SEQ ID NO:

235.

32. An anti-MuSK antibody or antigen-binding fragment thereof for use according to any one of claims 28 to 31, wherein the antibody or antigen-binding fragment comprises: a) a full-length heavy chain comprising SEQ ID NO: 268, and b) a full-length light chain comprising SEQ ID NO: 269, and c) wherein the full length heavy chain comprises L234A and L235A mutations numbered according to the EU numbering system.

33. An anti-MuSK antibody or antigen-binding fragment thereof, a polynucleotide, an expression vector, a host cell, a cell-free expression system or a composition for use according to any one of claims 20 to 27, wherein the anticholinergic compound is administered at the onset of the disease or within 1, 2, 3, 4, 5, 6 or 7 weeks after the onset of the disease.

34. A combination comprising an anti-MuSK antibody or antigen-binding fragment thereof and an anticholinergic compound, preferably for use in treating ALS in a human subject.

35. The combination of claim 34, wherein the antibody or antigen-binding fragment is administered to an asymptomatic human subject, preferably within 1, 2, 3, 4, 5 or 6 months before disease onset, and / or wherein the anticholinergic compound is administered at disease onset or within 1, 2, 3, 4, 5, 6 or 7 weeks after disease onset.

36. The combination of claim 35, wherein the asymptomatic human subject treated with the antibody has been first diagnosed as being susceptible to developing a neuromuscular disorder or disease.

37. The combination of claims 34 to 36, wherein the anti-MuSK antibody or antigen-binding fragment thereof binds to the MuSK Frizzled (Fz)-like domain sequence of SEQ ID NO:

129.

38. The combination of any one of claims 34 to 37, wherein the anti-MuSK antibody or antigen-binding fragment thereof comprises: a heavy chain variable domain (VH) comprising an amino acid sequence having at least 80% identity or similarity to SEQ ID NO: 234, and A light chain variable domain (VL) comprising an amino acid sequence that is at least 80% identical or similar to SEQ ID NO:

235.

39. The combination according to any one of claims 34 to 38, wherein the antibody or antigen-binding fragment comprises: a) a full-length heavy chain comprising SEQ ID NO: 268, and b) a full-length light chain comprising SEQ ID NO: 269, and c) wherein the full length heavy chain comprises L234A and L235A mutations numbered according to the EU numbering system.

40. An anti-MuSK antibody or antigen-binding fragment thereof, combination, polynucleotide, expression vector, host cell, cell-free expression system or composition for use according to any one of claims 1 to 39, wherein the anti-MuSK antibody or antigen-binding fragment thereof, combination, polynucleotide, expression vector, host cell, cell-free expression system or composition is administered to an asymptomatic human subject at the onset of the disease, preferably the anti-MuSK antibody or antigen-binding fragment thereof, combination, polynucleotide, expression vector, host cell, cell-free expression system or composition is administered to an asymptomatic human subject within 1, 2, 3, 4, 5 or 6 months before the onset of the disease.

41. The anti-MuSK antibody or antigen-binding fragment thereof, combination, polynucleotide, expression vector, host cell, cell-free expression system or composition for use according to claim 40, wherein the disease onset comprises at least one symptom selected from the group consisting of muscle twitches, muscle spasms, cramps, muscle weakness, slurred speech and / or nasal voice, difficulty chewing or swallowing, dysphagia, dysarthria and dyspnea.

42. An anti-MuSK antibody or antigen-binding fragment thereof, combination, polynucleotide, expression vector, host cell, cell-free expression system or composition for use according to any of the preceding claims, wherein the neuromuscular disorder is analyzed by electrophysiological or pharmacodynamic assessment in the following: neurofilaments (e.g., neurofilament light chain (NFL)) in serum, plasma and / or cerebrospinal fluid (CSF); or NMJ biopsy.

43. An anti-MuSK antibody or antigen-binding fragment thereof, combination, polynucleotide, expression vector, host cell, cell-free expression system or composition for use according to any of the preceding claims, wherein administration of the anti-MuSK antibody or antigen-binding fragment thereof, combination, polynucleotide, expression vector, host cell, cell-free expression system or composition to the human subject results in one or more of the following therapeutic effects: - an increase in the number or percentage of fully innervated NMJs in said subject, a maintenance of the number or percentage of fully innervated NMJs in said subject, a decrease in the number or percentage of fully denervated NMJs in said subject, an improvement in the reliability of synaptic transmission, a prevention, stabilization or reduction of motor neuron death in said subject; and / or - Improvement in the subject's athletic performance and / or grip strength ; and / or - an improvement in the contractile properties of the muscle at the NMJ of the subject; and / or - an improvement in the resistance to fatigue of the muscles at the NMJ of the subject; and / or - inducing an increase in muscle mass at the NMJ of the subject; and / or - an improvement in the subject's quality of life or a delay in the onset of a deterioration in quality of life; and / or - Reduction of perisynaptic Schwann cell (PSC) muscarinic activity (or reduction of muscarinic hyperexcitability) in said subject or NMJ repair in said subject.

44. An anti-MuSK antibody or antigen-binding fragment thereof, combination, polynucleotide, expression vector, host cell, cell-free expression system or composition for use according to any one of the preceding claims, wherein the treatment results in stabilization of the disorder.

45. An anti-MuSK antibody or antigen-binding fragment thereof, combination, polynucleotide, expression vector, host cell, cell-free expression system or composition for use according to any of the preceding claims, wherein the treatment of the neuromuscular disorder results in an improvement in the treated human subject as assessed by an electrophysiological assessment or a pharmacodynamic assessment; an improvement in neurofilaments (e.g., neurofilament light chain (NFL)) in serum, plasma and / or cerebrospinal fluid (CSF); or an improvement in a NMJ biopsy relative to a human subject not treated with the anti-MuSK antibody or antigen-binding fragment thereof, polynucleotide, expression vector, host cell, cell-free expression system or composition.